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Drug discovery and clinical development is a risky, costly and time-consuming enterprise and 
traditionally occurs in stages, although the clinical phases of drug testing usually show 




Drug discovery and development process, showing the gradual decline of compounds in development against 
growing costs, whereby any delay in development time threatens the profitability of a new drug because of 
limited patent duration.1-3 
 
Over the last five decades, pharmaceutical companies have endeavored to develop new drugs 
targeting psychiatric diseases with varying rates of success. In some areas, substantial 
progress has been made with pharmacological treatment (such as in anxiety and insomnia) 
whereas particular diseases remain notoriously difficult to treat. Novel antidepressants 
(including the widely used serotonin reuptake inhibitors) have been described as being only 
slightly more effective than placebo in the treatment of major depressive disorder (MDD), and 
not more efficacious than drugs such as amitriptyline, developed more than 40 years ago.4,5  
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The same holds for second-generation antipsychotics (SGA), which may be slightly better 
tolerated in some respect, but still may not show better efficacy than first-generation 
antipsychotics (FGA) such as perphenazine.6,7  Despite a vastly growing number of drugs 
approved, many patients with schizophrenia or depression fail to respond to treatment, or keep 
suffering from residual symptoms affecting their daily life. In a survey among almost 6000 
MDD patients, 30.9% considered themselves to have responded to treatment, 31.2% 
considered themselves to have only partially responded, whereas 37.9% did not consider 
themselves to have responded at all.8  In a large, US National Institutes of Health trial 
sponsored trial, known as CATIE, 74% of patients with schizophrenia discontinued drug use 
within 18 months therapy due to either poor tolerability or insufficient therapeutic effect.6  A 
meta-analysis, based on 38 randomized, controlled trials (RCTs) in schizophrenia with 7,323 
participants, demonstrated a relatively small absolute gain of 17% in response rate to SGA 
compared to placebo (overall 41% versus 24% responded to treatment with SGA drugs and 
placebo, respectively).9  In a comprehensive analysis of 167 RCTs involving 28,102 
participants with mainly chronic schizophrenia, approximately twice as many patients 
improved with antipsychotics as with placebo, but only a minority (24% on drug versus 14% 
on placebo) showed ‘good response’.7   
 
Challenges in psychiatric drug development 
The limited response to drug treatment in psychiatric diseases may be attributed to a variety of 
factors. Diagnosis is typically by observation, detection is late, and prediction is poor. This is 
because the neurobiology of most disorders is complex, not confined to a single 
neuroanatomical circuit, and their etiology in many cases largely unknown.10  Although 
people with a specific genetic background may show increased vulnerability to develop a 
specific mental disorder, validated biomarkers for disease severity are genuinely lacking, and 
for most syndromes, there are no objective criteria to base a diagnosis upon.11  As a result, 
diagnostic boundaries are rather arbitrary and may not reflect distinct neurobiological entities, 
so that symptoms from recognizable syndromes may show substantial overlap.12  Individual 
symptoms (such as depressed mood and hallucinations) can be mediated and modulated by a 
variety of neurobiological mechanisms, and – although receptor binding data from imaging 
studies may aid in the demonstration of a molecule’s target engagement - hardly any dose-
linear relationships have been established between neurotransmitter receptor occupancies and 
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clinical response to drug treatment.13  Last but not least, drug treatment effects are quantified 
using standardized psychometric assessments that are based on clinical interviews, 
observations, self-reflections and/or cognitive testing, each with their respective limitations 
and risks for bias.  
 
Inconclusive clinical trials 
As long as the chance for clinical improvement remains limited, patients will be difficult to 
recruit for RCTs and keep motivated staying compliant with prescribed treatment regimens 
under experimental settings. Due to the challenges described above, the timelines (and costs) 
for developing new drugs targeting the central nervous system (CNS) are substantially higher 






























Clinical Phase Approval Phase
 
Figure 1.2 
Mean clinical and approval phase times (in years) for new drugs, registered between 2005 and 2009, grouped by 
therapeutic class.3  
 
It is therefore not surprising that many pharmaceutical companies (including Novartis, Glaxo-
Smith-Kline, Astra Zeneca, Sanofi Aventis, and Merck) have gradually abandoned their 
efforts to develop new drugs for neuropsychiatric diseases, because not only the costs, but 
also risks for failure become more and more considered to be unacceptably high (Figures 1.3 
& 1.4).2,14,15  An additional, major complication is caused by the increased response rate to 
placebo observed over the last ten years in RCTs in psychiatric diseases, including MDD, 
schizophrenia, and bipolar mania (see Chapter 2), resulting in negative and failed clinical 
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trials.* This has resulted in an increased interest in methods to enhance the success rate or 




































                                                 
* A trial is called negative, when an active drug- control differs significantly from placebo and the investigational drug does  
  not, and failed, when neither drug differs significantly from placebo. 
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OUTLINE OF THE THESIS 
 
Tested drug development strategies 
In order to retain costs and efforts, several strategies can be adopted to develop new drugs for 
neuropsychiatric diseases during the various phases of development. Some of these are 
described below and were tested in multicentre studies (Chapters 3-5 of the thesis). 
In the early development phase, signal enhancement strategies may be implemented to 
mitigate placebo response and increase the accuracy of outcome measurements. These may 
include adaptive protocol designs, use of specific outcome measures, and exclusion of 
patients with an increased likelihood of responding to placebo. The continuous search for 
mediators of placebo response in depression studies is reviewed in Chapter 2.  
As long as a novel mechanism of action needs to be proven, it is prudent to test new drugs 
as adjunctive treatment to established drugs, targeting unmet needs in partially responsive 
patients. Such an approach was adopted for the study presented in Chapter 3, which also 
involved novel methods to enhance rater accuracy and statistical techniques to discriminate 
direct from secondary effects on the primary outcome variable.  
It is not uncommon these days to enroll (already in the pre-registration phase) a relatively 
large sample of patients for a face-to-face comparison with a market leading product, whereby 
a wide range of comorbid conditions and adjunctive medications are allowed. An example of 
such a Phase III trial under more ‘naturalistic’ conditions is provided in Chapter 4. An 
approach like this, not only facilitates the generalizability of study results to the average 
patient population but may also show the newcomer’s benefit/risk ratio in comparison with 
established drugs.  
Continued access to the experimental drug upon successful trial completion can be a very 
important asset for patients volunteering to participate in an RCT. This can be accomplished 
through a so-called ‘humanitarian’ extension study, allowing the sponsor at the same time to 
collect long-term outcome data. The study presented in Chapter 5 can be regarded as a 
successful example in this respect.  
Normally speaking, a well designed clinical program is required to demonstrate the 
effectiveness of a test drug. Important to keep in mind when interpreting the results of RCTs 
is that the absence of evidence does not automatically imply evidence of absence.16  Response 
to placebo, inadequate dosages tested, and missing data (e.g., due to drop-out), but in 
particular not selecting the right patients, dosing, and endpoint may be common reasons for 
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the occurrence of so-called inconclusive trials (i.e., a test drug not showing superiority over 
placebo, despite potentially exhibiting biological activity).17  Due to patients’ lack of insight 
in their own disease, disturbing side effects of treatment, cognitive impairment, social 
isolation, common symptoms inherent to the disease itself (such as suspiciousness), and 
comorbid substance abuse, the challenges of drug treatment and prevalence of nonadherence 
are relatively high among patients with schizophrenia.18,19  By rule of thumb, investigators 
will need to establish a good relationship with their patients before being able to enroll them 
successfully as participants in an RCT.20,21  More than in other indications, withdrawal of 
consent is a major reason for drop-out in schizophrenia studies. Since a high drop-out rate 
decreases the power of an RCT, it should be avoided at all times. Chapter 6 explores what 
makes a patient decide to discontinue participation in a study. 
Once a drug has been approved for prescription in a particular region, a sponsor may be 
able to expand its registration status through a so-called bridging study, whereby the effects of 
parallel treatment in populations from different geographic regions are compared. The 
objectives of such a study are (1) to show that the drug is effective in the new region, and (2) 
to compare the results of the study between the regions with the intent of establishing that the 
efficacy & safety profile of the drug is not sensitive to ethnic factors. The ultimate aim is then 
to gain access to a wider market without the need to repeat the full development program in 
the new region. An example of such a study is provided in Chapter 7. 
 
Concluding remarks 
Although the development strategies highlighted in this thesis are far from exhaustive, in 
Chapter 8, some concluding remarks are made with regards to the particular perspectives 
each may entail. Implications for further research are provided, stressing the importance of the 
engagement and involvement of representative patient populations in drug development 
trajectories, whereby a patient’s motivation to participate in clinical studies is better 
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Evaluation of placebo response factors in 
depression 
 
Towards a better understanding of factors reducing power in 
randomized, controlled trials (I) 1 
 
  
                                                 
1 This chapter was published as: 
Schoemaker, Joep H., Kilian, Sanja, Emsley, Robin, Vingerhoets, Ad J.J.M. (2018).  
Factors associated with placebo response in depression trials: a systematic review of published meta-analyses 









Background: Placebo response is common in patients with major depressive disorder (MDD) 
and decreases the likelihood of demonstrating drug superiority over placebo in a randomized, 
controlled trial (RCT). This paper aims to review the collective evidence for particular patient 
characteristics and trial features being associated with placebo response in MDD.  
Methods: MEDLINE/PubMed publication database and Cochrane Library were searched for 
meta-analyses of placebo response in MDD, published in English from January 1990 to 
December 2017. The evidence for factors predicting a low or high placebo response was 
tabulated and weighted on the basis of methods, results, and quality of supporting studies. 
Results: We identified 58 papers, examining the possible association of 40 different factors 
with placebo response in MDD. Research methods varied considerably across articles so that 
our reporting remained descriptive. The evidence for any factor being associated with placebo 
response in MDD appeared very weak to weak. 
Conclusions: Despite 25 years of pooling data from RCTs in MDD, there is no single factor 
for which strong evidence exists that it influences placebo response.  





Sponsors of randomized controlled trials (RCTs) have been facing an increasing response rate 
to placebo in major depressive disorder (MDD) and other neuropsychiatric disorders over the 
last decades, resulting in failed studies, delayed or abandoned projects, and steep increases in 
Research and Development costs.1-5  In the previous 25 years, this has led to a multitude of 
pooled analyses investigating predictors of placebo response in MDD. 
The evidence from pooled analyses is frequently not convincing and sometimes even 
contradictory for the many predictors examined.6   This could be due to sampling bias (e.g., 
when factors are explored on multiple occasions for their association with placebo response 
under non-uniform conditions), or methodological flaws, such as the use of inappropriate 
statistical models, regression to the mean effects, and the use of the relative efficacy of 
antidepressants versus placebo as outcome variable (which can only provide indirect evidence 
for a factor being associated with placebo response). In order to identify moderators of 
placebo response, it is essential to use data from as many RCTs as possible, preferably at 
patient-level rather than study-level, and to correct for heterogeneity in study design when 
executing pooled analyses. The use of individual study participant data is ideal in any meta-
analysis, in that it allows standardizing the statistical analysis of each study, obtaining 
summary results directly, checking the assumptions of models, examining interactions, and 
adjusting each patient’s change score by their baseline value and other patient-level 
characteristics.    
A limited number of meta-analyses have been reviewed by several authors (here called 
“meta-reviews"), with conclusions sometimes being drawn without regard to the methods 
applied in the meta-analyses, the existence of contradictory results reported elsewhere, or 
without providing criteria for weighing the level of evidence coming from these meta-
analyses.6-8  On the basis of a review of 13 meta-analyses, Rutherford and Roose concluded 
that there is “strong” evidence for a positive association between placebo response in 
depression RCTs and (1) a lower probability of receiving placebo or multiple active treatment 
arms, (2) the average number of study sites in a RCT, and (3) poor rater blinding, without 
providing the criteria on the basis of which they reached this conclusion.7  After reviewing 14 
meta-analyses in depression (5 original, and 9 already reviewed by Rutherford and Roose), 
Weimer et al. reported (1) lower probability of receiving placebo, (2) low illness severity, and 
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(3) more recent RCTs to be associated with greater placebo response.8  Papakostas et al. 
reviewed 23 relevant meta-analyses (of which 12 original, not yet included in the two 
previous meta-reviews), and reported repetitive evidence for a positive association between 
placebo response and (1) lower probability of receiving placebo, (2) low illness severity, and 
(3) increased visit frequency.6  The authors of three meta-analyses (at study-level), published 
between 2004 and 2010, unanimously concluded that at least a lower probability of receiving 
placebo is likely to inflate placebo response in depression trials.9-11  However, the results of 
four more recent meta-analyses (of which three at study-level) published between 2012 and 
2016, strongly indicate that there is no such effect.12-15  The inconsistency in results shows 
that, even when repeated findings lead to seemingly justifiable conclusions, subsequent meta-
analyses exploring the same relationship may generate conflicting results, especially when 
data are aggregated at study-level. It underlines the need for authors of reviews to collect data 
from as many sources as possible, and to preferably weigh the results of individual studies on 
the basis of certain quality criteria.    
 
Aims of the study 
The objective of the current work is to review the collective evidence regarding associations 
of placebo response with trial design and patient characteristics that have been previously 
explored in pooled analyses, meta-regressions, and other effect models whereby the results of 
RCTs in MDD are combined. Unlike previous systematic reviews of meta-analyses, the aim 
of the current paper is to bring together the results of all previous work and grade the strength 
of evidence for identified predictors on the basis of pre-defined criteria for quality, quantity, 
and specificity of the data underlying each analysis. This approach has several advantages. 
Firstly, the importance of contradictory or isolated findings, whenever occurring, can be 
weighed to a certain extent, which reduces the risk of drawing false or unjustified 
conclusions. It may also help to create a better understanding of the relatively weak predictive 
value of results coming from pooled analyses when these are based on aggregated data at 
study-level rather than at patient-level. This is important particularly when only RCTs are 
analyzed with relatively low placebo response (i.e., excluding negative, or failed studies 
which were never published), or when heterogeneity in the design of underlying RCTs is not 
well accounted for. Finally, it may contribute to a better trial design for the demonstration of 
efficacy of new products in depression.   





The MEDLINE/PubMed publication database and the Cochrane Library were searched for 
meta-analyses and pooled-analyses (from here, all called ‘meta-analyses’ for the sake of 
simplicity) of placebo response in MDD. The search term ‘placebo’ was cross-referenced with 
the terms ‘depression’ or ‘antidepressant,’ ‘response’ or ‘effect,’ and ‘trial’ in Title/Abstracts 
to identify articles focusing on contributing factors to the placebo response, published in 
English between January 1990 and December 2017. Results were filtered to only show meta-
analyses, reviews, and systematic reviews. Relevant abstracts were hand-searched, full 
articles obtained, and information from these utilized to synthesize the present systematic 
review. Reference lists of articles were also examined to identify further relevant studies not 
identified by the keyword searches. Meta-analyses that aimed to evaluate the association of 
study features with placebo response or the differential response to antidepressants and 
placebo were included in the current review, provided they were based on ‘statistical 
aggregation’ of (patient-level) data or (study-level) results from placebo-`controlled RCTs in 
depression. To be included, underlying RCTs were required to have enrolled patients with 
depressive symptoms, fulfilling further diagnostic criteria of MDD according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM, version III, III-R, IV, or IV-
TR) or Research Diagnostic Criteria (RDC), and assessed with commonly accepted primary 
outcome variables such as the Hamilton Rating Scale for Depression (HAMD, 17 or 21-item 
version), Montgomery & Åsberg Depression Rating Scale (MADRS), and/or Clinical Global 
Impression scale (CGI, severity and/or improvement).16-23  
In order to evaluate the predictive strength of study outcomes, we assessed whether the 
meta-analyses (1) were based on a representative sample of RCTs, (2) focused on illness 
severity (improvement, or mean change in symptoms), or curative effect (percentage of 
participants fulfilling criteria for ‘response’ or ‘remission’) on placebo, rather than trial 
outcome (i.e., drug superiority over placebo, expressed in percentage of positive trials, or 
standardized mean difference between treatments) as endpoint, (3) applied formal and 
appropriate statistical testing, and (4) adhered to basic quality principles for meta-analysis. 
These four assessments are further explained below. 
Ad (1). As far as could be verified, most of the meta-analyses were based on a sample of 
RCTs from two large and partially overlapping data sets, that were included in two studies by 
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Khan et al. (2010) and Furukawa et al. (2016). The two reference papers analyzed a total of 
314 RCTs, testing the antidepressant qualities of 49 different drug formulations against 
placebo between the years 1978 and 2015.15,24  For each meta-analysis, the amount of 
underlying RCTs already listed in the two reference papers was used to calculate the Jaccard 
index (T) as a measure of overlap or representativeness, using the formula:  
T = Nc / ( Na + Nb – Nc ) 
 
whereby Na is the total number of underlying RCTs included in the meta-analysis, Nb is the 
total number of RCTs listed in the two reference papers (Nb=314), and Nc is the number of 
RCTs in the meta-analysis that were also included in the two reference papers. When authors 
of a paper did not provide further details on RCTs underlying their meta-analysis, the 
maximum Jaccard index was calculated, assuming that all of the underlying RCTs already 
were included in the list of reference trials. In addition to the Jaccard index, the total number 
of trial participants exposed to placebo or active drug were extracted and tabulated, as well as 
the period in which underlying RCTs were completed or reported (whichever was mentioned).  
Ad (2). For those meta-analyses in which a positive trial outcome or effect size (the 
difference between active drug and placebo) was used as an endpoint (rather than cure, or 
illness severity changes on placebo), results were considered to not provide direct evidence 
for an effect on placebo response.  
Ad (3). Associations between explored variables and placebo response were only 
considered to be positive or negative when statistically significant under the reported testing 
conditions. 
Ad (4). To further assess the scientific rigor of the meta-analyses, similar criteria were 
applied as on the basis of which the Overview Quality Assessment Questionnaire (OQAQ) 
was earlier validated as an index of the quality of review articles.25  More specifically, this 
concerned the following criteria: (a) unpublished studies are included or searched for 
(comprehensive search); (b) search terms are clearly specified (selection bias was avoided); 
(c) descriptive data are presented for each study, such as design, subject characteristics, 
intervention, outcome, year(s) of study conduct or publication of results (validity of studies 
was assessed); (d) level of heterogeneity is explored and controlled for (studies were 
combined appropriately). As a fifth criterion, we added: (e) data were derived at patient-level, 
assuming a higher level of accuracy of findings in comparison with study-level data 
extraction, as explained in the introduction. 




A systematic extraction form was used to collect core details from all meta-analyses, 
including evidence for patient-, and trial variables that were somehow found to be associated 
with improvement on placebo or to have no apparent impact on placebo response. For the 
sake of convenience, predictors showing positive associations were color-coded in green, 
whereas those with negative associations were color-coded in red, and those without any 
significant relationship in blue. All predictors explored in the meta-analyses were listed using 
pre-defined, categorical terms for investigated aspects of demographics, illness severity at 
baseline, illness duration, diagnostic subtype, study enrolment criteria, dosing strategy, visit 
schedule, primary outcome variable, RCT selection process, patient recruitment, and analysis 
methods. Through the elimination of differences in variable names, the total number of 
explored predictors was thus kept to a minimum, and cross-comparison of results between 
meta-analyses was facilitated.   
As a second step, all 314 RCTs from the two reference papers were listed and amended 
with design details, as provided by Undurraga and Baldessarini (2012) for many of these, in 
an excel spreadsheet.  Based on the information contained in each meta-analysis paper, the 
total number of RCTs included, in combination with the number of RCTs matching with 
RCTs in the reference list were used for automated calculation of the Jaccard index.  
As a third step, results were tabulated and compared for all meta-analyses, counting the 
number of papers suggesting a positive-, negative-, or zero-effect association of a specific 
factor with placebo response. The overall direction of the association was determined on the 
basis of following terms (in decreasing order of importance): positive or negative associations 
on the basis of a patient-level analysis, positive or negative associations on the basis of large 
to very large samples, and the number of counts for any (or absence of) relationship.   
As a fourth step, the level of evidence for each factor’s overall positive, negative, or zero-
effect (i.e., absence of) association with placebo response was determined. We first assessed 
whether there was support for the existence of any association that was (1) substantial (i.e., 
findings suggesting a positive, zero, or negative effect on placebo response, based on an 
analysis at patient-level or involving a representative sample); (2) convincing (i.e., findings 
suggesting a positive, zero, or negative effect on placebo response, based on at least one 
patient-level analysis and at least one analysis involving a large, representative sample); (3) 
consistent (i.e., findings in one direction only, or only findings suggesting a zero association 
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with placebo response); (4) contradictory (i.e., findings in two directions, suggesting both a 
positive and negative association with placebo response). In order to reduce bias, we 
subsequently used custom decision criteria to draw conclusions about the level of evidence, as 
suggested by the availability of substantial, convincing, consistent, and/or contradictory 
evidence. The decision criteria are available as Supplement I to this paper. 
Finally, the collective support for factors to be associated with placebo response was 
gathered and compared for patient-level meta-analyses only, which used change in illness 
severity, response, or remission on placebo as dependent variable (from here called ‘patient-
level response evaluation’). For that purpose, the total sum of the Jaccard indices of all studies 
in support of a particular association was taken as a measure for the level of evidence. 
For the first two steps, the extraction of information from all meta-analysis papers was 
done by the first author (JS), and from a random selection of 25% of the papers by the second 
author (SK). Factor retrieval, color-coding of detected associations, and calculations of the 
Jaccard index from both authors were entirely consistent, and without discrepancies. At that 
point it was decided, that duplicate extraction of information from all the remaining meta-
analysis papers by a second investigator was not necessary due to the high inter-investigator 
reliability. For steps three and four, both investigators (JS and SK) assessed the overall 
direction of all identified factor associations with placebo response, as well as the level of 
evidence present for each association. Again, there were no differences between the 
investigators’ judgments, so that no further measures were deemed necessary to control for 
potential bias in drawing up conclusions about the overall strength of evidence for particular 
factors influencing placebo response.   
Since none of the pooled analyses that we included could be regarded as a meta-analysis 
in its strict sense, and analytical approaches varied considerably, the current work is 




The search in PubMed yielded 1213 hits, from which titles were reviewed for relevant papers. 
Based on study titles alone, 38 studies were pre-identified. After reading the abstracts, ten 
studies were excluded from further consideration, because five of them summarized previous 
work without presenting new results from the further analysis, one presented results from a 
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single study and four failed to investigate factors possibly associated with placebo response. 
Full texts of the remaining 28 studies were obtained and further examined for their relevance 
to the topic under investigation. Ten studies were excluded from further consideration because 
of not fulfilling the selection criteria for pooled analysis and/or quality of underlying study 
results. The examination of the reference lists of the remaining 18 studies yielded an 
additional 40 studies, resulting in a total of 58 studies included in the current systematic 
review (Figure 2.1).1,9-15,24,26-74  The vast majority of identified meta-analyses (75%) were 





Study selection procedure 
 
The effects of 40 independent variables on placebo response were explored. These 

























illness duration, diagnostic subtype); (2) trial design features (enrolment criteria, dosing 
strategy, visit schedule, primary outcome variable); and (3) data sampling and handling 
procedures (trial selection, patient recruitment, analysis method).  
Three different types of dependent variables were used in the meta-analyses, all with the 
aim to predict a potential impact of specific patient-, trial-, sampling-, or analysis features on 
placebo response. Sixteen meta-analyses focused on improvement on placebo versus drug as 
outcome variable (i.e., change in illness severity), 25 studies focused on response or remission 
on placebo (i.e., a ‘curative effect’), and 17 on drug superiority over placebo or standardized 
mean difference between treatments (i.e., trial outcome). Although the latter can only yield 
indirect evidence of a factor’s effect on placebo response, and ‘(non-)response’ or ‘(non-) 
remission’ as a dichotomous variable is less informative and sensitive than other categories of 
variables, such as mean difference in change from baseline scores on placebo versus drug, 
none of the authors provided an adequate rationale for their chosen outcome variable. Also, 
the applied statistical analysis methods varied widely, and even though appropriately applied, 
were mostly selected without justification.   
Almost 60% (N=34) of the analyses were done at study-level, involvng  12 to 252 RCTs. 
In addition, 24 analyses were done at patient-level, most of which were based on a sample of 
fewer than 10 RCTs.  None of the meta-analyses fulfilled all five quality criteria, and most of 
them involved a limited sample of non-unique RCTs, resulting in very low to relatively low 
Jaccard index values (between 0.00 and 0.05 in the patient-level analyses). 
Suggested associations between explored parameters and placebo response from all meta-
analyses are listed in Table 2.2. Convincing findings, based on at least one analysis at patient-
level (in bold) and one involving a large, representative sample (indicated by **) were 
consistently recorded for a variety of factors, providing strong to very strong evidence for 
absence of an effect of age, sex, placebo run-in, region (% US vs. non-US sites), and trial 
completion year on the magnitude of placebo response. Substantial findings, based on patient-
level analyses or a large representative sample, were obtained for the vast majority of factors 
but appeared only consistent (i.e., unidirectional) in a small, scarcely investigated, minority, 
providing moderate evidence for a positive (enhancing) effect of structured vs. non-structured 
interviews and number of participating sites per study, and absence of an effect of body-mass 
index on the magnitude of placebo response.  
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The level of evidence for a positive or negative association with placebo response was 
absent, or very weak to weak for all other factors explored, either because of contradictory or 





Cumulative Jaccard index counts of patient-level meta-analyses, suggesting a positive (green), negative (red) or 
zero (blue) association between patient-, trial-, or sampling-related factors on the one hand, and placebo response 
on the other 
 
A comparable overall pattern of lack of associations with placebo response was also found 
in the patient-level response evaluation (Figure 2.2). Interpretation of the data in this subset of 
studies is hampered by the relatively few RCTs they were based upon, as reflected by the low, 
cumulative Jaccard indices. An early meta-analysis of results from 241 patients in three 
RCTs, led Brown et al. (1992) to conclude that precipitating stress and response in previous 
episodes are positively associated with placebo response.26  Khan et al. (2014a, 2014b) 












































structured clinical interviews in their analyses of results from a total of 221 patients treated in 
a single center.71,72  In all cases where support was found for a variable to be negatively 
associated with placebo response, there was at least equal support found for the same variable 





The present systematic review of previous meta-analyses for the first time brings together all 
collective evidence of factors putatively influencing placebo response in depression trials. 
Although there is potential overlap in underlying RCTs included, the meta-analyses can be 
regarded as more or less independent evaluations because of differences in chosen predictor 
and outcome variables, study populations, and heterogeneity in RCT design. Our results 
indicate that the level of evidence for a positive or negative association with placebo response 
is very weak to weak at best for all evaluated factors.  
Although our findings suggest that there is moderate evidence for a positive effect on 
placebo response of structured (vs. non-structured) interview techniques and total number of 
sites/trial, these findings are based on two very small patient-level meta-analyses of single-
center data focusing on illness severity (structured interviews), and three study-level analyses 
focusing on cure as endpoint (sites/study). One should be cautious to conclude that the effect 
of structured interview techniques on placebo response, as determined by Khan et al. in a 
selected sample of 221 RCT participants from a single center, is representative of what can be 
expected in the general population of depressed patients, as long as the observation has not 
been replicated in a multi-regional trial.71,72  Similarly, one should be cautious to conclude 
that a higher number of sites per RCT, as found by Bridge, Undurraga, Furukawa, and 
coworkers, would directly increase the likelihood of a response to placebo in an individual 
participant, unless this observation is replicated in patient-level analyses.15,50,64  Furthermore, 
it remains to be clarified whether an increased placebo response in RCTs with a relatively 
high number of sites is not an artifact associated with other factors potentially influencing 
placebo response, such as competitive recruitment and other efforts for more rapid patient 
enrolment, whereby sponsors and/or investigators may trivialize the potential risks, and stress 
the potential benefits of double-blind treatment to participating patients. 
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A positive association between low illness severity at baseline and placebo response was 
reported in two out of three narrative meta-reviews of a series of meta-analyses (see 
Introduction above).6-8  However, caution is needed when comparing and interpreting results 
from the various meta-analyses, as we shall briefly illustrate for the putative role of illness 
severity below. Factors’ associations with placebo response may be strongly influenced by (1) 
choice of the study outcome variable, (2) sampling bias in the underlying RCT, (3) whether 
study-level or patient-level data are extracted, (4) whether heterogeneity in RCT design and 
duration, as well as patient characteristics, are examined and controlled for, and (5) methods 
used to analyze the data. In what follows, we will elaborate on each of these aspects. 
First, as pointed out by Papakostas and coworkers, the degree or probability of 
improvement as a function of any patient characteristic or trial feature may vary according to 
whether improvement is defined as a continuous measure (favoring patients with more severe 
symptoms, as they may demonstrate a numerically greater reduction in scores), or 
dichotomous one (favoring patients with milder symptoms, when they require a smaller 
degree of symptom reduction until being considered improved or no longer ill).6  On the other 
hand, using the relative efficacy of antidepressants versus placebo as outcome measure (e.g., 
effect size) can only provide indirect evidence of a factor being associated with placebo 
response, since observations may be confounded by an enhanced or impaired response to 
active treatment.  
Second, sampling bias may play a role, for example, whether the influence of baseline 
severity on placebo response is explored in severely or mildly ill patients. Study-level 
analyses of 52 RCTs by Khan et al. (2002, 2004) and 35 RCTs by Kirsch et al. (2008) 
suggested reduced placebo response with increased illness severity (i.e., a negative 
association). However, the RCTs they had included in their analysis almost exclusively 
comprised samples of patients with a mean baseline HAMD17 score ≥23, i.e., very severe 
depression.31,47  Melander and coworkers (2008), in contrast, concluded on the basis of a 
study-level analysis of 56 RCTs submitted to the European regulatory authorities comprising 
samples of patients with a relatively low enrolment threshold (HAMD17 score ≥15) that there 
was no statistical evidence of a relation between average baseline HAMD17 scores and 
percentage ‘responders’ on active treatment or placebo.  Results from Fournier et al. (2010) 
may partly explain the discrepancy in findings, suggesting that placebo response (and even 
more so the response to the active agent) increases with increasing baseline HAMD score in 
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patients with mild to severe depression, but that the effect of placebo wanes in patients with 
very severe depression. Thus, some observations could reflect nothing more than just a 
regression to the mean, whereby the response to placebo becomes (relatively more strongly) 
attenuated by treatment resistance in patients with very severe depression.53 
Third, as long as meta-regression models rely on study averages, conclusions about the 
potential influence of patient characteristics on outcome remain crude and potentially 
influenced by variability in trial design and data acquisition methods. In a study-level analysis 
by Khan and co-workers (2004) of 52 RCTs submitted to the FDA, an increased baseline 
illness severity was significantly associated with an increased difference in HAMD change 
scores between active drug and placebo, suggesting a decreased response to placebo.9  
Nevertheless, the same authors were unable to confirm this in a patient-level analysis of data 
from 15 RCTs at their site one year later.38  Several years later, using more or less the same 
study-level data in a hierarchic multiple regression model, Khan and co-workers (2007) were 
unable to demonstrate a statistically significant association between baseline illness severity 
on the one hand, and difference in HAMD change scores between active drug and placebo on 
the other.41  In contrast, when using study-level data from 130 RCTs that were published 
between 1981 and 2008 using hierarchic multiple regression models, Khan and co-workers 
(2010) found a statistically significant association between increased baseline illness severity 
and increased improvement on placebo.24  However, as earlier, Khan and co-workers (2011) 
were unable to demonstrate the presence of a statistically significant association between 
baseline illness severity and improvement on placebo in a multiple linear regression model 
using patient data from 15 RCTs conducted at their site between 1995 and 2004.54 
Fourth, in a conventional pooled-analysis, participant data from various studies with a 
common aim and design are shared to produce combined datasets that are subsequently 
analyzed as a single study. In a conventional meta-analysis, study-level effect estimates are 
averaged and aggregated to approximate the overall effect - for all studies combined - in the 
investigated treatment setting. In the 58 papers included in the current systematic review, 
neither of these two approaches was used. Instead, analogous to the conventional technique of 
statistical inference, data from various RCTs were integrated and properties deduced from the 
underlying distribution by analysis of the data in accordance with basic assumptions about 
heterogeneity, sampling, distribution, and covariance of relevant parameters in the chosen 
statistical model. Unfortunately, because none of the studies were designed to investigate the 
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association of study features with placebo response, the power of the statistical techniques 
applied in the reviewed publications is rather low and the risk for erroneous conclusions high. 
This may explain why there were no associations between illness severity and placebo 
response in 18 meta-analyses, whereas a negative association was suggested eight times, and a 
positive relationship four times. 
Fifth, conclusions from Kirsch and coworkers (2008) about the presence of an association 
between baseline illness severity and placebo response relied on randomized cohorts rather 
than randomized individuals. A re-analysis of these data, fitting random effects models in 
both Bayesian and frequentist statistical frameworks (using raw mean difference and 
standardized mean difference scales) implied, however, that there is no significant role of 
baseline illness severity in treatment outcome.69  This conclusion is further supported by the 
lack of evidence for any association between baseline illness severity and placebo response 
from a recent patient-level meta-analysis of 34 RCTs.74  
As far as we are aware, this is the first exhaustive ‘meta-review’ of published meta-
analyses investigating factors contributing to placebo response in depression RCTs, whereby 
findings in support of no association were included rather than ignored, and the level of 
evidence for any contributing effect was systematically explored for each factor on the basis 
of pre-defined criteria. The main strength of the present study, i.e., the use of pre-defined 
criteria for the systematic weighing of evidence in support of an association between explored 
features and placebo response, may at the same time be regarded as a serious weakness. The 
criteria have been set to increase objectivity when comparing the results of a wide variety of 
analyses. However, these criteria have not yet been validated. When evidence is labeled as 
‘convincing’ or ‘substantial,’ this does not take into account the accuracy or reliability of the 
analysis and observations. It may thus be that the evidence is considered meaningful, although 
the underlying research is of relatively poor quality. Our separate patient-level response 
evaluation aimed to remove noise coming from studies that used (1) aggregate study data or 
(2) trial outcome as dependent variable. Results were more or less comparable with those 
from the overall evaluation, although based on studies which used far less underlying RCTs. 
The cumulative Jaccard indices in this approach appeared to be very low, and may in some 
cases even be overestimates of ‘evidence’ being present, since the individual values are 
strictly spoken not additive, especially not when studies are partly based on the same RCTs or 
apply different statistical models. Although inclusion of the Jaccard index as a measure of the 
32│CHAPTER 2 
 
strength of evidence may introduce bias against older studies (since fewer RCTs were 
available at the time of the analysis), we felt that only the results of studies based on a 
representative sample of RCTs may have likely implications for placebo-controlled, clinical 
trials. The ‘representativeness’ of an underlying sample of RCTs was defined by a Jaccard 
index value of twice the median (i.e., more than 0.256). This truncation value was rather 
arbitrarily chosen. However, when set to ‘above median’ (i.e., more than 0.129), the strength 
of evidence for all predictors remains the same except for concomitant medication and 
published vs. unpublished RCTs (both changing from ‘very weak’ to ‘weak’ evidence). The 
Jaccard index itself, of which the values vary by definition from 0.00 (no overlap) to 1.00 (full 
overlap) has to be interpreted with caution because sample sizes of underlying RCTs may 
vary substantially, and results of a meta-analysis of a selection of large RCT can be more 
informative than when based on a selection of small RCT, while the Jaccard index may be the 
same. Furthermore, a high volume of data does not necessarily predict high-quality output or 
absolute reliability of results. Several problems connected with meta-analysis remain 
unaddressed in this review. Inappropriate statistical techniques may sometimes have been 
used. For instance, a fixed-effects model is appropriate for study-level meta-analyses when all 
included RCTs are identical, and all observed variation is caused by chance or within-study 
sampling error. However, whenever there is an interest to generalize the results, and not all 
RCTs are of identical design and conduct, a random-effects model would be more 
appropriate.75  As long as we do not know which patient characteristics or trial aspects can 
influence placebo response, the choice of either method is somewhat arbitrary. The approach 
of using pooled analyses of RCTs for evaluating factors other than (drug or placebo) 
treatment associated with response, ignores the fact that the principle of randomization is 
aimed to address the clinical question whether a treatment is efficacious and sufficiently well 
tolerated, and not in which patients or under which conditions. The validity of any association 
seemingly present between covariates and placebo response will, therefore, need to be 
replicated in large, well-designed, prospective, trials.  
In conclusion, our systematic review demonstrates that meta-analyses published during 
the past 25 years did not answer questions about potential ways to avoid placebo response and 
trial failure in depression RCT. Despite frequently acclaimed associations between placebo 
response and specific patient or trial features, such as the probability of receiving placebo, 
increased visit frequency, the number of sites/trial, baseline illness severity, dosing regimen 
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and year of trial conduct, the level of evidence for these associations remains very weak to 
weak at best. There is stronger evidence for a plethora of factors not to be associated with 
placebo response. As long as there is no broad access to the individual patient data from 
RCTs, we recommend that future research includes the design of prospective RCTs evaluating 
placebo response in subpopulations treated under specific conditions. The medical-ethical 
challenges associated with such an approach may be prohibitive, however, and trial sponsors 
will have to continue dealing with high placebo response rates in a rather crude way, e.g., by 
increasing sample sizes, until it is sufficiently clear which patients, investigators, or study 
procedures should be avoided in order to minimize the likelihood of placebo response in 
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Decision criteria as used to establish level of evidence 
 
Evidence 
Support for a positive-, negative- or zero-effect 
association with placebo response 
Very 
strong 
Consistent, ‘convincing’ findings: 
(A) Patient-level analysis, and 
(B) Large representative sample (T > 0.25), and 
(C) No contradictory, ‘substantial’ findings,     
      i.e. (A) or (B) does not apply for other effects 
Strong Consistent convincing findings, with one substantial 
contradictory finding: 
(A) and (B) apply, and 
(A) or (B) also applies for other effect-type 
Moderate Consistent substantial findings: 
(A) or (B) applies in ≥2 meta-analyses, and 
(A) or (B) does not apply for other effect-type 
Weak Skewed convincing, or isolated substantial findings: 
1. Convincing positive- or negative-, and zero- 
    effect finding(s), or 
2. Isolated substantial finding  
Very 
weak 
Other skewed or above median findings:  
1. Substantial or non-substantial positive- or     
    negative-, and zero- effect finding(s), or 
2. Above median convincing or substantial,    
    positive- or negative-, versus opposite-effect   
    findings, or 
3. Above median non-substantial positive-,  
    negative-, or zero-effect findings, or 
4. Any of the above, based on drug superiority    









Adjunctive medication for difficult to treat 
symptoms in schizophrenia 
 
Evaluation of sustained, add-on treatment, while controlling for rater 
performance and indirect drug effects 1 
 
  
                                                 
1 This chapter was published as: 
Schoemaker, J.H., Jansen, W.T., Schipper, J., & Szegedi, A. (2014).  
The selective glycine uptake inhibitor Org 25935 as an adjunctive treatment to atypical antipsychotics in 
predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.  







Background: Using a selective glycine uptake inhibitor as adjunctive to second-generation 
antipsychotic (SGA) was hypothesized to ameliorate negative and/or cognitive symptoms in 
subjects with schizophrenia.  
Methods: Subjects with predominant persistent negative symptoms (previously stabilized ≥3 
months on a SGA) were enrolled in a randomized, placebo-controlled trial to investigate 
adjunctive treatment with Org 25935, a selective inhibitor of the type-1 glycine transporter, 
over 12 weeks in a flexible dose design. Org 25935 was tested at 4-8 mg twice-daily and 12-
16 mg twice-daily versus placebo. Primary efficacy outcome was the mean change from 
baseline in Scale for Assessment of Negative Symptoms (SANS1-22) composite score. 
Secondary efficacy endpoints were the total and subscale scores on the Positive and Negative 
Syndrome Scale (PANSS), depressive symptoms (Calgary Depression Scale for 
Schizophrenia, CDSS), global functioning (Global Assessment of Functioning, GAF) and 
cognitive measures using a computerized battery (Central Nervous System Vital Signs). 
Responder rates were assessed post-hoc.  
Results: A total of 215 subjects were randomized, of which 187 (87%) completed the trial. 
Both dose groups of Org 25935 did not differ significantly from placebo on SANS, PANSS 
(total or subscale scores), GAF, or the majority of tested cognitive domains. Org 25935 was 
generally well tolerated within the tested dose range, with no meaningful effects on EPS 
symptoms and some reports of reversible visual side effects.  
Conclusion: Org 25935 did not differ significantly from placebo in reducing negative 
symptoms or improving cognitive functioning when administered as adjunctive treatment to 
SGA. In our study population Org 25935 appeared to be well tolerated in the tested dose 
ranges. 
  





In the treatment of schizophrenia, a substantial number of subjects present persistent negative 
symptoms and cognitive impairment, in many cases despite continued treatment with 
available antipsychotics.1, 2  These symptom domains appear to account together for much of 
the long-term morbidity and poor functional outcome of subjects with schizophrenia.3  There 
is a clear medical need to explore new options of effective treatments for these symptom 
clusters.  
A growing body of evidence implies that alterations of glutamatergic neurotransmission 
may be of relevance in the neurobiology of schizophrenia, particularly in the domains of 
negative symptoms or cognitive impairment, in addition to dopaminergic dysregulations.4  
Multiple lines of evidence suggest a hypoactivity at the level of glutamatergic (especially N-
methyl-D-aspartate [NMDA]) receptors in schizophrenia, which appear not to be addressed 
by currently available antipsychotics. A series of experimental drugs, aiming at a safe and 
tolerable increase of glutamatergic activity, have been investigated in schizophrenia, mainly 
as adjunctive therapy. A meta-analysis across studies with glycine, D-serine, D-cycloserine, 
and sarcosine suggests that NMDA-enhancing molecules may be effective in various 
symptom domains, with a combined effect size of up to 0.4 in depressive and negative 
symptoms, and 0.3 in positive and cognitive symptoms.5  
The development of selective and potent inhibitors of the reuptake of glycine at the level 
of the glycine transporter type 1 (GlyT-1) has been suggested as a promising possibility to 
address currently unmet medical needs in the treatment of various symptom domains in 
schizophrenia, especially for negative symptoms or cognitive impairment.6,7  Direct 
pharmacological activation of NMDA or other ionotropic glutamate receptors by an agonist is 
unlikely to be a useful approach because of the risk of overexcitation, which could cause 
neurotoxicity or seizures. Glycine binds to NMDA receptors and acts as a co-agonist for 
glutamatergic neurotransmission.8 GlyT-1 inhibition is therefore regarded as a reasonable, 
non-excitotoxic approach for the enhancement of glutamatergic hypofunction associated with 
schizophrenia.  
Org 25935 (cis - N - methyl- N - (6 - methoxy - 1 - phenyl -1,2,3,4- tetrahydronaphthalen-
2 - ylmethyl) amino - methylcarboxylic acid hydrochloride) (Figure 3.1) is a highly selective 
inhibitor of GlyT-1 (IC50=100 nM).




methyl-glycine (sarcosine) moiety, suggesting glycine-competitive binding at the transporter 
binding site.10  The compound has negligible effects on GlyT-2 and raises extracellular 
glycine levels in rat brain areas up to 2.3-fold after systemic administration.11,12  Human 
glycine cerebro-spinal fluid (CSF) levels are increased in healthy volunteers up to about 2.5- 
fold after a single oral dose of 16 mg, whereas a smaller increase (about 1.5-fold) is found 
after a 4-mg dose, thereby providing evidence for relevant pharmacodynamic activity in the 
aforementioned dose range.13 
In order to explore the therapeutic potential of Org 25935 in negative symptoms of 
schizophrenia, we conducted the Glycine uptake Inhibitor Add-on in Negative symptoms 
Trial (GIANT) in subjects stabilized on a second generation antipsychotic (SGA) with two 
adjunctive treatment regimens of Org 25935 and placebo. In addition to the effects on 
negative symptoms, we also aimed to explore the effects on positive symptoms, symptoms of 











GIANT was a multicenter, 12-week double-blind, parallel-group, randomized clinical trial of 
adjunctive Org 25935 or placebo for the treatment of predominant persistent negative 
symptoms of schizophrenia. It was conducted according to Good Clinical Practice guidelines 
at 25 sites across Europe (Finland, Norway, France, the Czech Republic), Russia, and Latin 
America (Argentina, Chile) from April 2007 through September 2008. The trial protocol was 
approved by the independent ethics committee at each site, and all subjects provided written 
informed consent after the scope and nature of the investigation, including recording of 









Subjects of both sexes meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) criteria for schizophrenia (nonfirst episode) with predominant persistent 
negative symptoms were eligible for the study, if they were in the age range of 18 and 55 
years of age, receiving stabilized treatment for 3 months with an SGA other than clozapine 
(without any change in psychiatric care or SGA dosing regimen during 4 weeks prior to 
screening), and continued to experience predominant negative symptoms, presenting: a score 
≥4 on three or more of the following core items of the Positive and Negative Syndrome Scale 
(PANSS)14 at screening: blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), 
passive social withdrawal (N4), lack of spontaneity (N6), motor retardation (G7), active social 
avoidance (G16); an overall summary score >20 on these core items;  a score 5 (“marked” 
severity or higher) on less than two of following PANSS items: delusions [P1], hallucinatory    
behavior [P3], excitement [P4], grandiosity [P5], or suspiciousness / persecution [P6]; a score 
<20 on the PANSS positive subscale; a score <9 on the Calgary Depression Scale for 
Schizophrenia (CDSS)15; a score 3 on the clinical global impression of Parkinsonism of the 
adapted version of the Extrapyramidal Symptom Rating Scale (ESRS)16 at screening. 
Subjects were also required to have a caregiver or identified responsible person to support 
the compliance of the subject with the study procedures, and to be medically stable (with 
stable drug treatment 4 weeks for any medical condition). Furthermore, subjects were not to 
be at imminent risk of self-harm as documented by a score 9 on the InterSePT Scale for 
Suicidal Thinking (ISST).17   
Key exclusion criteria were a history of any seizure disorder or progressive eye disease, 
treatment with clozapine or any investigational drug, a diagnosis of alcohol or drug 
dependence within six months before screening, history of a malignancy or other chronic 
and/or degenerative processes, as well as an imminent risk to harm others.  
 
Treatment 
Eligible subjects were randomly assigned (in a 1:1:1 ratio) to treatment with Org 25935 4–8 
mg twice daily ("low Org"), Org 25935 12–16 mg twice daily ("high Org"), or matching 
placebo in addition to the continued treatment with an SGA. The actual dose at which the 




the first six weeks, truncation of upward titration to the higher dose and, if necessary, 
downward titration to the starting dose were allowed. After that, subjects were to be 
maintained on the dose to which they had been titrated for the remainder of the trial period. 
Background SGA treatment had to be continued unchanged during the study. 
Subjects were allowed concomitant use of benzodiazepines at a dose equivalent to 
maximally 4 mg lorazepam per day, and could remain on any anticholinergic, beta blocker, 
antidepressant, anti-anxiety, or hypnotic treatment that had been started 4 weeks before 
screening.  
The investigational product (IP) was administered as oral tablets, provided in blisters. 
Formulation of Org 25935 and matching placebo was indistinguishable with respect to 
appearance, shape, smell, and taste. Adherence to treatment was assessed by medication 
review and tablet count at all visits. Subjects were to be withdrawn from the study whenever 
compliance became less than 70% over the entire trial period (from baseline onwards), either 
for the SGA or IP. 
A blood sample for assessment of Org 25935 concentration was taken during the visit on 
days 14, 42 and 84 (Endpoint) at a random time point after last dose taken. The time and date 
of blood sampling for assessment of each sample together with the time of dosing of trial 
medication was recorded on the lab requisition form. Bioanalysis was performed according to 
a validated assay under Good Laboratory Practice (GLP). In order to keep personnel blinded 
to the treatment allocation of individual subjects, samples were relabeled at the central 
laboratory with virtual subject numbers. After unblinding of the trial, mean plasma levels 
were listed by treatment group. 
 
Clinical Assessments 
Overall severity of negative symptoms was measured using the composite score on the first 
22 items of the Scale for Assessment of Negative Symptoms (SANS1-22).
18  The SANS1-22 
composite score was chosen as the primary efficacy variable based on the majority of expert 
recommendations from a dedicated advisory board held in August 2005  (unpublished). SANS 
assessments were conducted at baseline, week 3, week 6, and week 12 (endpoint). 
Alternative measures of negative symptoms included the SANS summary score (sum score 
of the five global items 7, 13, 17, 22, and 25), PANSS negative subscale, and PANSS Marder 
factor score for negative symptoms (PANSS-M).19  The PANSS positive subscale, CDSS, and 
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ESRS were used to assess positive, depressive, and extrapyramidal symptoms, respectively. 
PANSS, CDSS, and ESRS assessments were done at screening, week 4, week 8, and 
endpoint. The scale for Global Assessment of Functioning (GAF)20 was used to assess global 
severity at all visits (screening, week 1, 2, 3, 4, 6, 8, 10, and endpoint). The Neurological 
Evaluation Scale (NES)21 was used to categorize subjects into those with a baseline level of 
neurological soft signs below (NES <5) or above (NES ≥5) the median, and to measure 
change in these symptoms at endpoint.  
Vital signs and body weight were assessed at each visit. Physical examinations were 
carried out at screening and endpoint. Electrocardiograms (ECTs) were performed at 
screening, week 3, and endpoint. Visual function, including measurements of acuity, visual 
field, and color/hue vision, was evaluated at screening and days 21 and 70, when facilities 
were locally available (in 14 of the 25 sites). Visual acuity was measured using ETDRS 
charts22, possible defects in the visual field were determined using automated perimetry 
(Humphrey 30–2 or equivalent)23, and color/hue perception was tested by determining the 
Bowman score with a computerized version of the Farnsworth Dichotomous test (D-15).24  
Routine blood and urine tests were undertaken at screening, week 2, week 6, and endpoint. 
Tolerability was assessed in terms of (serious) adverse events ([S]AEs), either reported by the 
subject or observed by the investigator at any visit, up to 7 days after the last dose (30 days 
for SAEs). 
 
Rater Training and Qualification 
Raters on SANS, PANSS, and GAF were required to have at least two years’ experience with 
the clinical evaluation of schizophrenia, and have a medical degree (MD) to qualify as a 
potential rater for GAF, ESRS, NES, and ISST. Rater candidates were trained on patient 
interviewing skills, and needed to qualify as a rater for SANS and PANSS by independently 
viewing, scoring, and submitting scores for a standard set of audiovisual interview recordings. 
Candidates were admitted as a rater for SANS when their scores did not deviate more than ±1 
from the Gold Standard Rating (GSR) on the five global sub-scores of SANS, and SANS1-22 
showed less than 15% deviation from GSR. Candidates were admitted as a rater for PANSS 
when their scores for at least 80% of the items were within the predefined GSR range. 
In this trial, a new method aimed at improving the quality of psychopathological ratings at 




tested for the first time.25,26  This so-called Expert Rater Assisted Score Evaluation (ERASE) 
method will be described in more detail elsewhere. The results reported in this manuscript are 
based on the final ratings of the site raters, after having been allowed to make adjustments to 
their preliminary system scores on the basis of input from independent raters. Explicit 
informed consent was obtained from all patients allowing the implementation of a video 
monitoring system, whereby independent raters, native speaker of the local language and 
blind to preliminary site rater scores, reviewed audiovisual recordings of patient interviews 
for PANS (at screening) and SANS (at baseline and endpoint), did an independent severity 
grading of symptoms, and subsequently shared their scores with the site raters.   
 
Cognitive Battery 
The cognitive domains of verbal memory, visual memory, speed of processing, perception of 
emotions (social cognition), reasoning, executive functioning (problem solving), working 
memory, and sustained attention were assessed using the computerized CNS-Vital Signs 
Neurocognitive Test Battery at baseline, week 6, and endpoint. The Neuro Cognitive Index 
(NCI),  based on a weighted calculation of individual item scores, was used as an overall 
measure of cognitive functioning. The cognitive battery included tests for verbal memory 
(repeats), visual memory (repeats), symbol digit coding, shifting attention, emotional acuity, 
reasoning, and four part continuous performance (also known as the “N-Back” CPT).   
 
Statistical Analyses 
Sample size calculation indicated that 60 subjects per treatment arm were sufficient to 
demonstrate an effect size (ES) of 0.50 at a power of 80%. This ES shows a meaningful 
improvement of 4.5 points over placebo in SANS1-22 composite score change from baseline, 
assuming a standard deviation of 9.0. Because sample size calculation did not compensate for 
drop-out rates (assuming minimum treatment duration of eight weeks is necessary to measure 
improvement in negative symptoms), subjects dropping out before week 8 were to be 
replaced.  
The efficacy analysis for the primary and secondary variables was performed for all 
subjects in the Intent-To-Treat (ITT) population who had been assessed for efficacy after at 
least eight weeks treatment (ITT-Wk8). The approach was taken because this was a proof-of-
concept trial in a limited number of subjects, whereby a sufficiently long exposure to drug 
ADJUNCTIVE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA | 57 
 
 
(close to the total duration as by protocol) was deemed necessary to demonstrate any 
meaningful change in behavior and emotions over time.  
For all continuous variables, change from baseline was analyzed using an analysis of 
covariance (ANCOVA) model with the baseline value as covariate and with treatment group 
and center as fixed factors. Treatment differences between each of the two Org 25935 groups 
and placebo, as well as 95% confidence intervals of the treatment differences, including P-
values, based on the ANCOVA model, were calculated. Treatment by center interaction was 
explored. Model assumptions (normality and homoscedasticity) were checked by visual 
inspection of the residuals. The statistical test of each Org 25935 group against placebo was 
performed two-sided at the 0.05 significance level, using a last-observation-carried-forward 
(LOCF) method to impute missing data. No multiplicity correction was made.  
A frequency table was prepared for occurring (S)AEs by treatment and preferred term, but 
no statistical tests were performed for safety data. 
A path analytic approach was taken to explore whether a differential efficacy for negative 
symptoms favoring either Org 25935 or placebo was likely to be due to direct and/or indirect 
therapeutic effects.27 Assuming a linear relationship between negative symptoms and 
covariates in other symptom domains, the direct effect on negative symptoms was estimated 
using two regression analyses. One according to an extended model and the second according 
to a reduced model, where the resulting ratio in the average “rate of change” (b2/b1) provided 
an estimate of the degree by which the treatment effect on negative symptoms (SANS1-22 
change from baseline) could not be explained by concurrent changes in positive 
(PANSS+=PANSS positive subscale), cognitive (NCI), depressive (CDSS), and 
extrapyramidal (ESRS) symptoms: 
 
1.  A regression analysis with reduced model: 
SANS1-22 = b1*Treatment 
2.  A regression analysis with extended model: 
SANS1-22 = b2*Treatment + bp*PANSS+ + be*ESRS + bc*NCI + bd*CDSS 
 









Drop-out rates throughout the study were low and similar across treatment arms: low Org 
(15%), high Org (11%), and placebo (13%). Baseline characteristics by treatment, including 
background treatment, were comparable without statistically significant differences between 
treatment groups (Table 3.1; P-values not shown). 
 
Treatment Adherence 
Patient compliance with dosing instructions as measured by pill count was comparably high in 
all three treatment groups and was on average 99% with intake of prescribed antipsychotics 
and 97% with IP intake.  Among subjects exposed to Org, the mean daily dose was 10.9±2.9 
mg in the low Org group (28 subjects (19%) receiving a final dose of 4 mg BID and 43 
subjects (30%) receiving a final dose of 8 mg BID), and 25.8±2.9 mg in the high Org group 
(27 subjects (19%) receiving a final dose of 12 mg BID and 46 subjects (32%) receiving a 
final dose of 16 mg BID). 
 
Pharmacokinetic Results 
Mean (8.4-10.5 hrs) and median (10.0-11.9 hrs) sampling time after last drug intake were 
comparable in both active dose groups. Mean plasma level at days 14, 42, and 84 in the low 
Org group was 83, 108, and 128 ng/mL respectively, and in the high Org group 173, 229, and 
217 ng/mL. Mean plasma level by received dose was 81, 65, and 72 ng/mL on 4 mg BID, 86, 
126, and 159 ng/mL on 8 mg BID, 188, 186, and 165 on 12 mg BID, and 152, 250, and 243 
ng/mL on 16 mg BID respectively. 
 
Negative Symptoms 
When analyzing the primary efficacy outcome parameter, subjects in the ITT-Wk8 population 
showed a mean reduction of 17% to 24% in negative symptoms (SANS1-22) without 
statistically significant differences between low Org or high Org in comparison with placebo 
(Table 3.2, Figure 3.2). The effect size (Cohen's D) on low Org was –0.19 and on high Org 
0.03. Similar results were obtained when comparing PANSS negative subscale (Table 3.2, 
Figure 3.3a) and the PANSS-M (Table 3.2) scores, the low Org group showing a trend 
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towards higher reduction in scores versus placebo without reaching statistically significant 
difference at any time point. When defining response as an individual improvement of at least 
20% as compared with baseline, no significant differences were observed for the PANSS-M  
nor the SANS1-22 scores, though also in this post hoc analysis the low Org group had a 
numerical advantage over placebo (P=0.06).  
 
Table 3.1 
Baseline subject characteristics 
 
Org 25935 
4–8 mg bid 
(N = 71) 
Org 25935 
12–16 mg bid 
(N = 73) 
 
Placebo 
(N = 70) 
Age, mean ± SD 37.4 ± 9.5 38.8 ± 11.0 38.1 ± 10.5 
Gender, female, n (%) 30 (42.3) 27 (37.0) 24 (34.3) 
Smoking, Yes, n (%) 32 (45.1) 31 (42.5) 26 (37.1) 
Marital status, married, n (%) 11 (15.5) 15 (20.5) 5 (7.1) 
Negative symptoms persistence, n (%) 
>5 years 31 (43.7) 31 (42.5) 37 (52.9) 
Neurological soft signs (NES), n (%) 
Below median (<5) 31 (44.3) 31 (43.1) 38 (55.1) 
SANS, mean ± SD    
SANS1-22 composite score 60.1 ± 10.7 63.4 ± 10.1 63.9 ± 11.9 
Blunted affect 2.9 ± 0.8 3.3 ± 0.6 3.2 ± 0.9 
Alogia 2.3 ± 0.9 2.6 ± 0.8 2.5 ± 0.8 
Avolition 3.3 ± 0.8 3.2 ± 0.8 3.4 ± 0.8 
Anhedonia 3.7 ± 0.7 3.6 ± 0.7 3.9 ± 0.6 
Attention 2.3 ± 1.0 2.3 ± 1.0 2.3 ± 0.8 
PANSS, mean ± SD 
Total score 77.6 ± 11.5 80.9 ± 11.5 79.3 ± 10.4 
Positive subscale 12.9 ± 3.3 13.3 ± 3.1 13.4 ± 3.0 
Negative subscale 26.3 ± 3.7 27.1 ± 3.8 26.7 ± 3.9 
General subscale 38.4 ± 7.1 40.5 ± 7.4 39.1 ± 6.7 
Negative Marder factor 26.6 ± 3.6 27.4 ± 3.7 26.8 ± 3.9 
GAF, mean ± SD 51.9 ± 10.6 51.3 ± 9.1 50.1 ± 10.6 
NES, mean ± SD 6.2 ± 5.0 5.5 ± 4.9 5.8 ± 5.1 
CDSS, mean ± SD 2.4 ± 2.4 2.5 ± 2.3 2.6 ± 2.5 
ESRS, mean ± SD 2.4 ± 4.5 2.1 ± 4.3 2.4 ± 4.3 






In further sub-analysis stratifying by baseline neurological soft signs, in subjects with 
relatively mild soft signs (NES <5 at baseline), mean ± sd SANS1-22 change from baseline was 
–16.22 ± 14.69 on low Org (n=27), –11.07 ± 14.17 on high Org (n=28), and –10.79 ± 10.88 
on placebo (n=33). The difference between low Org and placebo was statistically significant 
(P=0.02), but not between high Org and placebo (P=0.62).  
 
Table 3.2 




4–8 mg Twice-daily 
Org 25935 
12–16 mg Twice-daily 
 
Placebo 
(N = 62) (N = 67) (N = 62) 
   CFB    SD     %   P*   CFB    SD     %   P*    CFB    SD     %   
SANS            
Composite score 1-22 –13.50 12.58 –23.8 0.27 –10.91 11.85 –17.1 0.97 –11.21 11.28 –17.8 
Sum (global items)   –3.13   3.29 –22.0 0.35   –2.78   3.08 –18.3 0.68   –2.65   2.87 –17.4 
Blunted affect   –0.56   0.76 –21.4 0.66   –0.63   0.76 –18.9 0.61   –0.58   0.71 –18.5 
Alogia   –0.56   0.92 –25.7 0.34   –0.49   0.84 –17.0 0.77   –0.50   0.67 –21.1 
Avolition   –0.85   1.01 –26.0 0.08   –0.67   0.77 –20.4 0.52   –0.61   0.88 –17.9 
Anhedonia   –0.68   0.78 –18.0 0.13   –0.48   0.93 –11.7 0.67   –0.52   0.76 –11.7 
Attention   –0.47   1.08 –10.9 0.94   –0.51   1.08 –15.8 0.78   –0.44   0.88 –16.8 
PANSS            
Total score –11.84 10.34 –25.8 0.11 –10.69 10.40 –20.9 0.64 –9.73 11.23 –19.3 
Positive subscale  –1.44   1.93 –21.7 0.19   –1.61   4.02 –23.2 0.14 –1.00   2.69 –18.8 
Negative subscale  –4.77   4.74 –25.3 0.22   –3.64   3.94 –17.8 0.70 –3.95    3.94 –20.1 
General subscale    5.63   5.80 –25.4 0.13   –5.43   5.21 –21.8 0.85 –4.77   6.16 –17.2 
Negative Marder Factor  –5.44   5.26 –29.3 0.08   –4.40   4.18 –22.1 0.88 –4.26   4.11 –22.6 
GAF    7.85   9.00   16.3 0.39     6.69   7.18   13.6 0.95   7.10   7.78   15.7 
CDSS  –0.95   1.88 –48.6 0.04   –0.76   1.88 –37.0 0.16 –0.56   2.67 –26.3 
ESRS  –0.80   2.20 –25.9 0.66   –0.30   1.20 –17.2 0.26 –1.0   3.40 –32.0 
Cognitive battery            
NCI   3.21   9.99     4.5 0.50   4.14 10.74   6.7 0.38   2.32 14.20     3.5 
Verbal memory –0.76   7.61   –0.2 0.27   0.41   7.85   3.0 0.22 –0.78   8.60     0.1 
Visual memory –0.35   4.98   –0.1 0.10 –1.73   6.20 –3.0 0.82 –1.34   6.59   –2.1 
Sustained attention   0.96 10.76 –35.8 0.74   3.81 11.14 24.9 0.55   1.95 15.88   71.5 
Working memory   0.96   4.62   –0.4 0.44   0.37   4.75   4.0 0.49   0.82   6.72 –37.9 
Executive functioning 10.16 19.55   34.2 0.99   9.33 20.09 39.7 0.73 12.57 23.26   43.8 
Reasoning   0.65   4.30 –38.2 0.84   0.66   3.95 28.8 0.82   0.78   4.68   23.4 
Speed of processing   5.62   8.53   29.7 0.63   5.73 13.21 –9.5 0.89   5.17 12.94   48.0 
Memory score –1.26 10.64  –0.9 0.15 –1.32 11.61 –0.3 0.36 –2.12 12.35   –1.6 
Perception emotions   1.42   4.18    3.5 0.02   1.55   4.35 16.1 0.02 –0.80   5.91 –44.5 
 
* Differences in change from baseline between the 2 doses of Org 25935 versus placebo were pair-wise tested with an ANCOVA model    
  with baseline as a covariate and pooled sites as a factor, using LOCF approach.  
  CFB = change from baseline, SD = standard deviation. 
 
Analyses of potential "pseudospecificity" of effects on negative symptoms showed that the 
rate of change in SANS1-22 was –0.017 according to the reduced model and –0.071 according 
to the extended model. This means that according to the used model, 1 - (0.017/0.071) = (1-
0.24)*100 or 76% of reduction in SANS1-22 can be explained by concurrent changes in 
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Mean change from Baseline in SANS1-22 composite score by adjunctive treatment in subjects having completed 




Improvement in additional secondary efficacy variables is presented in Table 3.2. The relative 
change from baseline (in %) in SANS summary score and PANSS (total and subscales) are of 
similar magnitude (18%–26%) as the observed 17% to 24% improvement in SANS1-22, 
without significant differences between treatment groups.  
The results for the score changes on the PANSS total score (Figure 3.3b), negative and 
positive subscales (Figures 3.3a and 3.3c respectively), GAF, CDSS, and tested cognitive 
domains are summarized in Table 3.2. Note that subjects with too many positive symptoms 
were to be excluded from the study. 
Generally, no statistically significant differences were observed for either dose group of 
Org 25935 compared with placebo with a few exceptions. Depressive symptoms as measured 
by CDSS and the perception of emotions test (POET) as part of the CNS-VS battery showed 




placebo in the low dose Org 25925 group at an effect size of –0.17 and 0.43, respectively. 
POET showed also statistically significant improvement over placebo (effect size = 0.46) in 






Mean change from baseline (CFB) in PANSS negative subscale score (a), PANSS total score (b), and PANSS 




Treatment with Org 25935 appeared to be generally well tolerated and safe. A total of five 
serious adverse events were reported during the trial (of which three were related to 
worsening of the underlying disease, one due to dizziness, one subject experienced a 
convulsion, and one subject had a foot fracture after accidental collapse). There were no AEs 
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occurring at a frequency higher than 10% in any of the treatment groups, and most AEs were 
mild in intensity. AEs of which the incidence appeared to be higher on Org 25935 than 
placebo and to increase with dose, included (percentages for subjects on placebo, low Org, 
and high Org, respectively): dizziness (0.0%, 2.8%, 9.6%), nasopharyngitis (1.4%, 4.2%, 
9.6%), anxiety (2.9%, 2.8%, 5.5%), somnolence (1.4%, 2.8%, 5.5%), and blurred vision 
(0.0%, 1.4%, 4.1%).  
No increase in EPS was found, as assessed by the ESRS scale (Table 3.2). No effects were 
seen on any safety parameters, including routine laboratory panels, ECGs, vital signs, and 
body weight that can be interpreted as clinically meaningful. 
Ophthalmologic assessments were done in 66 subjects. Sporadic minor changes in visual 
field and acuity were observed. However, the changes were not considered clinically relevant 
since none of the affected subjects experienced a visual AE. A clinically significant 






This study was to our knowledge the first dedicated clinical trial with a selective and potent 
GlyT-1 inhibitor in subjects with predominant persistent negative symptoms in schizophrenia. 
The trial did not provide evidence of significant clinical benefits for either dose group of Org 
25935 on negative symptoms as measured by the prespecified, primary outcome variable. 
When using data generated without the input from independent raters, ie, the preliminary, 
unadjusted site rater scores on SANS, the overall trial outcome was the same. Over a period 
of 12 weeks, a substantial reduction of symptoms was seen with adjunctive placebo treatment, 
which did not differ significantly on most measures from the adjunctive treatment with either 
dose regimen of  GlyT-1 inhibitor. Although in some sub-analyses numerical differences were 
noted, generally trending in favor of the low Org group, sensitivity analyses generally did not 
support the presence of a robust signal in this trial. Also measures of overall functional 
improvement and effect sizes did not point towards clinically relevant difference between 
treatment groups. There may have been a difference between the subgroup of subjects with a 




Presence of NSS has earlier been associated with negative symptoms and poor clinical 
response.28-30  The clinical relevance of a positive outcome in this subpopulation is, however, 
disputable, since "pseudospecificity" analyses do not appear to support the conclusion of 
convincing drug effects on negative symptoms in this trial.  
We also did not find evidence for a beneficial effect of either dose of adjunctive Org 25935 
on most cognitive domains as measured by the CNS-VS computerized battery. A possible 
exception is the result on the perception of emotions, as measured by the POET test, which 
might be subject for further explorations.  
A potential limitation of the study was the relatively high improvement (~18% reduction in 
SANS composite score) and low drop-out rate (13% over 12 weeks) on placebo compared 
with results obtained in earlier adjunctive, negative symptom trials. During the first 12 weeks 
of a 6-month study with adjunctive D-cycloserine in subjects with prominent negative 
symptoms, a drop-out rate of 10/28 (36%) and a negative symptom improvement of 3.4% was 
observed on placebo.31 In an 8-week trial with glycine added to clozapine, both drop-out and 
negative symptom improvement rates on placebo were very small.32  In an 8-week trial with 
pregnenolone added to an SGA, no drop-outs and a 5% reduction of negative symptom 
severity were observed on placebo.33  In a 6-week study with mirtazapine added to poorly 
responsive subjects on first-generation antipsychotics, the drop-out rate was very low and the 
negative symptom severity improved with 3% on placebo.34  Also due to the lack of an 
established active positive control in this indication, it remains unclear at this stage to what 
extent the relatively high placebo response in the GIANT trial may have contributed to the 
lack of significant findings with Org 25935, neither what may have caused the favorable 
response on placebo. Since most patients with schizophrenia have mixed positive and 
negative symptoms, the selection of patients with predominant negative symptoms can be 
considered a biased sampling. The study might have been less vulnerable to non-specific 
treatment effects when patients with high positive symptoms would not have been excluded 
from participation. 
We would like to add a comment on the dose design at 4-8 and 12-16 mg Org 25935. Two 
non-overlapping dose regimens were selected within the predicted therapeutic range, based on 
PK/PD results obtained in healthy volunteers, whereby a steady increase in CSF glycine level 
was observed after administration of single rising dosages of 4, 8 and 16 mg Org 25935 and 
disturbing, visual adverse events were considered prohibitive for further dose increments 
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beyond a twice daily 16 mg level. The overall results in the current study may seem in 
contrast to recently announced results with another selective inhibitor of GlyT-1 (RG 1678), 
for which superiority over placebo was claimed in the lower dose range in a similar treatment 
setting.35  At closer inspection, however, the results of both studies demonstrate some 
similarities. In view of the fact that in the respective study the positive results were seen at 
lower doses and potential signals of efficacy in the GIANT trial occurred largely in the low-
dose group, it cannot be excluded that the drug Org 25935 has been administered in too high 
doses for a clinical benefit in negative symptoms. PET scan studies with Org 25935 might 
provide insight into GlyT-1 binding at various dose levels and possible saturation thresholds, 
before clinical studies with lower dose levels are undertaken to further investigate this issue. 
Although we have no comparable data on Org 25935 that would allow predicting equivalence 
to doses of RG1678 that were reported to be effective, both 16 mg Org 25935 and 30 mg/kg 
RG1678 have been shown to increase glycine CSF plasma levels up to 2.5 times baseline 
levels in humans and rats respectively.13,36  On the other hand, an important differentiating 
characteristic of the GlyT-1 inhibitors is the way these bind to the transporter complex. 
RG1678 binds non-competitively, whereas Org 25935 can be expected to bind competitively 
to the transporter as a result of a N-methyl-glycine moiety that is present in its molecular 
structure, possibly rendering the binding of Org 25935 as being sensitive to glycine 
concentrations.10  Both Org 25935 and RG1678 are highly selective inhibitors of GlyT-1, and 
further studies will be required to investigate whether the mode of interaction with the 
transporter complex can have implications for the potential clinical usefulness of specific 






GIANT Study Group: Clínica Privada Neuropsiquiátrica San Agustín, La Plata (Argentina): 
A. Bertoldi, M.D., Ph.D.; FLENI, Buenos Aires (Argentina): R. Fahrer, M.D., Ph.D.; Clínica 
Psiquiátrica San Jorge, Lanús Este (Argentina): A. Mega, M.D., Ph.D.; Clínica Privada 
Banfield, Banfield (Argentina): E. Amado Cattaneo, M.D.; Directora Instituto Neurociencias, 




M.D.; Private practice, Salzburg (Austria): A. Whitworth, M.D.; Cipam – Clínica Pedro 
Montt, Santiago (Chile): V. Larach, M.D., Ph.D.; Centro de Estudios y Tratamiento de 
Enfermedades Psiquiátricas, Santiago (Chile): G. Vergara, M.D.; Hospital Base de Valdivia, 
Valdivia (Chile): F. Bertran, M.D.; Nestátni zdravotnické zarizeni, Melnik (Czech Republic): 
H. Matlakova, M.D.; Terapie.info, Prague (Czech Republic): T. Rektor, M.D.; Telemens, 
Prerov (Czech Republic): J. Rektor, M.D.; Psychiatricka ambulance, Kutna Hora (Czech 
Republic): S. Pietrucha, M.D.; Private clinic, Brno (Czech Republic): R. Prikryl; Private 
clinic, Kuopio (Finland): J. Jääskeläinen, M.D.; Paloniemen sairaala, Hormajärvi (Finland): 
H. Katila, M.D.; Niuvanniemen sairaala, Kuopio (Finland): J. Tiihonen, M.D., Ph.D.; 
Kellokosken sairaala, Kellokoski (Finland): E. Sailas, M.D.; Helsinki University Central 
Hospital, Helsinki (Finland): G. Joffe, M.D., Ph.D.; CHS La Chartreus – Dijon Cedex 
(France): G. Badet, M.D.; CHU de Grenoble – Hôpital Sud, Grenoble Cedex (France): T. 
Bougerol, M.D., Ph.D.; Centre Medico Psychologique, Dole (France): B. Bonnaffoux, M.D.; 
Centre Médical Claude Bernard, Elancourt (France): J. Gailledreau, M.D.; Brattvåg 
Legekontor, Brattvåg (Norway): O.J. Høyberg, M.D.; Jæren D.P.S., Bryne (Norway): S. 
Heskestad, M.D., Ph.D.; Private practice, Oslo (Norway): Ø. Kavlie, M.D.; City Psychiatric 
Hospital, Saratov (Russia): V. Vilyanov, M.D., Ph.D.; Psychoneurological Hospital 
(Smolensk State Medical Academy), Smolensk (Russia): A. Okhapkin, M.D., Ph.D.; Samara 
Psychiatric Hospital, Samara (Russia): M. Sheyfer, M.D.; Treatment and Rehabilitation 
Research Center “Phoenix”, Rostov-on-Don (Russia): A. Bukhanovsky, M.D., Ph.D.; 
Psychoneurology Health Center, Saint-Petersburg (Russia): V. Tadtayev, M.D.; Psychiatric 
Hospital, Saint-Petersburg (Russia): M. Popov, M.D. 
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Introduction: We conducted a double-blind 1-year trial of asenapine in patients with 
schizophrenia or schizoaffective disorder. 
Methods: Patients were randomized to asenapine (5 or 10 mg BID; n=913) or olanzapine 
(10–20 mg QD; n=312), and monitored regularly. 
Results: Trial completion rates were 38% with asenapine and 57% with olanzapine; main 
reasons for discontinuation were withdrawal of consent (22%, 16%) and insufficient response 
(25%, 14%); fewer discontinuations were due to adverse events (6%, 7%). Mean weight gain 
was 0.9 kg with asenapine, and 4.2 kg with olanzapine. Extrapyramidal symptoms reported as 
adverse events were more common with asenapine. Mean reductions in PANSS total score 
with asenapine and olanzapine were –21.0 and –27.5 (P<0.0001); the exclusion of patients 
who had previous poor experience with olanzapine may have biased the results in favor of 
olanzapine. Scores on the Subjective Wellbeing on Neuroleptics scale and functionality 
measures were similar between groups. 
Conclusion: Asenapine was well tolerated over one year of treatment, causing less weight 
gain than olanzapine but more frequent extrapyramidal symptoms. PANSS total score 
improved with both agents; the improvement was greater with olanzapine than with asenapine 
using last observations carried forward but not in an observed-case analysis. 
  






Schizophrenia and schizoaffective disorder are serious mental disorders that impair patients’ 
ability to function. Schizophrenia is characterized principally by positive and negative 
symptoms,1 although nearly 70% of patients exhibit cognitive dysfunction and often have 
depressive symptoms as well.2,3  Schizoaffective disorder is characterized by a major 
depressive, manic, or mixed episode in addition to symptoms of schizophrenia.1 
First-generation (conventional) and second-generation (atypical) antipsychotics are 
effective in treating the positive symptoms associated with these disorders, but efficacy for 
negative symptoms and cognitive dysfunction is an unmet need. Considerable accumulated 
data suggest that antipsychotics differ more in terms of safety and tolerability than efficacy.4,5 
Asenapine is an atypical antipsychotic approved in the United States for the acute 
treatment of schizophrenia in adults and for manic or mixed episodes of bipolar I disorder 
with or without psychotic features in adults. Its human receptor signature is characterized by 
strong affinity for serotonin receptor subtypes (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-
HT5, 5-HT6, 5-HT7), dopamine receptor subtypes (D1, D2, D3, D4), α-adrenergic receptors, and 
histaminic receptors, but no appreciable affinity for muscarinic receptors.6  Asenapine is 
administered as a fast-dissolving sublingual tablet for rapid absorption through the oral 
mucosa. 
The efficacy of asenapine for symptoms of acute schizophrenia has been demonstrated in 
two 6-week trials.7,8  In both studies, asenapine was significantly better than placebo as 
measured by improvements on the Positive and Negative Syndrome Scale (PANSS)9 total 
score and was generally well tolerated, showing a low incidence of clinically significant 
weight gain, hyperprolactinemia, and extrapyramidal symptoms (EPS). 
The goal of this study was to assess the long-term safety and efficacy of asenapine in a 
flexible-dose regimen in patients with schizophrenia or schizoaffective disorder, and to 











This randomized, double-dummy, double-blind, flexible-dose, 52-week phase III trial 
(clinicaltrials.gov registry: NCT00212784) was conducted at 102 sites in Australia, Belgium, 
the Czech Republic, France, Germany, the Netherlands, Poland, Russia, South Africa, Spain, 
and the United Kingdom from September 2003 through February 2006. The trial protocol was 




Inpatients or outpatients aged 18 years or older (no upper age limit) were eligible for this trial 
if they had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text 
Revision (DSM-IV-TR) diagnosis of schizophrenia or schizoaffective disorder; a PANSS 
total score ≥60, including scores of ≥4 on at least 2 of 5 items on the PANSS positive subscale 
at screening and baseline; and a Clinical Global Impression–Severity of Illness (CGI-S)10 
score of ≥4 (moderately ill; score of 5 indicates severe illness) at baseline. Previously treated 
patients had to have a history of a positive response to an antipsychotic other than clozapine; 
treatment-naïve patients also were eligible. 
Patients with a history of inadequate response to or intolerable adverse effects with 
olanzapine were excluded, as were those who were using disallowed concomitant 
medications, such as mood stabilizers or a second antipsychotic, and those responding well to 
current antipsychotic treatment and who had no clinical need to stop or change treatment. 
Patients also were excluded if they had a score greater than “mild” on any item of the 
Abnormal Involuntary Movement Scale11  or were considered by the investigator to be at risk 
of self-harm or harm to others.  
Patients meeting eligibility criteria were randomly assigned (in a 3:1 ratio) to treatment 
with asenapine 5 mg twice daily (BID) or olanzapine 10 mg once daily (QD). Asenapine (or 
matching placebo) was provided in sublingual tablets whereas olanzapine (or matching 
placebo) was provided in oral capsules. To maintain blinding, a double-dummy design was 
used; patients in the asenapine group also received once-daily oral placebo and those in the 
olanzapine group also received twice-daily sublingual placebo. After the first 7 days, dosages 
were flexible (asenapine 5 or 10 mg BID; olanzapine 10 or 20 mg QD) for the remaining 




treatment period. During the study period, concomitant treatment with hypnotics, anxiolytics, 
anticholinergics and antidepressants (other than tricyclic agents or monoamine oxidase 
inhibitors) was allowed. 
 
Safety and Tolerability Assessments 
Vital signs and body weight were assessed at each visit (screening, baseline, weeks 1, 2, 3, 4, 
6, 8, and then every 4 weeks through week 52). Physical examinations were conducted at 
screening and weeks 6, 24, and 52; electrocardiograms were performed at screening and 
weeks 3, 6, 24, and 52. Laboratory tests (hematology, biochemistry, urinalysis) were done at 
screening and weeks 1, 3, 6, 16, 24, 32, 40, and 52. 
Tolerability was assessed in terms of adverse events, either reported by the patient or 
observed by the investigator during patient visits, up to 7 days after the last dose (30 days for 
serious adverse events). Extrapyramidal symptoms were assessed using the Barnes Akathisia 
Rating Scale,12 the Simpson-Angus Scale,13 and the Abnormal Involuntary Movement Scale11 
at baseline and weeks 1, 3, 6, 16, 24, 32, 40, and 52; EPS-like symptoms were reported as 
adverse events when considered clinically relevant by the investigator. 
 
Efficacy and Other Assessments 
Changes in various symptom domains and overall disease severity for up to 3 days after the 
last dose were assessed using the PANSS,14 CGI-Improvement (CGI-I),10 and CGI-S. CGI 
assessments were performed at baseline and at every post-baseline assessment to endpoint. 
PANSS assessments were performed at screening and baseline, and at weeks 2, 4, 6, 8, 12, 20, 
28, 36, 44, and 52. Other assessments included the Subjective Well-being Under Neuroleptic 
Treatment (SWN) scale15 and the physical and mental component scales of the Medical 
Outcomes Study 12-Item Short Form (SF-12) health survey.16 Assessments using the SWN 
and SF-12 were performed at baseline and at weeks 8, 20, 28, 36, 44, and 52. At the end of 
treatment, both the patient and the investigator used a 5-point scale, from “much better” to 









Safety data were obtained from all randomized patients who received ≥1 dose of study 
medication (all-patients-treated, or safety population). Efficacy was assessed using data from 
the intent-to-treat (ITT) population, which comprised treated patients who had a baseline 
PANSS assessment and ≥1 post-baseline PANSS assessment. Olanzapine was used as active 
control, but no formal power calculations were done to establish non-inferiority or superiority 
of asenapine versus olanzapine. The exploratory analysis of efficacy utilized an analysis of 
covariance (ANCOVA, with baseline as a covariate, treatment group as a fixed factor, and site 
as a random factor) on the change from baseline at each time point in the ITT population 
(using last observations carried forward [LOCF]) and in observed cases. Discontinuation rates 





Of 1377 patients screened, 1225 were randomly assigned to treatment and 1219 received ≥1 
dose of study medication. Baseline demographics and clinical characteristics were similar 
between the treatment groups (Table 4.1). In the majority of patients in both groups, the 
diagnosis was a recurrent episode of paranoid schizophrenia; most patients (82%) had no 
history of suicide attempt. In both groups, more than half the patients were men; 93% of 
patients were white and 6% were black. In both groups, 61%–62% of patients were single, 
20%–21% were married, and 15% were divorced; 43%–44% lived with their parents, 19%–
20% lived with their spouses, and 18%–20% lived alone; and 30%–32% were unemployed 
while 14%–16% earned some form of income. 
Patient disposition, including the number of patients completing the trial in each treatment 
group, is shown in Figure 4.1. A total of 350 (38%) patients on asenapine and 178 (57%) 
patients on olanzapine completed the trial (P<0.0001). The most frequent reasons for 
premature discontinuation were withdrawal of consent (22% with asenapine, 16% with 
olanzapine) and worsening of disease/lack of response (25%, 14%). The frequency of 
discontinuations because of adverse events not related to worsening of disease or inadequate 
response to treatment was much lower in both treatment groups (6% with asenapine, 7% with 
olanzapine). 




At study end, the final dose in the asenapine group was 5 mg BID for 53% of patients and 
10 mg BID for 47% of patients. In the olanzapine group, the final dose was 10 mg QD for 
59% of patients and 20 mg QD for 41% of patients. The mean (standard deviation ± SD) daily 
exposure to each study drug was 13.5±5.1 mg for asenapine and 13.6±4.5 mg for olanzapine.  
The most commonly used concomitant medications in both treatment groups were 
lorazepam (24% in the asenapine group, 21% in the olanzapine group), acetaminophen (10%, 
9%), clonazepam (10%, 6%), zolpidem (10%, 6%), diazepam (10%, 8%), phenazepam (8%, 
6%), and zopiclone (6%, 5%). At endpoint, a higher percentage of patients in the asenapine 
group were taking hypnotics, anxiolytics, or anticholinergics compared with the olanzapine 
group; use of antidepressants was similar between groups (Table 4.2). 
 
Safety and Tolerability 
Data on adverse events reported over the course of the year-long trial are summarized in 
Table 4.3. The incidence of treatment-emergent adverse events was 82% in both groups. The 
incidence of adverse events that were, in the investigators’ judgment, treatment-related was 
60% for asenapine and 61% for olanzapine. Most reported adverse events were rated as mild 
or moderate. 
For the asenapine and olanzapine groups, respectively, incidence rates of treatment-emergent 
serious adverse events were 19% and 12%, and rates of treatment-related serious adverse 
events were 6% and 2%. The mortality rate was <1% in both groups: there were 7 deaths in 
the asenapine group (5 by suicide, among 11 attempts) and 1 death in the olanzapine group 
(by suicide, among 6 attempts). None of the deaths that occurred in the course of the trial was 
considered treatment-related. 
Frequently reported adverse events are summarized in Table 4.4. As shown, most of the 
treatment-emergent adverse events were considered to be treatment-related, except for 
worsening psychiatric condition and insomnia; for these adverse events, the overall incidence 
(treatment-emergent) was substantially higher than the incidence that was considered 
treatment-related. 
Routine laboratory analyses showed no signs of serious metabolic changes, blood 
dyscrasia, or persistent abnormalities in endocrine, renal, or liver function. Transient 
abnormalities in liver function tests were seen more frequently with olanzapine. Mean 




and gamma-glutamyl transpeptidase were smaller with asenapine than with olanzapine (Table 
4.5). Markedly abnormal increases (to levels >3 times upper limit of normal) in ALT were 
seen in 3% of the asenapine group and 11% of the olanzapine group; for AST, the percentages 
were 1% and 3%, respectively. 
Plasma prolactin levels decreased from elevated levels at baseline in both treatment groups 
(Figure 4.2). No notable changes or between-group differences were seen in measures of total 
cholesterol or glucose, but triglyceride levels rose substantially with olanzapine and declined 
slightly with asenapine (Table 4.5). There were no other notable findings regarding 




Patient disposition.  
* Represents combined discontinuations due to lack of efficacy and due to adverse events related to worsening of  
   disease.  





5 or 10 mg BID
n=913
Olanzapine
10 or 20 mg QD
n=312
Received 1 dose 
of study drug
n=908
DC before endpoint, 558







DC before treatment, 5
DC before endpoint, 133
Insufficient therapeutic effect,* 45
Adverse events,† 21
Other causes, 67
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Demographics and clinical characteristics at baseline, safety population 




Men, n (%) 475 (52) 182 (59) 
  Age, y 
Mean ± SD 
Range 
 
     36.8±11.8 
16–71 
        36.2±12.4 
  18–81 
Weight, kg, mean ± SD 
Body mass index, kg/m2, mean ± SD 
     74.6±15.8 
     25.6±4.9 
        73.6±14.4 
        25.2±4.6 
DSM-IV-TR diagnosis, n (%) 
Schizophrenia 
   Paranoid 
   Disorganized 
   Catatonic 





    4 (<1) 





    1 (<1) 
        13 (4) 
  38 (12) 







 30 (10) 
Duration of current episode, n (%) 
<2 week 
<1 month 
1 to <6 months 








  44 (14) 
  64 (21) 
136 (44) 
  43 (14) 
24 (8) 













Among the most extremely ill patients 




    1 (<1) 
  0 (0) 
113 (36) 
146 (47) 
  51 (16) 
    1 (<1) 
 
PANSS=Positive and Negative Syndrome Scale; SF-12=Medical Outcomes Study 12-Item Short Form; SWN=Subjective Well-being under 







Concomitant medication use at baseline and endpoint by drug class, safety population 





Hypnotics   
        Baseline 119 (13) 36 (12) 
        Endpoint 137 (15) 33 (11) 
Anxiolytics   
        Baseline 266 (29) 89 (29) 
        Endpoint 279 (31) 63 (20) 
Antidepressants   
        Baseline    8 (1)  5 (2) 
        Endpoint 114 (13) 39 (13) 
Anticholinergics   
        Baseline   8 (1)   1 (<1) 





Incidence and severity of adverse events (AEs), safety population 
 












  67 (22) 
135 (43) 
  52 (17) 







  63 (20) 
  94 (30) 
  33 (11) 
Serious AEs   
- All serious AEs 












Deaths   
- All deaths 





Discontinuations due to AEs   
- Any AE 
- Related to worsening symptoms 
- Not related to worsening symptoms 
- Treatment-related AE 
- Serious AE 
- Treatment-related serious AE 
155 (17) 
  98 (11) 
57 (6) 
  87 (10) 
75 (8) 
33 (4) 
  38 (12) 
17 (6) 
 21 (7) 
 26 (8) 
 12 (4) 










Most frequently reported adverse events, safety population 





























             22 (7) 
             11 (4) 
111 (12) 
           73 (8) 
           63 (7) 
           75 (8) 
           83 (9) 
           84 (9) 
           76 (8) 
           91 (29) 
         16 (5) 
         14 (5) 
           32 (10) 
           30 (10) 
         21 (7) 










Hepatic Function       U/L       U/L 
ALT   1.7±24.4   5.4±39.5 
AST   1.4±14.7   2.4±22.6 
-GT –0.7±23.4   5.7±31.8 
Metabolic Function     mg/dL     mmol/L     mg/dL   mmol/L 
Total cholesterol –6.0±35.9 –0.16±0.93   3.2±38.36 0.08±0.99 
Triglycerides, fasting –9.8±92.2 –0.11±1.04 30.4±202.60 0.34±2.30 
Glucose, fasting   2.4±21.7   0.13±1.20   3.5±25.14 0.20±1.40 
 
ALT=alanine aminotransferase, also called serum glutamic-pyruvic transaminase (SGPT); AST=aspartate aminotransferase, also called 











Baseline Change* Baseline Change* 
SAS total score 1.2±2.6 –0.4±2.5 1.2±2.8 –0.7±2.7 
BARS total score  0.7±1.6 –0.1±1.9 0.6±1.4 –0.3±1.5 
AIMS 7 total score 0.5±1.4 –0.1±1.3 0.3±1.0 –0.2±1.2 
 
AIMS=Abnormal Involuntary Movement Scale; BARS=Barnes Akathisia Rating Scale; SAS=Simpson-Angus Scale. 






























































Median serum prolactin levels over time in safety population.  





















Weight change over time in the safety population.  
(a) Last observations carried forward (LOCF) analysis. (b) OC analysis. 














































































































Percentage of patients with clinically significant weight gain (≥7% increase from baseline) or weight loss (≥7% 
decrease from baseline) at endpoint in safety population 
 
 
Change in weight was greater with olanzapine than asenapine. At baseline, mean ± SD 
weight was comparable in the asenapine and olanzapine groups: 74.6±15.8 kg (164.5±34.8 
lbs) and 73.6±14.4 kg (162.3±31.7 lbs), respectively. At endpoint, using LOCF data from all 
treated patients, mean ± SD changes were 0.9 ± 4.8 kg (2.0 ± 10.6 Ibs) and 4.2 ± 7.6 kg (9.2 ± 
16.8 Ibs), respectively (Figure 3a). At week 52, using observed case data, mean ± SD change 
was l.6 ± 5.7 kg (3.5 ± 12.6 Ibs) for asenapine and 5.6 ± 8.4 kg (12.3 ± 18.5 lbs) for 
olanzapine (Figure 3b). From week 1 onward and at endpoint, between-group differences in 
change from baseline in body weight were statistically significant, in favor of asenapine 
(P<0.01). Incidence rates of clinically significant weight change at endpoint (≥7% increase or 
decrease from baseline) are shown in Figure 4.4. 
Weight gain was reported as an adverse event in 14% of patients treated with asenapine 
and in 31% of those treated with olanzapine; most of these cases (12% and 29%) were 
considered treatment-related. Weight loss was reported as an adverse event in 2% and 3% of 
patients in the asenapine and olanzapine groups. 
In a post hoc subanalyses, weight change was stratified by baseline body mass index 
(BMI). For BMI <23 kg/m2, mean ± SD changes were 1.72±4.05 kg (3.8±8.9 lbs) with 
asenapine and 6.98±8.32 kg (15.4±18.3 lbs) with olanzapine, and incidence rates of clinically 
significant weight gain were 22.0% and 57.1%. For BMI 23–27 kg/m2, changes with 




rates of significant weight gain were 12.8% and 29.7%. For BMI >27 kg/m2, changes with 
asenapine and olanzapine were 0.04±5.62 kg (0.1±12.4 lbs) and 1.84±7.94 kg (4.1±17.5 lbs), 
and rates of significant weight gain were 9.3% and 21.9%. 
EPS-like symptoms (movement disorders), usually mild, were reported as an adverse event 
by 18% of asenapine-treated patients and 8% of olanzapine-treated patients; most of these 
events (14% and 7%) were considered treatment-related. The most commonly reported type 
of movement disorder in the asenapine and olanzapine groups was akathisia (treatment-
emergent: 10% and 4%; treatment-related: 8% and 4%). EPS, chiefly akathisia, was the 
reported cause of premature discontinuation in 12 patients taking asenapine (1%) and 3 
patients taking olanzapine (1%). Tardive dyskinesia was reported in 3 patients, all taking 
asenapine (1 of these patients had the condition at baseline). On formal assessment of EPS, 
mean scores on rating scales decreased from baseline in both groups (Table 4.6). Among 
observed cases in the asenapine and olanzapine groups, respectively, the proportion of 
patients using anticholinergic drugs was 7% and 2% at week 6, and 8% and 2% at week 52; 
and among all treated patients, 6% and 2% at endpoint. 
The incidence of abnormalities in vital signs was low in both treatment groups at all time 
points, and no notable between-group differences were seen. Electrocardiographic 
abnormalities were reported in 2.4% and 1.3% of patients in the asenapine and olanzapine 
groups, respectively. Most of these cases were related to lengthening of the baseline rate-
corrected QT interval (QTc, Fridericia correction); however, there were no instances of QTc 
≥500 msec at any time during treatment. 
  
Efficacy and Other Outcomes 
At baseline, patients in the asenapine and olanzapine treatment groups were moderately to 
severely ill, as reflected by almost identical mean CGI-S scores of 4.8 and PANSS total scores 
of 92.1 (Table 4.7). Both groups showed improvement over the course of the trial. 
In the LOCF analysis in the ITT population, changes (mean ± SD) from baseline in 
PANSS total score with asenapine and olanzapine were similar at week 6 (–17.9±17.8 and –
19.0 ±17.6) but showed a statistically significant difference in favor of olanzapine at endpoint 
(–21.0±22.8 and –27.5±22.0; P<0.0001). In the observed-case analysis among patients who 
completed the year-long trial, changes (mean ± SD) in PANSS total score with asenapine and 




olanzapine were similar at week 6 (–22.1±15.0 and –21.4±16.0 in 715 and 266 patients, 
respectively) and also at week 52 (–35.9±16.3 and –35.4±16.2 in 357 and 179 patients).  
LOCF and OC assessments of changes in PANSS Marder factor scores and CGI-S scores 
revealed no significant between-group differences (Table 4.7). On the CGI-I, mean ± SD 
scores at endpoint using LOCF analysis were 2.9±1.6 and 2.4±1.5, respectively. At endpoint, 
48% of patients in the asenapine, and 34% in the olanzapine group had CGI-I scores ≥3 
(indicating minimal improvement, no change, or worsening), whereas 52% and 66% of 
patients had scores <3 (indicating much or very much improvement). 
Clinical improvement with treatment was paralleled by increases in mean ± SD SWN total 
score, from 75.8±17.8 at baseline to 84.4±19.1 at endpoint with asenapine, and from 
76.1±16.4 to 85.1±17.7 with olanzapine. No meaningful change from baseline on the mental 
or physical component of SF-12 was observed at any time during the trial, indicating that 
patients’ overall health status was not notably affected by treatment with either drug. 
There were no notable changes within groups or significant between-group differences in 
living situation, employment, or level of functioning. Among patients enrolled as outpatients, 
the incidence of hospitalization was higher for asenapine than for olanzapine (6% vs 3%), 
although the total number of hospital days during the trial was marginally lower for asenapine 
than for olanzapine (mean ± SD days, 34.9±50.2 vs 36.3±41.6). 
At study end, 34% of asenapine-treated patients and 37% of investigators considered 
asenapine much better than previous antipsychotic medication; and 40% of olanzapine-treated 
patients and 48% of investigators considered olanzapine much better than previous treatment. 
  









Adverse events can decrease medication adherence and consequently increase the risk of 
relapse and costly re-hospitalization, impair patients’ health-related quality of life, be 
stigmatizing (particularly excessive weight gain and abnormal involuntary movements), and 
increase medical comorbidity and mortality.17  Thus, one of the goals of this study was to 
evaluate the long-term safety of asenapine in the treatment of patients with schizophrenia or 
schizoaffective disorder. 
In this year-long trial, asenapine was generally well tolerated. Overall discontinuation 
rates, however, were higher with asenapine (62%) than with olanzapine (43%), but mostly for 
reasons other than safety and tolerability. Still higher overall discontinuation rates have been 
observed in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), an 18-
month study in which 1432 patients with chronic schizophrenia were randomly assigned to 
double-blind treatment with olanzapine (7.5–30 mg/day), perphenazine (8–32 mg/day), 
quetiapine (200–800 mg/day), or risperidone (1.5–6.0 mg/day).18  Overall discontinuation 
rates in CATIE were lower with olanzapine (64%) than with the other antipsychotics (74%–
82%). Discontinuation rates due to lack of efficacy in CATIE were also lower with olanzapine 
(15%) than with other treatments (24%–28%), and those rates are consistent with the 
corresponding rates in our study (14% discontinuation rate due to lack of efficacy with 
olanzapine, 25% with asenapine). Fairly high discontinuation rates are not unusual in 
schizophrenia trials, and withdrawals because of adverse events are usually less frequent with 
second-generation antipsychotics than with first-generation agents, at least in flexible-dose 
trials.19  Although discontinuations due to insufficient therapeutic effect accounted for 41% 
and 34% of withdrawals in the asenapine and olanzapine groups, respectively, both drugs 
improved mean PANSS total scores and more than half of patients in each group had endpoint 
CGI-I scores indicating that their symptoms were much or very much improved. 
Changes on the PANSS Marder factors paralleled the changes on the PANSS total score. 
On LOCF analysis, changes were numerically larger with olanzapine than with asenapine, 
whereas the OC analysis showed no notable between-group differences, and the changes in 
both groups were notably larger than those seen on the LOCF analysis. 
The improvement in patients’ subjective sense of wellbeing, as reflected in the increased 
scores on the SWN, is especially important, because the subjective sense of improvement in 
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the early stages of treatment is associated with a greater likelihood of achieving clinical 
remission,20,21 which is likely correlated with improved adherence to treatment.22  In this 
study, the improvement on SWN scores with asenapine was comparable to the improvement 
with olanzapine. In some previous studies, improvements on SWN scores were larger with 
olanzapine than with other atypical antipsychotics,15,23 although a large double-blind study 
found no difference in improvement in SWN scores between olanzapine and risperidone.24  
As is often the case when clinical trials produce conflicting outcomes, the differences may be 
due to variability in patient populations, medication dosages, and other factors. It is also 
interesting to note that the improvements seen in SWN scores in the present study were not 
matched by any notable change in SF-12 scores. Although both instruments reflect the 
patient’s state of wellbeing, the SF-12 is a generic scale whereas SWN was specifically 
developed for schizophrenia or psychosis patients being treated with antipsychotics. Thus, the 
SWN would be expected to have greater sensitivity in detecting treatment effects in this 
patient population.  
The concomitant use of anxiolytics and sedative-hypnotics was higher in the asenapine 
group than in the olanzapine group, which may in part reflect a greater sedative effect with 
olanzapine or a higher incidence of worsening symptoms reported as an AE with asenapine, 
or both. The use of anticholinergic drugs was also higher with asenapine (see below), but the 
use of antidepressants was similar with both treatments. 
In our study, mean weight gain at study end was greater in the olanzapine group, as was 
the percentage of patients with clinically significant weight gain. These findings applied not 
only to the study population as a whole but also to every BMI category when weight change 
was stratified by baseline BMI. For both treatment groups, weight gain was greatest among 
patients with the lowest BMI at baseline. Change in weight over time in observed cases 
(Figure 4.3) suggests that patients taking olanzapine were still gaining weight at study end, 
while weight gain had plateaued in patients treated with asenapine. Thus, long-term weight 
gain appears to be lower with asenapine than with olanzapine. 
We also noted differential effects on liver enzymes; increases in ALT and AST were 
greater with olanzapine than with asenapine over the 52-week study period. Transient 
increases in hepatic enzymes with olanzapine have previously been reported, with clinically 
significant increases in ALT documented in about 2% of patients taking olanzapine.25  On 
other laboratory measures, we found that total cholesterol and triglyceride levels increased 
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with olanzapine but decreased with asenapine; the increase in triglycerides in patients treated 
with olanzapine was noteworthy. Olanzapine has long been associated with adverse metabolic 
effects,17 and a recent comprehensive review has concluded that these effects show correlation 
with serum drug levels, implying a dose relationship.26  Small increases in fasting glucose 
were seen in both treatment groups. 
A decreased risk of EPS at therapeutically effective doses is a defining feature of second-
generation antipsychotics compared with first-generation agents.25  In this regard, asenapine 
appears similar to current second-generation antipsychotics. The incidence of akathisia (the 
most frequently reported form of EPS) among patients treated with asenapine in our study 
was higher than the incidence with olanzapine (10% vs 4%), which may in part account for 
the more frequent concomitant use of anticholinergic drugs in the asenapine group. The 
incidence of akathisia among patients treated with first-generation antipsychotics is 
substantially higher (approximately 50%),25 but there are no data directly comparing akathisia 
incidence with asenapine versus first-generation antipsychotics. Tardive dyskinesia is a more 
serious condition that can develop with long-term antipsychotic treatment and can persist 
even after medication is withdrawn. However, the incidence of tardive dyskinesia appears to 
be relatively low with second-generation antipsychotics.25  These drugs conferred a lower risk 
for tardive dyskinesia (0.9%) than first-generation antipsychotics (3.8%) at 6 months 
treatment in patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) 
study,27 which is consistent with our experience with asenapine in this trial. 
Strengths of our study include the large sample size, double-blind design, and long 
duration of treatment. One weakness of our study is the double-dummy design, requiring 
patients (who tend to show poor compliance) to take twice as many doses as otherwise would 
be necessary. Also, the use or non-use of different antipsychotics before enrollment and/or use 
of concomitant medication could have affected the outcomes. 
Another limitation, common to all randomized controlled trials, is that participants may not 
be representative of “real world” patients with schizophrenia. For example, the exclusion of 
patients deemed to be at risk of self-harm or harm to others may limit the applicability of 
these results to the real-world population of patients with schizophrenia, not only in terms of 
therapeutic response but also in terms of treatment adherence, which may be compromised by 
hostile and uncooperative interactions with professional caregivers.28  The low mortality rate 
observed in this trial (<1% with both treatments) may also reflect the exclusion of individuals 
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considered at-risk for suicide. Finally, the exclusion of patients who had not responded well 
or could not tolerate previous treatment with olanzapine may have produced a bias in favor of 
olanzapine. 
To summarize, assessment of safety and tolerability in this year-long trial indicated that 
EPS (mainly akathisia) were more frequent with asenapine, but weight gain was more 
common and more pronounced with olanzapine. Improvement on the primary measure of 
clinical efficacy, PANSS total score, was greater with olanzapine than with asenapine in an 
LOCF analysis but not in an observed-case analysis. There were no notable between-group 
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Introduction: Safety and efficacy results, collected in schizophrenia and schizoaffective 
disorder patients treated up to nearly 3 years, are presented for asenapine and olanzapine.  
Methods: Patients completing a 52-week randomized double-blind core study on flexible-
dose asenapine (5 or 10 mg BID) or olanzapine (10 or 20 mg QD) could continue treatment 
until study blind was broken. 
Results: 290 patients on asenapine and 150 on olanzapine continued treatment for variable 
lengths of time (mean ± SD (range) 311.0±146.1 (10−653) d and 327.4±139.6 (15−631) d, 
respectively). Adverse event (AE) incidence was lower during extension (asenapine, 62%; 
olanzapine, 55%) than during core study (78%, 80%). In both groups, body weight increase 
and incidence of extrapyramidal AEs were negligible during the extension. Mean PANSS 
total score changes during first year of treatment were –37.0 for asenapine and –35.3 for 
olanzapine, with further change of 1.6 for asenapine and –0.8 for olanzapine at the extension 
study endpoint..  
Conclusions: Clinical stability on asenapine as well as olanzapine was maintained, with few 
recurrent or newly emerging AEs beyond 1 year of treatment. 
 






Schizophrenia affects approximately 4 to 7 of every 1000 persons, with the median lifetime 
prevalence per 1000 persons being nearly equal for men and women (3.7 for men, 3.8 for 
women).1 Lifetime prevalence of schizoaffective disorder in the general population has been 
estimated at 0.32%.2 While psychosocial and support therapies are valuable in helping 
patients with schizophrenia or schizoaffective disorder function in society, antipsychotic 
medication is the mainstay of treatment. Antipsychotic medications such as chlorpromazine 
have been available since the 1950s, but these first-generation antipsychotics (FGAs) are 
associated with a risk of adverse events (AEs), particularly extrapyramidal symptoms (EPS).3 
The AEs associated with FGAs frequently contribute to poor treatment compliance and 
consequently poor functional outcome and decreased quality of life. The introduction of 
second-generation antipsychotics in the 1990s was considered a treatment advance because 
these agents seemed to be associated to a lesser extent with EPS and prolactin increase, while 
showing effect sizes of similar magnitude in comparison with FGAs.3-6  
Asenapine is an antipsychotic with a unique pharmacological profile approved in the 
United States for treatment of schizophrenia and acute treatment of manic or mixed episodes 
associated with bipolar I disorder, either as monotherapy or adjunctive therapy with lithium or 
valproate;7 asenapine is indicated in the European Union for the treatment of moderate to 
severe manic episodes associated with bipolar I disorder in adults.8 In two 6-week trials, 
asenapine 5 mg twice daily (BID) was superior to placebo in treating acute schizophrenia, as 
demonstrated by significantly greater decreases from baseline in Positive and Negative 
Syndrome Scale (PANSS) total score.9,10  
To evaluate the long-term safety and efficacy of asenapine in combination with functional 
outcome, a double-blind phase III trial (25517; clinicaltrials.gov registry NCT00212784) was 
conducted.11 In this trial, patients with schizophrenia or schizoaffective disorder were 
randomly assigned with a 3:1 ratio to treatment with asenapine 5 or 10 mg BID or olanzapine 
10 or 20 mg once daily (QD) for up to 52 weeks. Overall, asenapine was well tolerated over 
one year of treatment, causing no clinically relevant metabolic changes and less weight 
increase than olanzapine (0.9 kg with asenapine vs 5.6 kg with olanzapine). However, 
asenapine treatment was associated with higher incidence of EPS (18% vs 8% with 





(asenapine, 14%; olanzapine, 31%), worsening psychotic symptoms (25%, 20%), and 
insomnia (19%, 14%). In both groups, PANSS total score improved from baseline to 
endpoint. The improvement was significantly greater for olanzapine compared with asenapine 
with last observation carried forward (LOCF) analysis (mean reductions in the intent-to-treat 
[ITT] population: –21.0 with asenapine (n=869) vs –27.5 with olanzapine (n=297); P<0.0001) 
but were comparable with observed case (OC) analysis (–35.9 with asenapine vs –35.4 with 
olanzapine). Upon completion of the 1-year core study, patients were given the opportunity to 
continue double-blind treatment until the study blind was broken. The objective of this paper 
is to describe the long-term effects of asenapine in comparison with olanzapine during this 
extension period and to evaluate the level of change in functional outcome measures in 






This double-blind phase III extension study (25520; clinicaltrials.gov registry NCT00212771) 
was conducted at a total of 75 sites in Australia, Belgium, Czech Republic, France, Germany, 
Poland, Russia, South Africa, and Spain between October 2004 and October 2006. The study 
was conducted in accordance with principles of Good Clinical Practice and was approved by 
the appropriate institutional review boards and regulatory agencies. All patients signed a 
written informed consent document or, if illiterate, provided verbal witnessed consent before 
enrollment in the extension. The extension used a “humanitarian” protocol, allowing patients 
to continue treatment if they had benefited after 52 weeks of treatment in the core study.  
 
Patients 
Inclusion criteria for the core study were age ≥18 years; Diagnostic and Statistical Manual of 
Mental Disorders (4th Edition, Text Revision) diagnosis of schizophrenia or schizoaffective 
disorder; PANSS total score 60, with scores of 4 on at least two of 5 items on the PANSS 
positive subscale at screening and baseline; and a score of 4 on the Clinical Global 
Impression–Severity of Illness scale (CGI-S) at baseline.11 Patients who completed the core 
study, had benefitted from treatment in the opinion of investigator and/or patient, and who 




wished to continue on double-blind treatment, were eligible for the extension. Patients were 
excluded from the extension if, in the judgment of the investigator, they had a medical 
condition or required concomitant treatment that would confound trial results or increase the 
risk of treatment failure or unacceptable AEs.  
 
Treatment  
Patients in the core study were randomly assigned to double-blind treatment with sublingual 
asenapine 5 mg BID or oral olanzapine 10 mg QD for the first seven days of treatment. A 
double-dummy design was used to maintain blinded conditions, with patients in the asenapine 
group also receiving once-daily oral placebo and those in the olanzapine group also receiving 
twice-daily sublingual placebo. Compliance was assessed by means of tablet count and 
estimated by the investigators in percentage of prescribed amount taken. After the first seven 
days, dosages were flexible (asenapine 5 or 10 mg BID; olanzapine 10 or 20 mg QD) for the 
remaining treatment period. Patients entering the extension continued on the same treatment 
regimen, with no re-randomization. The extension treatment was truncated in all ongoing 
patients when results from the core study were unblinded and reported (i.e., 23 months after 
the first patient had been enrolled in the extension). 
No concomitant medications were prohibited during the extension; however, patients were 
instructed not to take any medications without consulting the investigator. To avoid potential 
interactions with asenapine, possible cytochrome (CYP) 2D6 inhibitors and drugs 
metabolized by the CYP2D6 pathway were to be used with caution.  
 
Safety Assessments 
Safety assessments included physical examinations and monitoring of changes in vital signs, 
weight, laboratory variables (e.g., hematology, blood chemistries and enzyme levels, 
urinalysis, prolactin), and electrocardiographic findings. Tolerability was assessed through 
AE reports, which were elicited at each visit through questioning and examination of the 
patient. Extrapyramidal symptoms were reported as AEs, and their occurrence and severity 
were rated using the Barnes Akathisia Rating Scale, Simpson-Angus Scale, and Abnormal 








The primary efficacy endpoint was change in PANSS total score from core study baseline to 
extension endpoint. Secondary efficacy assessments included change in scores on PANSS 
subscales (positive, negative, general psychopathology), PANSS Marder factors (positive, 
negative, disorganized thought, hostility/excitement, anxiety/depression), CGI-S, Clinical 
Global Impression–Improvement scale (CGI-I), and Calgary Depression Scale for 
Schizophrenia (CDSS). Health-related quality-of-life measures included Subjective Well-
Being Under Neuroleptics (SWN), Medical Outcomes Study 12-item Short Form (SF-12), and 
an abbreviated, 4-item version of the Level of Function (LOF) scale, measuring quantity and 




Summary statistics are provided for demographic and clinical characteristics at baseline of the 
core study for all patients who were started on extension treatment.  
Safety and tolerability assessments are reported for all patients who completed the core 
study and treated in the extension. The in-treatment period was defined as the first day of drug 
exposure in the core study until seven days after the last day trial medication was taken. In 
patients enrolled in the extension, safety/tolerability data are presented showing the change at 
core study endpoint and the change over the entire treatment period using the baseline of the 
core study as a reference point.  
Efficacy is only descriptively explored in the current study. There was no hypothesis 
testing for treatment effects because this humanitarian extension study did not re-randomize 
patients after completion of the core study. The primary aim of study was to assess safety.  
Efficacy is reported in three descriptive ways, one using the LOCF method to impute for 
missing data in the extension ITT population (ITText = all patients started on extension 
treatment who had ≥1 PANSS assessment in the extension period), one using LOCF for all 
patients started on treatment in the core study (ITTcore = all patients started on treatment who 
had ≥1 PANSS assessment post-baseline), and one looking at patients who remained on 
treatment (OC). Efficacy data are presented for the entire treatment period using baseline and 
endpoint of the core study as reference points. Descriptive statistics were used for all 
assessments; formal statistical testing was not performed. 




The status of SWN, LOF, and SF-12 as independent measurements of quality of life was 
explored through calculation of Spearman rank correlations between these parameters. 
Likewise, the extent to which clinical improvement, as assessed by total PANSS scores, was 
associated with these functional outcome measurements was determined through calculation 






Patient Demographics  
No significant differences in baseline demographics or clinical characteristics were noted 
between the groups for patients who were started on extension treatment (Table 5.1).  
 
Patient Disposition 
Of the 1225 patients randomized to treatment in the core study (913 to asenapine, and 312 to 
olanzapine), 528 completed 52 weeks of treatment (Figure 5.1). Only patients who completed 
the core study, had benefitted from treatment in the opinion of the investigator and/or patient, 
and who wished to continue on double-blind treatment were eligible for the extension; 440 
patients (asenapine, 290; olanzapine, 150) were considered eligible and continued on double-
blind treatment during the extension and 326 (asenapine, 203; olanzapine, 123) were still on 
double-blind treatment when the extension was truncated (Figure 5.1, Table 5.2). The ITText 
population consisted of 414 patients (asenapine, 267; olanzapine, 147). During the extension, 
87 patients (30.0%) in the asenapine group and 27 (18.0%) in the olanzapine group 
discontinued treatment, withdrawal of consent being the most common reason for 
discontinuation in both groups (Figure 5.2).  
 
Drug Exposure and Patient Compliance  
Patients continued treatment for a variable duration (asenapine, 10−653 d; olanzapine, 
15−631 d). The mean ± SD duration of extension treatment was 311.0±146.1 days with 
asenapine and 327.4±139.6 days with olanzapine, and the mean ± SD duration of total 





days with olanzapine. Mean ± SD daily dosage was 13.4±4.6 mg for asenapine and 13.4±4.6 
mg for olanzapine in the extension only and 13.4±4.05 mg and 13.4±4.09 mg for asenapine 
and olanzapine, respectively, during the entire treatment period. Approximately two thirds of 
the patients (asenapine, 64.1%; olanzapine, 66.0%) were maintained at a modal dose of 10 
mg/d; the remainder received a modal dose of 20 mg/d for each treatment. Treatment 
compliance (%) was defined as 100 times the number of sublingual tablets and/or capsules not 
returned by the subject divided by the number of sublingual tablets and/or capsules that the 
subject should have taken. All tablets and capsules not returned were assumed to be taken. 






Figure 5.1  
Patient disposition. *Designated as completers (i.e., the number of patients in the trial at the time the decision 
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Male sex, n (%) 156 (53.8) 88 (58.7) 244 (55.5) 
Age, years    
Mean ± SD  37.1±11.9 36.5±12.6 36.9±12.1 
Range 16–68 18–77 16–77 
Weight, kg*    
Mean ± SD 74.7±15.4 73.4±15.4 74.2±15.4 
Height, cm    
Mean ± SD 171.4±8.8 170.7±9.9 171.1±9.2 
Body mass index, kg/m2*    
Mean ± SD 25.4±4.8 25.1±4.6 25.3±4.7 
DSM-IV diagnosis, n (%)    
Schizophrenia    
Paranoid 230 (79.3) 120 (80.0) 350 (79.5) 
Disorganized 10 (3.4)  4 (2.7) 14 (3.2) 
Catatonic  1 (0.3)  1 (0.7)  2 (0.5) 
Undifferentiated 13 (4.5)  7 (4.7) 20 (4.5) 
Schizoaffective disorder 36 (12.4) 18 (12.0) 54 (12.3) 
Previous schizophrenia episode, n (%)   
Yes 275 (94.8) 140 (93.3) 415 (94.3) 
No 15 (5.2) 10 (6.7) 25 (5.7) 
Hospitalized at baseline, n (%)   
Yes 108 (37.2) 54 (36.0) 162 (36.8) 
No 182 (62.8) 96 (64.0) 278 (63.2) 
PANSS total score    
        Mean ± SD 90.9±13.1 90.4±12.7 90.7±12.9 
CGI-S, n (%)    
        Mildly ill 1 (0.3) 0 (0) 1 (0.2) 
        Moderately ill 125 (43.1) 67 (44.7) 192 (43.6) 
        Markedly ill 130 (44.8) 66 (44.0) 196 (44.5) 
        Severely ill 34 (11.7) 17 (11.3) 51 (11.6) 
CGI-S=Clinical Global Impression–Severity of Illness scale; DSM-IV=Diagnostic and Statistical Manual of Mental Disorders (4th Edition, 













Figure 5.2  





Table 5.2.  
Summary of duration of treatment, all-subjects-started-extension group 





≥365 days  290 (100.0) 150 (100.0) 
≥449 days 269 (92.8) 147 (98.0) 
≥533 days 245 (84.5) 137 (91.3) 
≥617 days 191 (65.9) 101 (67.3) 
≥701 days 108 (37.2) 56 (37.3) 
≥785 days 70 (24.1) 42 (28.0) 
≥869 days 37 (12.8) 25 (16.7) 
≥953 days 10 (3.4) 3 (2.0) 
≥1037 days 3 (1.0) 0 (0.0) 
 
Concomitant Medication Use 
Concomitant psychotropic medication use is presented in Table 5.3. The percentage of 
patients using antidepressants and anticholinergics increased during the core study for both 
groups but was fairly stable during the extension. The percentage of patients using 
concomitant hypnotics during the extension increased for asenapine and remained stable for 
olanzapine. The percentage of patients using anxiolytics decreased during the core study and 
increased with both asenapine and olanzapine during the extension. 
 
Table 5.3.  





Types of medications used, n (%)   
Antidepressants   
Core study baseline 2 (0.7) 2 (1.3) 
Core study endpoint 42 (14.5) 21 (14.0) 
Extension endpoint 49 (16.9) 20 (13.3) 
Anticholinergics   
Core study baseline 0 (0.0) 0 (0.0) 
Core study endpoint 23 (7.9) 3 (2.0) 
Extension endpoint 28 (9.7) 4 (2.7) 
Hypnotics   
Core study baseline 21 (7.2) 12 (8.0) 
Core study endpoint 21 (7.2) 6 (4.0) 
Extension endpoint 31 (10.7) 7 (4.7) 
Anxiolytics   
Core study baseline 61 (21.0) 31 (20.7) 
Core study endpoint 46 (15.9) 19 (12.7) 
Extension endpoint 61 (21.0) 25 (16.7) 
 




Safety and Tolerability 
Adverse events 
Overall, fewer treatment-emergent and treatment-related AEs started during the extension 
than during the core study (Table 5.4). As in the core study, most AEs were mild or moderate 
and comparable between treatment groups. Three patients, all in the asenapine group, died 
during the extension. One patient, who took asenapine for 429 days, died due to acute cardiac 
insufficiency while on treatment. Another patient, who took asenapine for 470 days, died 4 
days after the end of treatment due to disseminated arteriosclerosis and thromboembolism of 
pulmonary artery. The third patient, who took asenapine for 505 days, died from unknown 
causes 16 days after the end of treatment. The investigators considered these deaths either not 
related or unlikely to be related to study drug. 
The most common AEs (i.e., those reported by ≥5% of patients) included insomnia, 
depression/depressed mood, weight increase, headache, and anxiety in both groups, as well as 
worsening schizophrenia for asenapine and nasopharyngitis and influenza for olanzapine. 
Weight increase was reported at much lower frequency during the extension than during the 




At core study baseline, mean ± SD body weight was 74.7±15.4 kg in the asenapine group and 
73.4±15.4 kg in the olanzapine group. Mean body weight during the extension only did not 
change beyond the weight gain in the core study (endpoint of core study: asenapine, 
76.3±14.8 kg; olanzapine, 78.8±15.4 kg; end of entire treatment period: asenapine, 76.3±15.1 
kg; olanzapine, 78.4±15.7 kg; Figure 5.3). 
 
Extrapyramidal symptoms 
Incidence rates of EPS-related AEs that started during the extension were lower for both 
asenapine (4.5%) and olanzapine (3.3%) compared with those that started during the core 
study (asenapine, 17.2%; olanzapine, 8.7%). Akathisia was the most common EPS-related AE 
reported in both treatment groups during the core study, but not many new cases of akathisia 
were reported during the extension period (Table 5.4). Changes in EPS rating scale scores 
from core study endpoint to extension study endpoint were equally minimal between groups, 





new cases of tardive dyskinesia, a movement disorder more likely to develop with long-term 
antipsychotic treatment, were observed during the extension period. 
 
Other safety and tolerability measures 
No major changes in laboratory variables, including cholesterol, prolactin, and liver enzymes, 
and vital signs were observed in either treatment group during the extension period. The 
incidence of electrocardiographic-related AEs was 3.1% for asenapine and 2.7% for 
olanzapine during the extension only (during the entire treatment period: asenapine, 5.5%; 
olanzapine, 3.3%). There were no cases of QT prolongation (500 ms) observed in either 
treatment group. 
 
Table 5.4.  
Summary of adverse events 
 Asenapine (n=290) Olanzapine (n=150) 


































































































AEs = adverse events. 
 

















Olanzapine 10 to 20 mg QD








































Figure 5.3.  
Mean change from baseline in weight over the entire course of treatment (observed case data for all enrolled 






Primary and secondary efficacy measures 
Figure 5.4a presents PANSS total score LOCF data for those subjects who continued in the 
extension (ITText). Figure 5.4b presents LOCF data for those patients representing the total 
study population (ITTcore.  In the ITText population mean PANSS total score changes during 
first year of treatment were -37.0 for asenapine and -35.3 for olanzapine respectively, with a 
further change of 1.6 for asenapine (n=203) and -0.8 for olanzapine (n=123) at the extension 
study endpoint (Figure 5.4a). Similar to PANSS total score, no important changes in other 
(secondary) efficacy measures (PANSS subscales, PANSS Marder factors, CGI-S, CGI-I, and 
CDSS) were found. More than 80% of patients who were still taking study drug in both the 
asenapine and olanzapine groups had a CGI-I classification of “at least much improvement” at 
core study endpoint and extension endpoint. 
In the OC population mean ± SD change on the PANSS total score at extension study 
endpoint was –35.4±17.4 with asenapine and –36.1±16.6 with olanzapine over the entire 
treatment period (Figure 5.4c). Upon truncation of the extension, clinical improvement(as 
reflected by a ≥20% decrease in PANSS total score from core study baseline) was reported in 





reductions of ≥30% in PANSS total score were observed in 85.8% and 89.1% of the patients 
still on asenapine and olanzapine, respectively. 
 
Health-related quality of life and functioning  
During the extension and over the entire treatment period, improvement on measures of 
health-related quality of life (SWN, SF-12) was comparable between treatment groups among 
OC (Table 5.5). At endpoint of the extension, minimal additional changes in these measures 
were observed in either group, indicating that the improvements were maintained during the 
extension. 
A modest association between change from baseline on clinical efficacy (PANSS total 
score) and functional improvement (SWN total and component scores, SF-12 physical and 
mental scores, and LOF total score) was found in patients treated with either asenapine or 
olanzapine (Figure 5.5). Equally modest intercorrelations were found between SWN total 
scores and SF-12 physical and mental scores (r = 0.32 and r = 0.43, respectively) and other 
functional outcome measures (Table 5.6). 
 





Figure 5.4  
Change in Positive and Negative Syndrome Scale (PANSS) total score over the entire course of treatment. 
(a) LOCF analysis of all patients (intent-to-treat [ITT]) entering the Extension phase.  
(b) LOCF analysis of the Core study ITT population. 
(c) C OC analysis of ITT patients in the core study 






Table 5.5  







SWN total score, mean ± SD     
Core study baseline 75.6±17.6 75.1±15.2 
Change for entire treatment period 13.1±18.6 14.6±18.0 
Change for extension only –1.3±13.1 1.3±8.7 
SF-12, mean ± SD   
Physical component summary     
Core study baseline 44.2±8.1 44.8±8.1 
Change for entire treatment period 3.0±9.9 1.5±10.2 
Change for extension only 0.2±8.0 –0.3±8.3 
Mental component summary     
Core study baseline 38.1±9.6 37.0±8.5 
Change for entire treatment period 6.9±12.3 8.2±12.1 
Change for extension only –0.3±9.0 0.6±7.5 
LOF, n (%)   
Meets with friends ≥once per week   
Core study baseline 55 (20.6) 32 (21.9) 
Core study endpoint 105 (39.3) 51 (34.7) 
Extension endpoint 100 (37.5) 64 (43.5) 
≥1 close relationship   
Core study baseline 42 (15.7) 22 (15.1) 
Core study endpoint 87 (32.6) 41 (27.9) 
Extension endpoint 87 (32.6) 46 (31.3) 
Employed continuously   
Core study baseline 28 (10.5) 18 (12.3) 
Core study endpoint 68 (25.5) 34 (23.1) 
Extension endpoint 75 (28.1) 34 (23.1) 
Very competent at work   
Core study baseline 13 (6.7) 7 (6.9) 
Core study endpoint 44 (21.5) 21 (19.3) 
Extension endpoint 41 (19.4) 19 (16.7) 
 









Figure 5.5  
Spearmen rank correlation between change from baseline on PANSS (total score) and health-related measures 
(pooled treatment data). LOF=abbreviated Level of Function scale; PANSS=Positive and Negative Syndrome 




Table 5.6  
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Establishing the long-term tolerability and efficacy of drugs used to treat schizophrenia and 
schizoaffective disorder is important because these disorders typically require chronic, 
frequently life-long treatment.14 In the initial 52-week core study in patients with 
schizophrenia or schizoaffective disorder, asenapine 5 or 10 mg BID and olanzapine 10 or 20 
mg QD were well tolerated, with asenapine causing less weight gain than olanzapine but 
associated with a higher incidence of EPS.11 Both medications improved psychotic symptoms, 
with PANSS total score reductions being comparable upon OC analysis but superior with 
olanzapine upon LOCF analysis. Consistent with the LOCF results in the core study,11 a meta-
analysis of 50 clinical trials in patients with schizophrenia or schizophrenia-like psychosis has 
reported that olanzapine improves PANSS total score slightly more than aripiprazole, 
risperidone, ziprasidone, and quetiapine, but not amisulpride or clozapine.15 In the ITT-
extension group, differences between mean changes in PANSS total score on asenapine and 
olanzapine appeared minimal at study endpoint over the core and extension treatment (Figures 
5.4B and 5.4C).  The conclusions drawn earlier for the core study are reinforced by these 
observations.11 
During the extension period, no meaningful differences in weight gain and EPS were 
observed between treatment groups. Clinical improvement was maintained equally well with 
both drugs as minimal changes were observed in mean or LS mean PANSS total score. The 
incidence of newly emergent AEs was low on both treatments, and there were no notable 
changes in laboratory variables, vital signs, or electrocardiographic findings. Taken together, 
these observations suggest that clinical stability can be maintained with asenapine as well as 
olanzapine over a prolonged period of time and that AEs experienced in the early course of 
treatment can usually be kept under control, with few recurrences or newly emerging AEs 
after 1 year of treatment. 
It should be acknowledged that a higher proportion of patients on asenapine discontinued 
the trial than on olanzapine. The difference in dropout rates between treatment groups was not 
only observed in the core study but also in the extension period, and may have influenced the 
results of the LOCF analysis that imputes for missing data, favoring the treatment group with 
fewer withdrawals. For a proper weighing of efficacy results over the entire treatment period 
(up to 3 years), the fact that double-blind treatment was truncated at an unforeseen time point 




is important to consider. This so-called “humanitarian” study was open-ended (i.e., the blind 
for the core study was broken while patients would still be on extension treatment). Study end 
for the extension was delayed until patient enrollment and data cleaning for the core study 
was fully completed, and the database lock ready. Duration of treatment continuation was 
therefore of variable length. Treatment duration for each patient was also influenced by the 
time point of extension study enrollment, in that the first patients enrolled continued the 
longest time (maximally 23 months) and the last enrolled continued for the shortest time 
(maximally 10 days). As a result, by the end of the trial (i.e., at the moment of truncation) the 
majority of subjects who had once entered the extension period had only been on double-blind 
treatment for less than 2 years (Table 5.2).  
Although the long-term data from this extension are valuable, one major limitation should 
be acknowledged. As explained above, no statistical analyses were done to compare results of 
asenapine and olanzapine. Thus, any comparative conclusions regarding the differential 
effects of treatment should be made with caution.  
Overall, clinical improvement in the current study was associated with modest 
improvements in functional outcome parameters, especially with the abbreviated LOF and 
SWN. The relatively higher correlation between changes in PANSS total score and these 
scales might be because LOF and SWN (unlike SF-12) have been specifically designed to 
measure functional outcome in schizophrenia. It is of interest that the intercorrelations 
between SF-12, LOF, and SWN are relatively low, suggesting that functional outcome can be 
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Evaluation of satisfaction with treatment 
and drop-out in schizophrenia    
 
Towards a better understanding of factors reducing power in 
randomized, controlled trials (II) 1 
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Introduction: Despite consistently high discontinuation rates due to the withdrawal of 
consent (WOC) and insufficient therapeutic effect (ITE) in schizophrenia trials, insight into 
the underlying factors contributing to poor satisfaction with treatment and drop-out is limited. 
A better understanding of these factors could help to improve trial design and completion 
rates.    
Methods: Using data from 1136 trial participants with schizophrenia or schizoaffective 
disorder, we explored associations between predictor variables with (1) drop-out due to WOC 
and ITE, and (2) satisfaction with treatment among patients and investigators by means of 
hierarchic multiple regression analyses.  
Results: ITE was associated with poor clinical improvement, investigator’s satisfaction with 
treatment, and patient’s insight into their own disease, whereas WOC only showed a 
meaningful association with a poor patient’s satisfaction with treatment. Investigator 
satisfaction with treatment appeared most strongly associated with PANSS positive factor 
endpoint scores, whereas patient satisfaction with treatment was best predicted by the 
endpoint score on the PANSS emotional distress factor. The occurrence of severe side effects 
showed no meaningful association with satisfaction with treatment among investigators and 
patients, neither did a patient’s experienced psychopathology, or self-rating of functional 
impairment.  
Conclusion: Whereas trial discontinuation due to ITE is associated with poor treatment 
effectiveness, a patient’s decision to withdraw from an antipsychotic trial remains 
unpredictable and may occur even when the investigator observes a global clinical 
improvement and is satisfied with treatment.   






Overall attrition rates in randomized, controlled trials (RCT) in schizophrenia frequently 
exceed 50% and appeared to increase with 1% with each publication year in the period from 
1960 to 2000.1  As a result, trials have become increasingly inefficient, and sample sizes need 
to correct for this in order to preserve sufficient power. Better knowledge and understanding 
of the underlying factors contributing to drop-out (e.g., baseline characteristics, trial 
procedures, and treatment effects) could be helpful to improve clinical trial design and 
completion rates.  
Patients’ withdrawal of consent (WOC) and investigator-rated insufficient therapeutic 
effect (ITE) are commonly observed in RCT with antipsychotics. In several large-scale, long-
term, antipsychotic RCT conducted during the last decade, drop-out rates due to WOC varied 
between 29% and 40%.2-5  Despite a consistently high percentage of drop-out due to WOC 
among patients with schizophrenia participating in RCT, the underlying reasons causing a 
participant to withdraw from a clinical study have, to the best of our knowledge, never been 
systematically investigated. Can WOC perhaps be associated with, and regarded as a form of 
poor compliance that is so commonly seen in schizophrenia patients? In daily practice, 
treatment of schizophrenia is often challenged by various degrees of treatment disengagement 
or non-adherence.6  Adherence rates in schizophrenia are substantially lower than the 
adherence rates in other, chronic (and potentially life-threatening) conditions. The median 
non-adherence rates to antipsychotics typically range from 40 to 55%7,8 and lack of insight 
and poor satisfaction with treatment have repeatedly been identified as major determinants.8-12  
However, also subjective well-being has been shown to exert a separate, independent 
influence on compliance, irrespective of the presence of clinical symptoms.13-15  In contrast, 
the severity of baseline psychotic symptoms, illness duration, the presence of mood symptoms 
(or diagnosis of schizoaffective disorder), inpatient status, history of substance abuse, and 
socio-demographic variables have yielded mixed results regarding associations with non-
adherence.12  
Poor treatment response, leading to drop-out, occurs on average around 20% in long-term 
RCTs in schizophrenia.2,3,16  Upon study discontinuation, investigators are usually requested 
to record the single most important reason for drop-out. This can be either lack of efficacy, 




This raises the question, what makes a patient decide to withdraw from a trial when 
investigators are satisfied with the efficacy and tolerability of the treatment. It is also of 
interest to know the extent to which trial discontinuation due to WOC and ITE is specifically 
associated with a poor satisfaction with treatment of patients (PST) and of investigators (IST).  
Factors earlier described as being possibly associated with patients’ satisfaction with 
treatment included measures of ‘distress,' ‘subjective well-being,' and ‘functional outcome’.17-
20 Several longitudinal studies reported a positive association between the amelioration of 
depressive symptoms and a patient’s subjective well-being or quality of life.21-24  
Interestingly, in standardized interviews, patients diagnosed with schizophrenia did not highly 
rank depressive thoughts and emotions as a priority treatment goal, whereas physicians 
particularly attached value to improved cognitive abilities and reduction of disease-related 
symptoms.18  Although factors determining satisfaction with treatment have become a 
research topic of growing interest, the majority of studies in this area so far have considerable 
limitations such as a small sample size, open-label treatment, and weighted selection of 
respondents towards those who have good experiences in survey analysis.17,25-27   
In an attempt to identify determinants of drop-out in RCTs, we extracted baseline data and 
treatment results from a large-scale, multiregional RCT for a posthoc analysis. We 
hypothesized, that drop-out due to ITE is primarily the result and reflection of a clinician’s 
satisfaction with treatment and decision to discontinue, whereas drop-out due to WOC is 
primarily the result and reflection of a patient’s satisfaction with treatment and decision to 
discontinue. We further hypothesized that IST and PST are driven by partly different 





A 52-week, double-blind, randomized, active-controlled, two-armed, multi-regional study was 
designed to explore the long-term efficacy and safety of asenapine in comparison with 
olanzapine in a large sample of patients diagnosed with schizophrenia or schizoaffective 
disorder (registered under number NCT00212784 at ClinicalTrials.gov). The posthoc analysis 
reported here relies on the baseline data and treatment effects from all participants in this 




study, except those who had never received treatment with antipsychotics before. Details of 
the underlying study design and entry criteria have been described elsewhere.28    
Study participants 
Twelve-hundred-twenty-five  in-patients  and out-patients fulfilling criteria for schizophrenia 
(SCZ) or schizoaffective disorder (SAD) according to the Diagnostic and Statistical Manual 
of Mental Disorders (4th ed, text rev.; DSM-IV-TR, American Psychiatric Association, 2000) 
were enrolled across 102 sites in Europe, Russia, Australia, and South Africa. They all 
received up to 52 weeks double-blind, double-dummy treatment with asenapine (5-10 mg bid) 
or olanzapine (10-20 mg qd).29  Eighty-three of them had never been on antipsychotics before 
and were excluded from the current analysis because satisfaction with treatment was 
measured in comparison with treatment received before (see below). From the remaining 
1142 enrolled patients with a non-first episode of schizophrenia or schizoaffective disorder, 
six were not further treated after screening, leaving a total of 1136 participants for evaluation. 
Outcome measures 
For all study participants not completing the 52 weeks double-blind treatment, investigators 
were instructed to record the single most important reason for drop-out, selecting from the 
following list: (1) adverse event or serious adverse event (including hospitalization related to 
worsening of disease), (2) lack of efficacy, (3) lost to follow-up, (4) withdrawal of consent, or 
(5) other reason. Patients who dropped out due to lack of efficacy or due to the serious 
adverse event ‘hospitalization, related to worsening of disease’ were considered as one group 
(i.e., dropping out due to ITE). Asymmetry in the data did not allow considering patients lost 
to follow-up (LFU) and patients withdrawing consent (WOC as one group, with PANSS total 
scores showing a mean reduction (at the last assessment prior to drop-out) of approximately 
30 points in the LFU group versus 14 in the WOC group and less than 1 points in patients 
dropping out due to lack of efficacy or hospitalization due to worsening. The WOC group, 
therefore, consisted only of patients who withdrew consent.  
For the assessment of satisfaction with treatment (PST and IST), patients and investigators 
were asked to rate their satisfaction with treatment in comparison with previous medication 
administered for their disease on a five-point Likert scale, ranging from (1) much worse to (5) 




Drop-out due to WOC and drop-out due to ITE were used as dependent variables in 
multiple regression models, exploring the extent to which these specific outcomes could be 
predicted by particular baseline characteristics and treatment results. In a subsequent step, 
using similar multiple regression models, the influence of specific symptom dimensions, 
subjective well-being, and health impairment on satisfaction with treatment among patients 
and investigators was explored. 
 
Outcome predictors 
To explore the influence of patient characteristics on outcome, the following baseline data 
were collected: gender, level of education (# years), marital status (with or without a partner), 
recent substance abuse (graded as abstinence, use without impairment, abuse, or dependence), 
diagnostic subtype (SCZ or SAD), number of years symptoms were present, hospitalization 
status (in- or out-patient), disease severity, and randomized treatment received. We 
additionally collected individual patient data for factors earlier described to be associated with 
drop-out due to lack of efficacy or treatment disengagement, including clinical improvement, 
level of insight,  occurrence of side effects (as reflected by the total number of severe adverse 
events with possible, probable, or definitive relationship with treatment according to the 
investigator), satisfaction with treatment, and subjective well-being.8-15  
Variables were assessed and considered to collectively predict outcome in the current 
analysis as follows. Disease severity and change from baseline were rated by the clinician on 
the Clinical Global Impression – Severity (CGI-S) and - Improvement (CGI-I) subscales.30  
Together with IST scores and the occurrence of disturbing side effects, CGI-I ratings were 
considered as indices of clinician-rated treatment response, or ‘effectiveness.' Individual 
symptom severity was rated by clinicians on the 30-item PANSS.31  The item scores were 
clustered into five dimensions of core disease symptoms following Kelly et al. 32: (1) the 
negative component (including the items ‘conceptual disorganization’, ‘blunted affect’, 
‘emotional withdrawal’, ‘poor rapport’, ‘social apathy’, ‘lack of spontaneity’, ‘motor 
retardation’, ‘active social avoidance’); (2) the positive component (‘delusions’, 
‘hallucinations’, ‘grandiosity’, ‘suspiciousness’, ‘unusual thought content’); (3) the 
disorganized component (‘conceptual disorganization’, ‘stereotyped thinking’, ‘mannerism 
and posturing’, ‘disorientation’, ‘poor attention’, ‘lack of insight’, ‘preoccupation’); (4) the 
excited component (‘excitement’, ‘hostility’, ‘uncooperativeness’, ‘poor impulse control’); 




and (5) the emotional distress component (‘anxiety’, ‘guilt’, ‘tension’, ‘depression’). Cluster 
scores on these components at endpoint, together with the occurrence of disturbing side 
effects, were considered as indices of clinician-observed psychopathology, or ‘illness.' The 
clinician-rated PANSS cluster scores and patient self-ratings on two separate instruments 
were used to confirm the earlier observations that patients attach more value to the 
amelioration of impairment and the allevaiation of distress, whereas investigators attach more 
value to the amelioration of cognitive abilities and positive symptoms.17-20  Scores on PANSS 
item G12 ‘lack of judgment and insight’ and PST were used as indices of a patient’s 
‘treatment engagement.' Patient self-ratings on the Subjective Well-being under Neuroleptic 
treatment (SWN) scale and the physical and mental component scales of the Medical 
Outcomes Study 12-Item Short Form (SF-12) health survey were considered as indices of 
disease as experienced by the patient, or ‘impairment’.33,34  Above described indices of 
‘effectiveness’ and ‘treatment engagement’ were entered into the regression models 
predicting drop-out, whereas the indices of ‘illness’ and ‘impairment’ were entered into the 
regression models predicting satisfaction with treatment.   
Compliance was assessed by the clinician through pill-counts of returned medication at 
each follow-up visit and ranked as ‘excellent’ when deviating not more than 5%, 
‘satisfactory’ when deviating not more than 25%, and ‘poor’ when deviating more than 25% 
of prescribed dosages over the entire treatment period. Although it seemed to make sense to 
include measurements of compliance as an index of ‘treatment engagement’ in the regression 
models, since clinicians judged compliance satisfactory in more than 95% of cases and 
excellent in more than 70% of cases, these rankings were not considered informative enough 
to include them as possible predictors of any of the outcome variables. 
Preselected predictor variables were tested for independence and relevance through 
correlational analysis, whereby a Pearson correlation coefficient between variables of 0.25 or 
higher (at a statistical significance level of p<0.05) was considered to be meaningful. 
Predictor variables showing lowest correlation with other predictor variables and highest 
correlation with one or more of the outcome variables (WOC, ITE, PST, or IST) were 
preserved for the regression models. Thus, a trade-off was made between available indicators 
of medical history (e.g., age vs. years symptoms present, alcohol vs. substance abuse), 
efficacy (e.g., CGI-I vs. PANSS total score change from baseline, treatment duration, 




safety (e.g., related, severe vs. serious or moderate AEs, AEs of any intensity or relationship 
with treatment, weight gain, or extrapyramidal symptoms). All analyses were carried out 
using SPSS (Windows) Version 23.0. 
 
Regression models and analyses 
The independent (baseline and treatment response) variables were split into blocks and 
entered in a hierarchic multiple regression procedure according to the chronological order in 
which they became available. Adjusted R2 was used as a measure of determination of the 
models, and change in R2 as a measure of improvement obtained by adding the variables of 
the subsequent blocks. Sociodemographics (gender, education, marital status) were entered 
first, followed by details of medical history (substance abuse, DSM-IV diagnosis, disease 
duration, hospitalization status), baseline severity (CGI-S), and treatment received in steps 
two to four. As there were no meaningful predictors identified in the analysis of the first four 
models (containing demographics, medical history, baseline severity, and treatment), blocks 
one to four were combined into one in the final regression analyses and referred to as model I 
comprising all ‘risk factors.' In subsequent steps, variables measuring ‘effectiveness’ and 
‘engagement,' or  ‘illness’ and ‘impairment’ were entered as predictors of drop-out (WOC, 
ITE) or satisfaction with treatment (PST, IST) respectively, and referred to as models II and 
III. Missing values were excluded pair-wise, and preliminary analyses were conducted to 




Baseline characteristics, treatment response, and outcome 
Descriptive statistics and intercorrelations of baseline characteristics are presented in Table 1. 
Mean total PANSS score at baseline was 92 (range 50-146), indicative of a population of 
markedly ill patients.35  A minority of the participants was diagnosed with schizoaffective 
disorder (SAD=159, 14.0%) and the great majority with schizophrenia (SCZ=977, 86.0%). A 
total of 491 participants (43.2%) completed one-year double-blind treatment. As shown in 
Fig. 6.1, overall attrition was 20.0% during the first six weeks, gradually increasing over time 




to 56.8% after 52 weeks of treatment. Main reasons for study discontinuation over the entire 
treatment period were ITE (n=260, 22.9%) and WOC (n=235, 20.7%).  
Descriptive statistics and intercorrelations of efficacy and safety parameters are presented 
in Table 6.2. CGI-I endpoint scores indicate that 45% percent of the participants were 
considered to have at least minimally improved at endpoint, 23% to have minimally worsened 
or not changed, and 10% to have worsened much or very much since the onset of their 
treatment. The majority of participants (67.1%) experienced no, or only mild adverse events, 
whereas 78 participants (6.9%) experienced one or more severe adverse event, at least 
possibly related to treatment (AE). In 156 cases, PST or IST scores were not available, 
leaving 980 participants for a cross-comparison of satisfaction with treatment.  
Whereas there were no meaningful intercorrelations between baseline characteristics, a 
moderate correlation between the SF-12 mental component and PANSS emotional factor 
scores (r = -0.37, p<0.01) was observed. Also, SWN total scores showed a moderate 
correlation with CGI and PANSS factor scores, and fairly high correlation with SF-12 
physical (r = 0.40) and SF-12 mental (r = 0.46) component scores. Intercorrelations between 
CGI and PANSS factor scores were substantial to very high (range r = 0.47-0.80). 
 
Factors associated with trial discontinuation   
The results of the hierarchical multiple regression analyses are summarized in Tables 6.3a and 
6.3b. The extent to which drop-out due to ITE could be predicted on the basis of treatment 
response was moderate (R2 = 0.383). A relatively high baseline severity and lack of 
improvement on CGI, as well as the lack of insight at endpoint (PANSS item G12) and a poor 
investigator’s satisfaction with treatment, were found to be significant predictors of study 
discontinuation due to ITE. Drop-out due to ITE appeared to be positively associated with a 
patient’s satisfaction with treatment (standardized β = 0.144, p<0.001). 
The extent to which drop-out due to WOC could be predicted was very modest (R2 = 
0.112). Mild illness at baseline and a poor patient satisfaction with treatment were identified 
as significant predictors (albeit with a very weak power). Drop-out due to WOC appeared to 
be positively associated with an investigator’s satisfaction with treatment (standardized β = 
0.260, p<0.001). The occurrence and frequency of severe side effects were not predictive for 






Fig 6.1   
Drop-out (%) over time (weeks) by reason (insufficient therapeutic effect, withdrawal of consent, adverse event, 
lost to follow-up, or other) 
 
Factors associated with satisfaction with treatment   
Almost 60% of the variance in IST and more than 40% of the variance in PST could be 
explained by by the full model (steps I-III). Occurrence of severe side effects was only 
marginally associated with IST (standardized β = -0.078, p=0.001) and not at all with  PST 
(standardized β = -0.040, p=0.127). High scores on the various PANSS factors predicted poor 
satisfaction with treatment, although the disorganized factor was found to have a modest, but 
significant effect on IST only (standardized β = -0.107, p=0.032) and not on PST 
(standardized β = -0.070, p=0.224). The PANSS positive factor had the strongest association 
with IST (standardized β = -0.293, p<0.001), whereas PST was more strongly predicted by the 
PANSS emotional distress factor (standardized β = -0.267, p<0.001). A relatively mild illness 
at baseline and diagnosis of SAD contributed negatively to satisfaction with treatment, 
although these two variables together only explained around 7% of the variance in IST and 
around 3% of the variance in PST.  Patient self-ratings did not show any significant effect on 
IST, but the SF-12 Physical and Mental component scores appeared a significant predictor for 
PST (although only explaining 1% of the variance when the other variables had been 
accounted for). 






The aim of the present study was to identify major determinants of trial discontinuation in a 
multiregional RCT. We hypothesized that patients and investigators attach different value to 
the effects of treatment and that poor patient satisfaction is the leading cause of WOC, 
whereas poor investigator satisfaction is the leading cause of ITE. Results were in line with 
our hypotheses: drop-out due to ITE and WOC showed strongest association with IST and 
PST respectively, whereby the PANSS positive and excited factor scores at endpoint were the 
main determinants of IST, and the PANSS emotional factor score the main determinant of 
PST. 
  As expected, drop-out due to ITE was most strongly associated with poor treatment 
effectiveness. In contrast, drop-out due to WOC appeared difficult to predict, and was not 
meaningfully associated with attenuated clinical improvement, the occurrence of severe side 
effects, or a patient’s lack of insight. Considering WOC as an ultimate form of treatment non-
adherence, our results failed to corroborate the findings of naturalistic studies that lack of 
insight has a negative impact on drug compliance or treatment adherence.36,37  Neither do our 
results confirm that undesirable side effects are a major contributor to WOC or PST, as could 
have been expected on the basis of surveys held among patients and psychiatrists.26,38,39  The 
present findings are also not in line with the earlier observations of Perkins et al. (2008), 
showing that poor treatment efficacy and tolerability are predictors of poor medication 
adherence, and that both - in combination – are associated with an increased likelihood of 
discontinuation against medical advice.40  Both Perkin’s and our study entailed secondary 
analyses of a flexible-dose, 52-week RCT with antipsychotics in patients diagnosed 
(according to DSM-IV criteria) with schizophrenia or schizoaffective disorder, concomitantly 
allowing for adjunctive medication such as benzodiazepines and anticholinergics. Main 
differences between the two RCTs were that in Perkins’s study the predictor analysis was 
done in first-episode patients (excluded from our analysis), a lower percentage of participants 
completed one-year treatment (29.8% vs. 43.2%), and more participants withdrew consent 
(28.8% vs. 20.7%). Adherence to prescribed drug intake was 50% to 75% in Perkins study, 
and presumably lower than the adherence rates observed in our study.  
Although differences in completion rates and adherence between the two studies may 




treatment effects or expectations among first-episode patients compared to more chronic 
patients. It is intriguing that, although drop-out due to ITE was positively associated with poor 
treatment effectiveness, there was a remarkable trend visible in our data for a negative 
association between drop-out due to WOC and CGI-I, suggesting a tendency towards 
improvement rather than worsening among participants withdrawing consent. This is in line 
with the recognition by psychiatrists that patients feeling better and thinking that their 
medication is no longer necessary are important causes of medication discontinuation in 
schizophrenia.38 
IST and PST were not influenced to a similar extent by the perceived or experienced 
severity of symptoms in specific domains. Whereas IST was most strongly associated with 
severity of ‘positive symptoms’ at discontinuation and (to a lesser extent) side effects, PST 
was predicted best by the severity of ‘emotional distress’ and, to a lesser extent, experienced 
impairment in functioning. The presence of mood symptoms, as reflected by a diagnosis of 
SAD, had a modest negative effect on both IST and PST. 
These results are in line with earlier findings demonstrating that investigators and patients 
weigh the merits of antipsychotic treatment in partially different ways. For example, Fervaha 
and co-workers found that change in overall illness severity, as determined by clinicians, was 
not interchangeable with patients’ view of improvement of their illness status. In their study, 
change in positive psychotic symptoms was the strongest predictor of clinician-rated illness 
severity scores, whereas improvement in depressive symptoms was the strongest predictor of 
improvement in illness severity, as rated by the patient.41,42  These findings, together with our 
results, concord with the interview findings of Kuhnigk et al., demonstrating that clinicians 
are primarily focused on psychotic symptom control while patients diagnosed with 
schizophrenia rank fewer depressive thoughts and emotional distress of highest importance as 
a treatment goal.18     
The strengths of our study are the relatively large sample size, the inclusion of diverse 
populations from multiple regions in which the RCT was executed, the reliable investigator 
ratings, and the relatively high level of compliance. More than one thousand patients were 
enrolled across three continents. There may have been various reasons for patients to 
participate, including economic (health insurance) reasons, poor response to previous 
treatment, and social reasons, each having a potential impact on overall motivation to stay in 
the trial. Region-specific differences in the main reason to participate may have been 




mitigated through the wide sample of patients enrolled. Although the assessment of adherence 
through pill-counts is not always reliable and may underestimate medication non-adherence, 
compliance was satisfactory in the large majority of participants and substantially better than 
could normally be expected on the basis of commonly reported poor adherence rates to 
prescribed antipsychotics.7,8,43  Last but not least, all investigators were required to participate 
in an inter-rater training program before trial execution, ensuring all PANSS items were 
evaluated according to pre-defined criteria. 
There are also several limitations inherent to our approach:  (1) The original study was not 
designed to demonstrate the disparity in satisfaction with treatment among investigators and 
patients. Neither were investigators required to justify recorded reasons for discontinuation or 
trained to base their choice of primary reason on objective criteria. (2) Although results seem 
to confirm the validity of our assumption that poor patient satisfaction is the leading cause of 
WOC and poor investigator satisfaction is the leading cause of ITE, they have to be 
interpreted with caution since our evaluation method did not allow us to discriminate between 
cause and effect. More precisely, satisfaction with treatment was assessed after 
discontinuation, but a patient’s and/or investigator’s disappointment may well have preceded 
the decision to discontinue and even may have been its prime reason (regardless of overall 
clinical effectiveness). (3) IST and PST were used as independent variables in the predictive 
models for drop-out, although both showed substantial overlap in the overall dataset. The 
same variables were also used as dependent variables in the predictive models for satisfaction 
with treatment, although we did not correct for multiplicity. (4) Regarding the use of PANSS 
factors as indicators of symptom severity in the different domains, it must be noted that 
underlying symptom clusters were derived from a single scale, designed to assess the severity 
of illness in its entirety. This may explain the relatively strong associations between factor 
scores so that results obtained should be considered as merely indicative and requiring 
confirmation in follow-up research. (5) Since participants in RCT may strongly differ from an 
epidemiologic sample, results of this RCT may not be generalized to the average practice 
population of patients suffering from schizophrenia. (6) Extrapyramidal side effects and 
weight gain have repeatedly been identified as contributors to antipsychotic discontinuation.44 
Although separate scales for the assessment of depressive symptoms, social functioning, 
extrapyramidal symptoms, and weight gain had been used in the present study, the overall flat 




regression models. Instead, we included the more generic PANSS factor scores and 
occurrence of severe AEs as main measures of psychopathology and tolerability. Our results 
can therefore not rule out, that specific symptoms (such as akathisia or weight gain) strongly 
influenced satisfaction with treatment and drop-out.  (7) Use of SWN and SF-12 as measures 
of impairment has its limitations because it may prove difficult to obtain completed forms or 
reliable entries on these in the case of severe psychopathology. The relatively high variance in 
endpoint scores on these self-rated instruments (even among the almost five hundred 
participants completing the study) may be a reflection of that difficulty and could well have 
been prohibitive for identifying SWN or SF-12 scores as strong predictors of satisfaction with 
treatment. 
In conclusion, our findings suggest that poor investigator satisfaction with treatment is the 
leading cause of an investigator’s decision to discontinue medication, and additionally is 
closely related to poor treatment effectiveness, whereas a patient’s decision to withdraw from 
an antipsychotic trial, although slightly associated with poor patient satisfaction with 
treatment, is rather unpredictable on the basis of the clinician-rated clinical improvement. 
Emotional distress appears to have a relatively strong impact on patients’ satisfaction with 
treatment, so that close monitoring of, and adequate measures to mitigate stress factors might 
somewhat reduce the chance for patients to withdraw consent. These measures could include 
efforts by the clinician to (1) foster a positive relationship with patients, encouraging patients 
to continue treatment as soon as improvement occurs, (2) promptly identify depressive and 
anxious feelings at onset, and (3) provide supportive treatment for these symptoms if 
necessary. Family members and caregivers may also be actively involved in the plan of care, 
ensuring a tension-free environment in which the patient lives, and adequately supporting a 
patient whenever habituation to new circumstances is necessary.   
 
Ethical standards 
All participants provided written informed consent for the collection, processing, analysis, 
and reporting of their anonymous medical information as necessary for scientific purposes, 
including use in future medical or pharmaceutical research, prior to their inclusion in the 
study. The RCT was approved by the appropriate ethics committees and therefore performed 
in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its 
later amendments.   
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Comparison of drugs across two ethno-
geographical regions in depression 
 
Demonstration of equal efficacy & safety as to avoid repeat studies 1 
  
                                                 
1 This chapter was published as: 
 Murasaki, M. (h.c.), Schoemaker, J., Miyake, M.., Gailledreau, J., Heukels, A.J., Fennema, H.P., Sitsen, J.M.A. 
(2010).  
Comparison of efficacy and safety of mirtazapine versus fluvoxamine in Japanese and caucasian patients with 
major depressive disorder. Japanese Journal of Clinical Psychopharmacology, 13,339-355 







Introduction: Primary aim was to demonstrate non-inferiority of mirtazapine compared to 
fluvoxamine, using a 2 points margin of difference in summary score change from baseline on 
the first 17 items of Hamilton Depression Rating Scale (HAMD17) in- and outside Japan. 
Secondary objective was to compare the safety profile of both mirtazapine in Japanese (J) and 
Caucasian (C) patients. 
Methods: A randomized, double-blind, 6-week, multi-center trial was conducted with flexible 
doses of mirtazapine (15-45 mg/day) and fluvoxamine (50-150 mg/day) in patients suffering 
from major depressive disorder in Japan and Europe.  
Results: In total 402 patients (20-73 years) were randomized and treated, of which 199 on 
mirtazapine (J=96, C=103), and 203 on fluvoxamine (J=98, C=105). A clinically significant 
decrease in mean HAMD17 total score was observed on mirtazapine (-14.3) and fluvoxamine 
(-13.6). The observed -0.7 points difference in HAMD17 total score change from baseline in 
favor of mirtazapine was not statistically significant, but allowed a conclusion of non-
inferiority. There was a tendency for Japanese patients to respond slightly better to 
mirtazapine, and for Caucasian patients to respond slightly better to fluvoxamine, but the 
herewith presumed treatment*region interaction was not statistically significant (P=0.075) 
and a possible result of random variation. Mirtazapine was characterized with a faster onset of 
action as compared to fluvoxamine. Both drugs were generally well tolerated. Mirtazapine 
was associated with a higher frequency of somnolence in Japanese patients, whereas 
fluvoxamine was associated with a higher incidence of nausea in both Japanese and Caucasian 
patients.  
Conclusion: Mirtazapine was shown to be non-inferior to fluvoxamine in the treatment of 
major depressive disorder. Both drugs were well tolerated with some adverse events being 
almost exclusively reported in Japanese patients and some in Caucasian patients. 
 
  






Because of improved tolerability as compared to tricyclic antidepressants (TCA), selective 
serotonin reuptake inhibitors (SSRIs) have taken their place in the first line treatment of major 
depressive disorder.1-3  One of the first SSRIs entering the market was fluvoxamine, available 
in many countries throughout the world and available in Japan since 1999. Although 
fluvoxamine is an effective antidepressant, its clinical use is associated with frequent 
occurrence of gastro-intestinal disorders (e.g. nausea) and the requirement of careful 
administration because of drug interaction caused by its cytochrome P450 (CYP1A2, 2D6, 
and 3A) inhibitory activity.4-6 
Mirtazapine is a novel antidepressant with specific antagonistic activity against central α2-
autoreceptor and 5-HT2 and 5-HT3 receptors.
7,8 The blockade of presynaptic α2-autoreceptor 
causes an increased release of noradrenalin. The subsequent excitation of postsynaptic α1-
adrenoceptors mediates 5-HT cell firing and the direct blockade of inhibitory α2-
heteroreceptors located on 5-HT terminals facilitate serotonergic neurotransmission. The 
effect of the released serotonin is exerted only via 5-HT1A receptors, since 5-HT2 and 5-HT3 
receptors are blocked by mirtazapine. Since mirtazapine has low Ki for CYP1A2, 2D6, and 
3A (Ki: 41-210 µM), drug interactions observed with fluvoxamine are not expected.9-11 
In the clinical development program the antidepressant activity of mirtazapine had been 
demonstrated to be superior to that of placebo, comparable to that of amitriptyline and other 
currently available tricyclic antidepressants (TCAs), and superior to that of trazodone.12-20 In 
addition, non-inferiority to SSRIs (sertraline，paroxetine，citalopram and fluoxetine) had 
been demonstrated.15,21-23   So far, none of these trials with mirtazapine had been performed in 
Japanese patients, so that additional studies were deemed required before mirtazapine could 
be allowed to the market as antidepressant in Japan.  
In order expand the registration of mirtazapine to Japan, an active-controlled study was 
considered useful as to demonstrate the effectiveness of mirtazapine in the Japanese 
population, while at the same time offering the possibility for adequate treatment to all trial 
participants. Since at the time of study design fluvoxamine was the only SSRI approved for 
first line treatment for depression in Japan, fluvoxamine was chosen as active comparator in a 
non-inferiority setting. Centers in Europe were included to allow comparison of results 





unequivocally demonstrated that mirtazapine is not inferior to fluvoxamine in both 
populations, and equally well tolerated in Japanese as it is in Caucasians, results from the full 
clinical development program of mirtazapine in Caucasians might be considered equally 
relevant for the treatment of depression in Japan, and in support of its allowance in this 
region. In other words, it was anticipated that on the basis of a single bridging study, 
extrapolation of clinical data obtained in foreign countries was possible and could satisfy the 
requirements for pre-registration evidence in Japan, without conducting one or more 
supplementary (placebo-controlled) studies.  
Here we report on the results from a non-inferiority, randomized, double-blind, multi-
center trial, comparing the outcome of six weeks, flexible-dose treatment with mirtazapine 
(15-45 mg/day) and fluvoxamine (50-150 mg/day) in depressed outpatients across Japan and 
Europe. Efficacy was primarily compared using the summary score on the first 17 items of the 
Hamilton Depression Rating Scale (HAMD17) by end of treatment (last observation carried 







The objectives of the study were (1) to compare the efficacy of mirtazapine and fluvoxamine 
in the treatment of major depressive disorder, and (2) to compare the safety profile in terms of 
adverse event (AE) patterns on both drugs in Japanese and Caucasian patients. 
A sample of 400 patients (200 patients for each treatment group) was considered adequate 
to establish non-inferiority of mirtazapine. One hundred patients for each group (200 in total) 
were to be recruited in Europe; the other half of the patients (100 patients for each group, 200 
in total) were to be recruited in Japan. 
Patients were eligible for enrolment when they (1) were at least 20 years but not older 
than 75 years of age at the time of screening; (2) fulfilled the DSM-IV criteria for a Major 
Depressive Episode (DSM-IV diagnosis: 296.2x or 296.3x); (3) showed a minimum score of 
18 on HAM-D17 at screening and baseline; (4) had the present episode of depression for at 




least two weeks but no longer than 12 months; (5) were willing to provide written informed 
consent.  
Patients were excluded from study participation when they (1) suffered from any medical 
condition or required concomitant treatment that would confound study results or put the 
patient at increased risk of treatment failure or unacceptable adverse events; (2) were 
hospitalized or required hospitalization at screening or baseline; (3) were pregnant or 
lactating; (4) were women of childbearing potential while not practicing a reliable method of 
contraception; (5) had a score of 3 or more on the HAMD item [11] ‘suicide’; (6) had a 
history or present condition of bipolar disorder, schizophrenia or psychotic symptoms, 
schizotypal or borderline personality disorder, or organic mental disorder; (7) had a present 
condition of anxiety disorder (according to DSM-IV), eating disorder, postpartum depression, 
epilepsy or history of seizure disorder, or ever received treatment with anticonvulsant 
medication for epilepsy or seizures, alcohol or substance abuse (according to DSM-IV) during 
the last six months; (8) had any clinically meaningful non-stable renal, hepatic, cardiovascular 
respiratory, cerebrovascular disease or other serious, progressive physical disease; (9) had any 
clinically meaningful abnormal finding uncovered during the physical examination, ECG 
and/or clinically significant abnormal laboratory results at screening; (10) had participated in 
other clinical trials within the last three months; (11) had received any of the following 
treatments (within the indicated intervals between brackets) before the start of active 
treatment: non selective MAO inhibitors or lithium (three weeks), depot neuroleptics (three 
months), other psychotropics (two weeks), ECT (three months), or other investigational drugs 
(three months); (12) had a body mass index greater than 30 or less than 18; (13) had a known 
allergy or hypersensitivity to mirtazapine or fluvoxamine; (14) had been treated during the 
present episode with either mirtazapine or fluvoxamine; (15) required treatment with 
terfenadine, astemizole, warfarin, theophylline, or cisaprid; (16) received concurrent treatment 
for a micturition disorder. 
The study was conducted in compliance with the Declaration of Helsinki, Good Clinical 
Practice (GCP), and other ordinance. Before the start of screening, written informed consent 
was obtained from each participant after the investigator, or another appropriate individual 
who was designated by the investigator, had informed the subject about the nature and 







The study was a randomized, double-blind, multicenter, flexible dose, parallel group study. 
Randomization to treatment was stratified within center. Patients fulfilling all inclusion 
criteria and violating none of the exclusion criteria were randomly allocated to six weeks 
treatment with mirtazapine once daily, or to six weeks treatment with fluvoxamine twice 
daily. Mirtazapine was to be dosed in the evening (at approximately 21:00 hours). 
Fluvoxamine was to be dosed in the morning after breakfast and in the evening (at 
approximately 21:00 hours). The study drugs were administered using a double-dummy 
technique to guarantee blinding to treatment. During the first week of treatment, patients 
allocated to mirtazapine were to receive a daily dose of 15 mg. Patients allocated to 
fluvoxamine were to receive 25 mg in the morning and 25 mg in the evening. If, after one 
week of treatment, there was insufficient response to the medication (as defined by a decrease 
of less than 20% on the HAM-D17 total score from baseline) and tolerability was acceptable, 
the investigator was allowed to increase the daily dose to either 30 mg mirtazapine or 100 mg 
fluvoxamine. From the third week onwards, provided tolerability remained acceptable and 
response was still not satisfactory in the opinion of the investigator, the dosage could be 
further increased to either 45 mg mirtazapine or 150 mg fluvoxamine. In case of tolerability 
problems, the dosage could be reduced again. However, a lower dose than the minimal 
starting dose was not allowed. The total daily dose, therefore, could vary between 15 mg and 
45 mg for mirtazapine, and between 50 mg and 150 mg for fluvoxamine. Clinical assessments 
were carried out at the screening visit, the baseline visit, and at weekly intervals during the 




The difference in change from baseline on HAMD17 by treatment was used as the primary 
outcome variable. The rating scale actually used in this trial was the semi-structured, 
anchored, 21-item version as described by Williams.24  All participating investigators attended 
a training session to standardize its use. Efficacy was also assessed using the Clinical Global 
Impression scale (CGI), which consists of a seven-stage rating of the severity of the illness 
within the preceding two days (CGI-S), and a global seven-stage ratings of the change in 
clinical status since the start of treatment (CGI-I).25  This scale was completed at baseline 




(only for severity), and at all further assessments during the treatment period (days 7, 14, 21, 
28, 35, and 42 with an allowance for each visit after baseline of ±2 days). 
 
Safety 
ECG and physical examinations were evaluated at screening and at day 42 (or as soon as 
possible after premature discontinuation). Routine laboratory tests were performed at 
screening, day 14 and day 42 (or as soon as possible after premature discontinuation). 
Information regarding AEs was to be obtained by questioning or examining the patient at each 
visit during the treatment period. AEs were also collected from spontaneous reporting. 
 
Statistical analysis 
The primary objective was to establish non-inferiority of mirtazapine versus fluvoxamine at 
endpoint (EP) of treatment on the change from baseline on HAMD17 summary score. 
Mirtazapine was considered non-inferior if the upper limit of the 95% CI of the difference 
between the two treatments was less than 2.0 points. Only patients who were randomized and 
treated with active medication, and who had a baseline measurement and at least one post-
baseline efficacy measurement were included in the efficacy analysis (Intent-To-Treat, or ITT 
group). The estimate of treatment effect and corresponding (two-sided) 95% confidence 
intervals was based on the additive two-way ANOVA with factors for treatment and region. 
Region was defined as the geographical region of centers in Japan (Hokkaido, five centers; 
Saitama, four centers; Tokyo, seven centers; Kanagawa, nine centers; Shin-Etsu, three 
centers, Western Japan, six centers) and countries in Europe (Denmark, four centers; France, 
three centers; Belgium and the Netherlands, six centers; Norway, four centers; Spain, three 
centers). Note that by adding region the analysis was automatically stratified for ethnicity. A 
test for treatment by region interaction was planned by extending the model with the 
interaction term. In case of a significant interaction (p ≤ 0.10) the differences between the 
regions with respect to the treatment effects were to be presented, discussed and further 
explored to evaluate whether it was still justified to present an overall estimate of the 
treatment effect. To investigate treatment differences between Japanese and Caucasian 
patients, an additive two-way ANOVA with a factor for treatment, ethnic group (Japanese and 





Response was defined by least 50% reduction in HAMD17 score from baseline to EP, and 
a score of <3 (‘much’ or ‘very much improved’) on CGI-I. 
For comparison of safety within (by region) and between treatment groups, adverse event 
frequencies and observed laboratory values outside the reference range are listed for all 
subjects who were randomized and treated with active medication (All-Subjects-Treated, or 
AST group). 
In order to explore heterogeneity between treatment groups, demographics and baseline 
characteristics were tabulated by drug and overall (pooled across ethnic groups). In addition, 
analyses of covariate adjustment for baseline factors with treatment imbalances at baseline 
(i.e. gender and disease condition) were performed for CGI-S, HAMD17, and HAMD Factor 
VI ‘sleep disturbance’ scores. 
For the evaluation of safety, descriptive statistics in the ITT group were calculated for 
adverse events, laboratory parameters, physical examinations, vital signs and ECG results. No 
inferential tests were performed. 







From a total of 434 patients who were screened for eligibility, 412 patients were randomized 
to treatment between August 2000 and March 2002. Because of GCP violation at one site in 
Japan, nine of these patients (five on mirtazapine, and four on fluvoxamine) were excluded 
from further analysis. From the remaining 403 randomized patients, one patient on 
mirtazapine dropped out before having taken any trial medication, leaving 402 patients in the 
all-patients-treated (AST) group. In five patients efficacy was not assessed after baseline, so 
that 397 patients remained available in the ITT group for efficacy analysis. Overall, both 
treatment groups were comparable with respect to number of allocated patients (Figure 7.1).   
The average baseline characteristics by treatment and region are provided in Tables 7.1a 
and 7.1b. Most remarkable differences were that in Japan, patients had a lower body mass 
index, appeared less severely depressed (as reflected by baseline HAMD17 and CGI-S scores), 




and were more frequently of male gender compared to the patients in Europe. Age and 
duration of the present episode of depression was similar between and within treatment 
groups. 
Exposure was comparable between and within treatments groups (Table 7.2). Mean 
duration of exposure was 36.7 days on mirtazapine (Japanese: 34.9 days, Caucasian: 38.4 
days) and 37.5 days on fluvoxamine (Japanese: 35.9 days, Caucasian: 39.0 days). The mean 
daily dose (SD), including the 1st-week fixed-dose period was 21.0 (7.7) mg for mirtazapine 
(Japanese: 19.2 (8.5) mg, Caucasian: 22.7 (6.5) mg) and 78.5 (26.3) mg for fluvoxamine 
(Japanese: 78.9 (29.8) mg, Caucasian: 78.1 (22.6) mg) (Table 7.2). There were no major 
differences in dosing between the two ethnic groups. Overall compliance with the intake of 







Disposition of subjects 





The percentage of patients who prematurely discontinued the study was 22.7% for 
Japanese (mirtazapine: 24.0%, fluvoxamine: 21.4%) and 19.7% for Caucasians (mirtazapine: 
21.4%, fluvoxamine: 18.1%). Due to premature discontinuations, the percentage of patients 
receiving the drug for 10 days or less in Japanese patients (mirtazapine: 15.6%, fluvoxamine: 


















Gender      
    Female 70 (68.0%) 67 (63.8%) 49 (51.0%) 38 (38.8%) 224 (55.7%) 
    Male 33 (32.0%) 38 (36.2%) 47 (49.0%) 60 (61.2%) 178 (44.3%) 
Age (years      
    Mean (SD) 42.0 (12.1) 39.4 (12.7) 41.3 (13.2) 42.2 (12.8) 41.2 (12.7) 
    Range 20 - 69 20 - 71 20 - 72 20 - 73 20 - 73 
Height (cm)      
    Mean (SD) 169.5 (9.6) 169.7 (8.2) 163.2 (8.2) 164.2 (9.7) 166.8 (9.4) 
    Range 147 - 192 153 - 190 146 - 182 142 - 186 142 - 192 
Body weight (kg)      
    Mean (SD) 68.6 (12.1) 68.4 (12.4) 59.5 (9.5) 60.9 (11.0) 64.5 (12.1) 
    Range 45.0 - 106.0 44.0 - 102.0 40.2 - 88.0 38.0 - 89.8 38.0 - 106.0 
Body mass index [kg/m2]      
      Mean (SD) 23.7 (3.1) 23.7 (3.4) 22.3 (2.7) 22.5 (2.9) 23.0 (3.1) 
      Median (range) 23.3 (18 - 30) 23.3 (17 - 33) 22.0 (18 - 30) 22.4 (17 - 29) 22.6 (17 – 33) 
BMI by region Caucasian (n=205) Japanese (n=194)  
    Mean (SD) 23.7 (3.3) 22.4 (2.8)  
    Median (range) 23.3 (17 - 33) 22.2 (17 - 30)  
DSM-IV diagnosis      
    296.2 (single episode) 











Duration present episode      
    2 weeks - 1 month 
    1 - 6 months 
    6 - 12 months 







































HAMD17       
    Mean (SD) 25.1 (3.67) 25.1 (4.09) 22.7 (3.36) 22.6 (3.90) 23.9 (3.95) 
    Range 19 - 38 18 - 40 18 - 31 16 - 34 16 - 40 
    Distribution       
        < 18  0 (0.0%)  0 (0.0%) 0 (0.0%)  1 (1.0%)   1 (0.3%) 
        18, <25 50 (49.5%) 49 (47.1%) 72 (75.8%) 72 (73.5%) 243 (61.1%) 
        25 51 (50.5%) 55 (52.9%) 23 (24.2%) 25 (25.5%) 154 (38.7%) 
HAMD17 by region Caucasian (n=205) Japanese (n=193)  
    Mean (SD) 25.0 (3.75) 22.6 (3.63)  
    Range 18 - 40 16 - 34  
    Distribution    
        < 18   0 (0.0%)    1 (0.5%)  
        18, <25   99 (48.3%) 144 (74.6%)  
        25 106 (51.7%)   48 (24.9%)  
CGI-S      
    mildly ill 2 (2.0%)  3 (2.9%) 14 (14.7%) 16 (16.3%) 35 (8.8%) 
    moderately ill 31 (30.7%) 38 (36.5%) 62 (65.3%) 66 (67.3%) 197 (49.5%) 
    markedly ill 58 (57.4%) 49 (47.1%) 17 (17.9%) 15 (15.3%) 139 (34.9%) 
















Daily dose (mg)     
Mean (SD) 19.2 (8.5) 78.9 (29.8) 22.7 (6.5) 78.1 (22.6) 
Median (range) 15 (0 - 38) 88 (17 - 126) 24 (10 - 38) 82 (16 -139) 
Daily dose by treatment  Mirtazapine (n=196) Fluvoxamine (n=202) 
Mean (SD) 21.0 (7.7) 78.5 (26.3) 
Median (range) 22 (0 - 38) 83 (16 - 139) 
Exposure (days)     
Mean (SD) 34.9 (14.1) 35.9 (12.4) 38.4 (10.7) 39.0 (9.8) 
Median (range) 42 (1 - 45) 42 (1 - 44) 42 (1 - 50) 43 (2 - 46) 
Exposure by treatment Mirtazapine (n=196) Fluvoxamine (n=202) 
Mean (SD) 36.7 (12.5) 37.5 (11.2) 







The percentage of dropouts for drug-related reasons (i.e. adverse events or lack of 
efficacy) was 10.8% in Japanese vs. 14.9% in Caucasians (Table 7.3). Adverse drug 
experiences were cause for premature termination in 12.1% of mirtazapine-treated patients 
and 7.9% in fluvoxamine-treated patients. There were no relevant differences in dropout rates 
or reason for dropout between treatment groups.  
 
Table 7.3 
Premature discontinuations by reason 
Single most important 
reason 













n % n % n % n % n % n % 
Adverse event  10 10.4 5 5.1 15 7.7 14 13.6 11 10.5 25 12.0 
Study violation    1   1.0 1 1.0   2 1.0   0   0.0   0   0.0   0   0.0 
Poor cooperation    2   2.1 2 2.0   4 2.1   6   5.8   3   2.9   9   4.3 
Lack of efficacy    2   2.1 4 4.1   6 3.1   2   1.9   4   3.8   6   2.9 
Other reason(s)   8   8.3 9 9.2 17 8.8   0   0.0   1   1.0   1   0.5 




In the pooled patient population, clinical improvement was evident in both treatment groups, 
with no statistically significant differences between drugs administered. The primary 
objective of non-inferiority of mirtazapine versus fluvoxamine at endpoint was met with an 
estimate of -0.69 (with a 95% confidence interval of -2.17 to 0.78) which was below the non-
inferiority margin of 2.0 points. No statistically significant treatment by geographical region 
interaction was observed (P=0.406), suggesting that there was no significant difference in the 
treatment effect of both compounds across geographical regions (Table 7.4). The mean 
decrease in HAMD17 total score on mirtazapine was similar in Japanese and Caucasian 
patients (-13. 8 and -14.4, respectively). On the other hand, the mean decrease in HAMD17 
total score on fluvoxamine was higher in Caucasian patients than in Japanese patients (-15.1 
and -11.7, respectively). Japanese patients seemed to respond slightly better to mirtazapine, 
whereas Caucasian patients slightly better to fluvoxamine, but the herewith presumed 
treatment*region interaction was not statistically significant (P=0.075) and a possible result of 
random variation. 
When comparing mirtazapine versus fluvoxamine on HAMD17 total score change from 
baseline by time of assessment, a greater extent of reduction was observed in the mirtazapine 




group than in the fluvoxamine group in the early stages of the trial, with statistically 
significant differences at day 7: -1.97 (P<0.001) and day 14: -1.86 (P=0.001) (Figure 7.2, 
Table 7.5). This pattern was similar in both the Japanese and Caucasian populations. The data 
suggest an earlier onset of action by mirtazapine. 
The HAMD responder rates (50% reduction on HAMD17 total scores) in the ITT 
population at EP were comparable for mirtazapine (64.8%) and fluvoxamine (61.4%) (Table 
7.6). The responder rate in Japanese was higher on mirtazapine (69.5%), but lower on 
fluvoxamine (55.1%) compared to the responder rates in Caucasians (60.4% and 67.3 % 
respectively). 
The CGI responder rates were similar for mirtazapine as compared to fluvoxamine with a 
similar tendency of early response as observed on HAMD17 (Table 7.7). In the fluvoxamine 
group, there was an apparent difference in responder rates between Caucasians and Japanese 
with a more pronounced responder rate in Caucasians (72.1% and 55.1% at EP, respectively) 
which was not observed in the mirtazapine group (62.4% and 60.0% at EP, respectively). 
 
Safety 
Adverse events reported for at least 5% of the patients in either treatment group during the 
treatment period (+5 days) are shown by WHO preferred term including causal relationship to 
the study drug as assessed by the investigator in Table 7.8.  
The most frequently reported adverse events (AEs) in patients treated with mirtazapine 
were somnolence (28%) (Japanese: 44%, Caucasians: 13%), followed by dizziness (12%) 
(Japanese: 9%, Caucasians: 14%), thirst (11%) (Japanese: 22%, Caucasians: 1%), headache 
(11%) (Japanese: 12%, Caucasians: 10%), nausea (8%) (Japanese: 6%, Caucasians: 10%), 
weight increase (8%) (Japanese: 6%, Caucasians: 10%), malaise 7% (Japanese: 15%, 
Caucasians: 0%), fatigue 7% (Japanese: 0%, Caucasians: 14%), and constipation 7% 
(Japanese: 13%, Caucasians: 2%).  
AEs occurring in at least 5% of the subjects of a treatment group are listed in Table 7.8 by 
system-organ class and relationship to trial medication (in which “related” is judged by the 
investigator as definitely, probably, possibly or unlikely). The safety profile of fluvoxamine 
differed from mirtazapine with increased incidences of gastro-intestinal system disorders, in 
particular nausea, diarrhea, dyspepsia and abdominal pain. Also upper respiratory tract 





included more pronounced incidences of somnolence malaise/fatigue, increased 
weight/appetite, and dry mouth/thirst.  
The overall incidence of adverse events tended to be higher in Japanese than in 
Caucasians on both drugs. Notable differences in the distribution of drug-related adverse 
events between ethnic groups included a higher incidence (regardless of treatment) of 
somnolence, thirst, dyspepsia, and hypoaesthesia, but lower incidence of nausea, dizziness, 
diarrhea, and increased appetite in Japanese patients. None of the Caucasians reported drug-
related malaise or constipation, while drug-related fatigue was reported by 12.6% of the 
Caucasian patients but by none of the Japanese patients. 
For five patients serious adverse events were reported during the treatment period. For one 
Japanese patient a suicide attempt was reported while on fluvoxamine treatment. For 
European patients on mirtazapine two cases of aggravated depression and a suicide attempt 
and a case of vaginitis were reported; for one patient on fluvoxamine an aggressive reaction 




HAMD17  total score change from baseline by treatment and region (ITT, LOCF)  
 LS mean SE d 95% CI P 
By treatment      
Mirtazapine -14.26 
0.75 -0.69 -2.17 - 0.78 0.406 
  Fluvoxamine -13.57 
By region      
    Japan   
-2.73 -5.73 - 0.28 0.075 
                       Mirtazapine -13.77 0.78 
                       Fluvoxamine -11.71 0.77 
    Europe   
                       Mirtazapine -14.39 0.76 
                       Fluvoxamine -15.06 0.75 
By treatment per region      
    Japan      
                       Mirtazapine -13.77 
1.113 -2.06 -4.25 - 0.14 0.066 
                       Fluvoxamine -11.71 
    Europe      
                       Mirtazapine -14.39 
1.049 0.67 -1.40 - 2.74 0.523 
                       Fluvoxamine -15.06 
 
LS = least square; SE = standard error; d = estimated difference; CI = confidence interval; P = probability of significance 
 
 





HAMD17 total score change from baseline over time by treatment and region (ITT, LOCF) 
 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 
By treatment       
      Mirtazapine -5.7  5.16 -9.1  5.86 -11.0  6.70 -12.0  7.08 -13.4  7.26 -14.2  7.37 
      Fluvoxamine -3.7  4.51 -7.3  6.13 -10.0  6.49 -11.6  7.20 -12.6  7.60 -13.6  7.82 
d -1.97* -1.86* -1.09 -0.38 -0.89 -0.71 
   (95% CI) (-2.90, -1.03) (-3.00, -0.72) (-2.34, 0.16) (-1.78, 1.01) (-2.34, 0.55) (-2.19, 0.76) 
By region 
   Japan 
      Mirtazapine -6.0  4.89 -9.1  5.71 -10.3  6.40 -12.0  6.76 -13.2  7.03 -14.1  7.14 
      Fluvoxamine -3.4  4.57 -6.8  5.96 -8.9  6.55 -10.4  7.35 -11.1  7.78 -12.0  7.97 
d -2.60* -2.38* -1.51 -1.71t -2.33* -2.27* 
   (95% CI) (-3.91, -1.29) (-4.01, -0.75) (-3.35, 0.33) (-3.72, 0.31) (-4.44, -0.22) (-4.42, -0.12) 
   Europe 
      Mirtazapine -5.4  5.40 -9.2  6.03 -11.7  6.93 -11.9  7.40 -13.6  7.49 -14.4  7.61 
      Fluvoxamine -3.9  4.47 -7.8  6.27 -10.9  6.31 -12.7  6.91 -14.0  7.18 -15.1  7.41 
             d -1.38* -1.38 -0.70 0.84 0.42 0.72 
  (95% CI) (-2.71, -0.05) (-2.98, 0.22) (-2.42, 1.02) (-1.09, 2.77) (-1.56, 2.41) (-1.30, 2.73) 
 
d = estimated difference between treatments; CI = confidence interval 
* = P < 0.05 






Frequency distribution of HAMD17 responders (ITT group, LOCF and EP approach) 
 
Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 EP 
n % n % n % n % n % n % n % 
  By treatment               
      Mirtazapine 21 10.8 63 32.5 99 51.0 101 52.1 120 61.9 127 65.5 127 64.8 
      Fluvoxamine 18 9.0 51 25.5 88 44.0 109 54.5 111 55.5 124 62.0 124 61.4 
  By region               
     Japan               
      Mirtazapine 12 12.9 34 36.6 50 53.8 54 58.1 60 64.5 66 71.0 66 69.5 
      Fluvoxamine 11 11.5 23 24.0 38 39.6 45 46.9 46 47.9 54 56.3 54 55.1 
     Europe               
      Mirtazapine 9 8.9 29 28.7 49 48.5 47 46.5 60 59.4 61 60.4 61 60.4 











Mean change  SE from baseline HAMD17 by treatment over time (ITT group) 






Mean change  SE from baseline HAMD17 by treatment and time (ITT group) in Japan 
* P < 0.05 (ANOVA) 
 
 






Mean change  SE from baseline HAMD17 by treatment and time (ITT group) in Europe 




Frequency distribution of CGI responders (ITT group, LOCF and EP approach) 
 
Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 EP 
n % n % n % n % n % n % n % 
  By treatment               
      Mirtazapine 34 17.5 71 36.6 100 51.5 102 52.6 118 60.8 120 61.9 120 61.2 
      Fluvoxamine 22 11.0 59 29.5 83 41.5 106 53.0 118 59.0 129 64.5 129 63.9 
  By region               
     Japan               
      Mirtazapine 13 14.0 31 33.3 43 46.2 46 49.5 52 55.9 57 61.3 57 60.0 
      Fluvoxamine 7 7.3 25 26.0 31 32.3 41 42.7 45 46.9 54 56.3 54 55.1 
     Europe               
      Mirtazapine 21 20.8 40 39.6 57 56.4 56 55.4 66 65.3 63 62.4 63 62.4 
      Fluvoxamine 15 14.4 34 32.7 52 50.0 65 62.5 73 70.2 75 72.1 75 72.1 
  
 
Within the fluvoxamine treatment group, discontinuations were predominantly due to AEs 
of the category psychiatric disorders (e.g. mood changes) or gastro-intestinal system disorders 
(e.g. nausea). Discontinuations on mirtazapine were predominantly due to AEs of the category 
psychiatric disorders (e.g. sleepiness) or central and peripheral nervous system disorders (e.g. 
dizziness). Neither of the two antidepressants appeared to cause clinically relevant changes in 





evaluations. No clinically significant abnormal values were observed for biochemistry 
parameters, haematocrit, hemoglobin, or platelet counts in either of the treatment groups. 
Plasma cholesterol values above 1.2 times the upper normal limit were observed in 12% of 
mirtazapine treated, and in 10% of fluvoxamine treated patients at endpoint, but increased 
plasma cholesterol levels were in most cases already present before treatment.  
 
Table 7.8 
Adverse events occurring in ≥5% of patients in at least one treatment group (in %) 














    
ADR1) 
    AE     
ADR1)
    AE     
ADR1)
    AE     
ADR1)
    AE     
ADR1) 
    AE     
ADR1)
    AE
Patients with ≥1 AE   68.4 77.6    61.9  65.7   65.0 71.4   78.1 80.2   51.5 57.3   64.3 68.3 
Somnolence 21.4 21.4 10.5 10.5 15.8 15.8 43.8 43.8 12.6 12.6 27.6 27.6 
Nausea 16.3 18.4 28.6 29.5 22.7 24.1 4.2 6.3 9.7 9.7 7.0 8.0 
Thirst 14.3 15.3 1.9 1.9 7.9 8.4 20.8 21.9 1.0 1.0 10.6 11.1 
Malaise  3.1 3.1 0.0 0.0 1.5 1.5 13.5 14.6 0.0 0.0 6.5 7.0 
Fatigue 0.0 0.0 14.3 14.3 7.4 7.4 0.0 0.0 12.6 13.6 6.5 7.0 
Constipation 14.3 15.3 0.0 0.0 6.9 7.4 12.5 12.5 1.0 1.9 6.5 7.0 
Dizziness 4.1 5.1 12.4 13.3 8.4 9.4 9.4 9.4 13.6 13.6 11.6 11.6 
Headache 8.2 12.2 13.3 13.3 10.8 12.8 9.4 11.5 9.7 9.7 9.5 10.6 
RTI 0.0 13.3 0.0 2.9 0.0 7.9 0.0 5.2 0.0 1.0 0.0 3.0 
Weight  0.0 0.0 6.7 6.7 3.4 3.4 6.3 6.3 9.7 9.7 8.0 8.0 
Appetite  0.0 0.0 4.8 4.8 2.5 2.5 2.1 2.1 9.7 9.7 6.0 6.0 
Diarrhea 6.1 8.2 8.6 8.6 7.4 8.4 1.0 2.1 3.9 3.9 2.5 3.0 
SGPT  2.0 2.0 0.0 0.0 1.0 1.0 8.3 8.3 0.0 0.0 4.0 4.0 
Dyspepsia 7.1 7.1 1.0 1.0 3.9 3.9 1.0 2.1 0.0 0.0 0.5 1.0 
Mouth dry 0.0 0.0 5.7 6.7 3.0 3.4 1.0 1.0 4.9 4.9 3.0 3.0 
Hypoaesthesia 1.0 1.0 0.0 0.0 0.5 0.5 6.3 6.3 0.0 0.0 3.0 3.0 
Abdominal pain 6.1 6.1 2.9 2.9 4.4 4.4 1.0 2.1 1.9 1.9 1.5 2.0 
Sweating  2.0 2.0 5.7 5.7 3.9 3.9 0.0 0.0 2.9 2.9 1.5 1.5 
Insomnia 0.0 0.0 4.8 5.7 2.5 3.0 5.2 5.2 1.0 1.0 3.0 3.0 
SGOT  1.0 1.0 0.0 0.0 0.5 0.5 5.2 5.2 0.0 0.0 2.5 2.5 
 
1) ADR = Assessment of the causal relationship by the investigator: ‘Definitely’, ‘Probably’, ‘Possibly’ or ‘Unlikely’ related.  
RTI = Respiratory tract infection;  = increased. 
 
One Japanese patient treated with mirtazapine discontinued prematurely because due to 
increased values of transaminases, alkaline phosphatase, and creatine kinase. Plasma levels of 
transaminases and creatine kinase were already above normal limits at trial entry so that the 
relationship with trial medication remains undetermined.  
All events of SGOT/SGPT increase were of mild intensity. For most of the patients with 
SGOT/SGPT increase, the event was reported at day 14, with all of the patients recovering 
during the treatment period. Such events did not lead to stopping the trial or AEs related to 




hepatic disorders. For two patients (one for each treatment group), SGOT/SGPT increase was 
reported at the last visit of treatment period (day 42). Both patients recovered until the follow-






The clinical improvement at endpoint in patients treated with mirtazapine and fluvoxamine 
was similar and the primary objective of non-inferiority of mirtazapine versus fluvoxamine as 
assessed by HAMD17 total score was met. The data suggest that mirtazapine has a faster onset 
of action than fluvoxamine. These results are also reflected by responder rates on HAMD17 
and CGI.  
The comparison of efficacy on mirtazapine and fluvoxamine within the ethnic groups 
revealed somewhat different results for the Japanese and Caucasian population. In Japanese 
patients the mean antidepressant effect of mirtazapine was more pronounced, although this 
difference was not statistically significant. On the contrary, in Caucasian patients the mean 
antidepressant effect of mirtazapine appeared slightly less pronounced than that of 
fluvoxamine (Table 7.4). This potential interaction of efficacy with ethnicity was not 
statistically significant within the ITT population, but did reach statistical significance within 
the per-protocol population (consisting of all subjects from the ITT group without any major 
protocol violation, including discontinuation before two weeks of treatment).  
Differences in baseline characteristics between Japanese and European patients do not 
offer a plausible explanation for the observed difference. First, differences are not that 
substantial, as can be seen in Table 7.1. Secondly, at least two characteristics that did differ 
have not been demonstrated predictive of efficacy, i.e., gender and weight differences.26  Most 
importantly, for characteristics to explain discrepant efficacy results, these should not only be 
predictive of efficacy, but also be spread unevenly enough across the studied groups. Japanese 
patients may, for example, experience somewhat higher exposure levels due to an average 
difference in body weight. However, the observed difference of 12% in exposure is still not 
very large, and a clear dose-response relationship has never been established for either 





the response in Japanese on both drugs would be higher than in Caucasians, but the reverse 
seems to hold.  
Another, theoretical explanation for the difference in efficacy could be that mirtazapine as 
compared to fluvoxamine is a more potent antidepressant in Japanese than in European 
depressed patients. However, there is currently no known pharmacological or 
pharmacokinetic basis for this hypothesis. A more likely explanation seems to be that the 
finding is based on coincidence and that the overall results (combining both populations) 
present a fair estimate of the efficacy of mirtazapine as compared to fluvoxamine. It is 
strengthened and supported by the observation that the decrease in HAMD17 total score on 
mirtazapine was similar in Japanese and Caucasian patients (-13.8 and -14.4, respectively), 
but improvement on fluvoxamine in Caucasian patients was higher than in Japanese patients 
(-15.1 and -11.7 points, respectively), and higher than documented in other studies with this 
compound.4,5,27,28 
As indicated in the beginning of results parts, 12 patients were excluded from this study 
analysis. If we include the 12 patients, the decrease in HAMD17 total score on mirtazapine and 
fluvoxamine remains similar in Japanese and Caucasian patients. 
Overall, both drugs were well tolerated. Mirtazapine was associated with a higher 
frequency of somnolence in Japanese patients, whereas fluvoxamine was associated with a 
higher incidence of nausea in both Japanese and Caucasian patients.  
A relatively high incidence of nausea in fluvoxamine treated patients fits the documented 
safety profile of this drug. In previous clinical studies, nausea being the most prominent 
adverse event has been reported in approximately 30-40% of patients treated with 
fluvoxamine.6,29,30  
The average incidence of somnolence on mirtazapine (28%) in this study is of a similar 
magnitude as found in other studies with mirtazapine (11 - 35%).21,22  For unknown reasons, 
somnolence is more frequently reported in Japanese patients (44%) than in Caucasian patients 
(13%). Also on fluvoxamine frequency of somnolence was higher in Japanese than in 
Caucasian patients. In a substantial number of patients experiencing somnolence, the 
symptom disappeared within the first two weeks. 
In the study, ‘SGOT increased‘ or ‘SGPT increased’ was reported as an adverse event for 
only Japanese patients. The intensity of all reported ADRs (Adverse Drug Reactions: 
Assessment of the causal relationship by the investigator: ‘Definitely’, ‘Probably’, ‘Possibly’, 




or ‘Unlikely’ related) were mild and no patients discontinued the drugs due to the ADRs. 
‘SGOT increased’ or ‘SGPT increased‘ is one of the known ADRs of mirtazapine and SSRIs, 
and evanescent SGOT/ SGPT increases were observed in ca 5% of Caucasian subjects in 
overseas studies with miratazapne.14  No marked differences between Japanese and Caucasian 
patients were observed in average SGOT/SGPT levels, allowing the conclusion that changes 
in liver enzymes are not considered to be particular for Japanese patients.  
The increased frequency of adverse events and reported transaminase increases in 
Japanese patients may be due to a more rigorous reporting practice in Japan, and not so much 
indicative of a higher vulnerability of Japanese patients to drug side effects. In particular, 
increases of laboratory values were typically reported as adverse events in Japan (e.g. SGOT/ 
SGPT increased), but were only reported in Europe when considered clinically relevant by the 
investigator (usually only when accompanied by symptoms like jaundice).  
Although some adverse events seem to occur almost exclusively in Japanese or Caucasian 
subjects, the difference in safety profile between both populations might be less prominent 
then it seems. In some cases there seem to be adverse events which were experienced both by 
Japanese and Caucasian patients but which were coded differently. This is quite clear for 
malaise in Japanese patients and fatigue in Caucasian patients. The same phenomenon applies 
to thirst in Japanese patients and dry mouth in Caucasian patients. Such discrepancies may be 
more related to translational issues rather than reflecting a true difference in safety profile in 
the two ethnic groups. 
 
Conclusions  
Both mirtazapine (15-45 mg/day) and fluvoxamine (50-150 mg/day) provided an effective 
treatment for Japanese and Caucasian patients with major depressive disorder where 
mirtazapine was characterized by a faster onset of action. With respect to safety both 
compounds were well tolerated, revealing distinct safety profiles. Mirtazapine was 
characterized by increased incidences of somnolence, dry mouth/thirst and malaise/fatigue, 
whereas fluvoxamine is characterized by increased incidences in nausea, dyspepsia and 
diarrhea. In general, the safety profile of mirtazapine was comparable between Japanese and 
Caucasian patients. Overall there was no indication that Japanese depressed patients respond 









The Mirtazapine Bridging Study Group 
Europe 
P Willemse, Mouscron (Belgium); A de Nayer, Montignies-sur-Sambre (Belgium); P 
Schrøder, Risskov (Denmark); F Bjørndal, Greve (Denmark); O Nielsen, Holstebro 
(Denmark); H Wernlund, Hjørring (Denmark); J de la Gandara, Burgos (Spain); M Franco 
Martin, Zamora (Spain); JR Gutiérrez Casares, Badajoz (Spain); J Gailledreau, Elancourt 
(France); J-P Hervé, Rennes (France); M Salfati, Saint Ouen (France); O-J Høyberg, Alesund 
(Norway); H Rogge, Nestun (Norway); I Eikenaes, Nestun (Norway; O Kavlie, Oslo 
(Norway); T Dammen, Oslo (Norway); M Hompland, Bønes (Norway); G Zwartjes, Tilburg 
(Netherlands); D Kromdijk, Zwolle (Netherlands); R ten Kate, Oldenzaal (Netherlands); D 
van Hyfte, Weert (Netherlands).  
Japan 
Takeshi Inoue, Saporro (Hokkaido); Toshiki Shioiri, Niigata (Niigata); Tsuyoshi Kondo, 
Hirosaki (Aomori); Masahito Fushimi, Akita (Akita); Akihiko Takahashi, Yamato 
(Kanagawa); Hideo Muraoka, Sagamihara (Kanagawa); Fujio Yokoyama, Iruma-gun 
(Saitama); Takami Yagyu, Osaka; Yoshifumi Watanabe, Ube (Yamaguchi); Shunzo 
Watanabe, Hirosaki (Aomori); Yuichi Sato, Kumagaya (Saitama); Shigero Mitsuno, Hofu 
(Yamaguchi); Shozo Fujii, Shimonoseki (Yamaguchi); Yoshio Igarashi, Chichibu (Saitama); 
Ikuo Kudo, Yokohama (Kanagawa); Masashi Yasui, Sagamihara (Kanagawa); Shinano Isawa, 
Kawasaki (Kanagawa); Hirofumi Wakatabe, Chigasaki (Kanagawa); Yasuyuki Kawakami, 
Oume (Tokyo); Keiichi Kumagai, Niigata (Niigata); Kazuhiko Nakayama, Minato-ku 
(Tokyo); Hiroo Kasahara, Kashiwa (Chiba); Ryoichi Ikeda, Shinjyuku-ku (Tokyo); Nobuhiko 
Ishii, Yokohama (Kanagawa); Shun Yamazumi, Kofu (Yamanashi); Koichi Yamada, 
Yokohama (Kanagawa); Michiya Sugawara, Ota-ku (Tokyo); Teruhiko Higuchi, Ichikawa 
(Chiba); Masahiro Ishikawa, Fujisawa (Kanagawa); Masatsugu Nagao, Kure (Hiroshima); 
Masahiro Nankai, Chiyoda-ku (Tokyo); Noriaki Kataoka, Chitose (Hokkaido); Motofumi 
Fukahori, Fukuoka (Fukuoka); Kazumasa Hirabayashi, Kita Azumi-gun (Nagano). 
Special thanks to Nippon Solvay for providing double-blind fluvoxamine tablets and 
matching placbo.  






1. Devane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Human 
Psychopharmacology: Clinical and Experimental 1995;10(S3):S185-S193. 
2. Entsuah AR, Thase ME. Response and remission rates in different subpopulations with major 
depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. 
Journal of Clinical Psychiatry 2001;62(11):869-877. 
3. Westenberg HG. Pharmacology of antidepressants: selectivity or multiplicity? Journal of Clinical 
Psychiatry 1999;60(suppl 17):4-8. 
4. Feighner JP, Boyer WF, Meredith CH, Hendrickson GG. A placebo-controlled inpatient comparison of 
fluvoxamine maleate and imipramine in major depression. International Clinical Psychopharmacology 
1989;4(3):239-244. 
5. Roth D, Mattes J, Sheehan KH, Sheehan DV. A double-blind comparison of fluvoxamine, desipramine 
and placebo in outpatients with depression. Progress in Neuro-Psychopharmacology and Biological 
Psychiatry 1990;14(6):929-939. 
6. Wagner W, Zaborny B, Gray T. Fluvoxamine. A review of its safety profile in world-wide studies. 
International Clinical Psychopharmacology 1994;9(4):223-228. 
7. De Boer T, Ruigt G, Berendsen H. The α2‐selective adrenoceptor antagonist org 3770 (mirtazapine, 
Remeron®) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology: 
Clinical and Experimental 1995;10(S2):S107-S118. 
8. Haddjeri N, Blier P, de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-
hydroxytryptamine system in the rat brain. Journal of Pharmacology and Experimental Therapeutics 
1996;277(2):861-871. 
9. Dahl M-L, Voortman G, Alm C, Elwin C-E, Delbressine L, Vos R, Bogaards J, Bertilsson L. In vitro 
and in vivo studies on the disposition of mirtazapine in humans. Clinical Drug Investigation 
1997;13(1):37-46. 
10. Störmer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in 
vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metabolism and Disposition 
2000;28(10):1168-1175. 
11. Timmer CJ, Sitsen JA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clinical 
Pharmacokinetics 2000;38(6):461-474. 
12. Bremner JD. A double-blind comparison or Org 3770, amitriptyline, and placebo in major depression. 
Journal of Clinical Psychiatry 1995. 
13. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed 
outpatients. Journal of Affective Disorders 1995;34(3):165-171. 
14. Khan M. A randomised, double‐blind, placebo‐controlled, 5‐weeks' study of org 3770 (mirtazapine) in 
major depression. Human Psychopharmacology: Clinical and Experimental 1995;10(S2):S119-S124. 
15. Leinonen E, Skarstein J, Behnke K, Ågren H, Helsdingen JT, Group NAS. Efficacy and tolerability of 
mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive 
disorder. International Clinical Psychopharmacology 1999;14(6):329-337. 
16. Mullin J, Lodge A, Bennie E, McCreadie R, Bhatt GS, Fenton G. A multicentre, double-blind, 
amitriptyline-controlled study of mirtazapine in patients with major depression. Journal of 
Psychopharmacology 1996;10(3):235-240. 
17. Richou H, Ruimy P, Charbaut J, Delisle J, Brunner H, Patris M, Zivkov M. A multicentre, double‐blind, 
clomipramine‐controlled efficacy and safety study of org 3770. Human Psychopharmacology: Clinical 
and Experimental 1995;10(4):263-271. 
18. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: A 6‐week randomized double‐blind 
multicentre trial in hospitalized depressed patients. Human Psychopharmacology: Clinical and 
Experimental 1995;10(3):173-180. 
19. Van Moffaert M, De Wilde J, Vereecken A, Dierick M, Evrard J, Wilmotte J, Mendlewicz J. 
Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients 
with major depression. International Clinical Psychopharmacology 1995. 
20. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the 





21. Behnke K, Søgaard J, Martin S, Bäuml J, Ravindran AV, Ågren H, Vester-Blokland ED. Mirtazapine 
orally disintegrating tablet versus sertraline: a prospective onset of action study. Journal of Clinical 
Psychopharmacology 2003;23(4):358-364. 
22. Benkert O, Kohnen R. Mirtazapine compared with paroxetine in major depression. Journal of Clinical 
Psychiatry 2000;61(9):656-663. 
23. Wheatley DP, van Moffaert M, Timmerman L, Group M-FS. Mirtazapine: efficacy and tolerability in 
comparison with fluoxetine in patients with moderate to severe major depressive disorder. Journal of 
Clinical Psychiatry 1998;59(6):306-312. 
24. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Archives of 
General Psychiatry 1988;45(8):742-747. 
25. Guy W. Clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology - 
Revised Volume DHEW Publ No ADM 1976;76(338):218-222. 
26. Morishita S, Arita S. Possible predictors of response to fluvoxamine for depression. Human 
Psychopharmacology: Clinical and Experimental 2003;18(3):197-200. 
27. March JS, Kobak KA, Jefferson JW, Mazza J, Greist J. A double-blind, placebo-controlled trial of 
fluvoxamine versus imipramine in outpatients with major depression. Journal of Clinical Psychiatry 
1990;51:200-202. 
28. Norton K, Sireling L, Bhat A, Rao B, Paykel E. A double-blind comparison of fluvoxamine, 
imipramine and placebo in depressed patients. Journal of Affective Disorders 1984;7(3-4):297-308. 
29. Ware MR. Fluvoxamine: a review of the controlled trials in depression. Journal of Clinical Psychiatry 
1996;58:15-23. 



















The development of new drugs is a long-term, costly and risky process, with total 
development time due to a limited patent period being constantly under pressure. In the 
absence of pre-clinical models, which predict the effects of new substances on central nervous 
system disorders with reasonable certainty, the development of new drugs for disorders of the 
central nervous system (CNS), i.e., psychiatric and neurological diseases, is usually more 
difficult than for other indications. In CNS disorders, the development process is also 
hampered by the lack of objective criteria for determining the correct diagnosis and severity 
of diseases. Investigators are therefore required to interpret disease severity by observation 
and (standardized) interrogation of the patient, resulting in a risk of subjective assessment 
errors or bias. Body functions and abnormalities, such as heart rate, blood pressure, endocrine 
disorders, tumor size and bacterial infections, can usually be measured more objectively with 
relatively high accuracy or can be simply assessed through the use of biomarkers such as the 
concentration of certain substances in the blood. When determining the presence of 
depression or the seriousness of a psychosis, and when measuring treatment results in such 
conditions, there is still much room for interpretation. Taken together, absence of pre-clinical 
models, biomarkers, and objective assessment criteria slow down the development of CNS 
products, and may explain the relatively higher costs (on average 18%, or about 100 million 
euros), longer time (on average 37%, or about two years), and lower chance of success (on 
average 50% less, or only 1 instead of 2 out of 12 experimental products reaching the finish 
line) associated with the development of drugs for psychiatric versus somatic diseases. More 
details can be found on this in Chapter 1. It is therefore not surprising that the pharmaceutical 
industry, on the one hand, is continually seeking more efficient methods of research for the 
development of CNS drugs and, on the other hand, withdraws more and more from this field 
because the costs no longer outweigh overall revenues. 
In this dissertation, some strategies for early and late stage development of antidepressants 
and antipsychotics are presented, all configured and tested with the aim to reduce costs and/or 
increase the chance of success, thereby accelerating the total development time of new 
products. In Chapter 2, the disturbing effect of placebo response on efforts to establish the 
efficacy of new products, and factors potentially contributing to placebo response in 
antidepressant trials are reviewed. If in double-blind studies, patients respond well to 
treatment with placebo (i.e., a substance with no specific activity), it is difficult to 
demonstrate that an investigational product (i.e., active ingredient) is effective against the 




condition for which it is tested. A high placebo response easily leads to failure of a study, 
requiring it to be re-performed as long as there is belief in the product and hope for better 
results. In depression studies, in particular, placebo response is a significant problem, and 
researchers have been trying to explain and identify the main factors contributing to placebo 
response in this disease for many years. Usually, through meta-analysis of results from 
independent RCTs, calculating the overall likelihood of improvement or response of patients 
randomized to placebo, or trial success rate under different settings. The results of all known 
meta-analyses published so far are listed in Chapter 2 and compared with each other. It 
appears that such (inappropriately called) "meta-analyses," not rarely produce conflicting 
results, and provide little insight into which patient characteristics or test methods facilitate or 
attenuate response to placebo. Prospective studies, exploring clinical improvement in patients 
treated with placebo under certain conditions might be more useful for the identification of 
predictors of placebo response. However, such studies are extremely costly and difficult to 
execute because of medical and ethical dilemmas when patients are deliberately kept from 
effective treatment. In conclusion, after 25 years of re-analyzing previous studies, we still 
have to accept the fact that response to placebo is unpredictable. Luckily, for the medical 
treatment of patients, it does not matter what the cause of the clinical improvement is. Any 
contribution to a good outcome of treatment is welcome here: whether it is caused by the drug 
itself, by hopeful expectations, or other aspects makes no difference in clinical practice.1   
Chapter 3 shows the practical example of an early stage, double-blind, placebo-controlled 
study in which, under most stringent test conditions and with sophisticated analysis 
techniques, as little as possible is left to chance to show that treatment augmentation with a 
new drug is effective against the (often difficult to measure) negative symptoms of 
schizophrenia (such as retardation, apathy, and the inability to express or recognize emotions). 
The usage of (1) second opinion, (2) separate assessment scales for allowing suitable patients 
to the study on the one hand, and measuring clinical efficacy on the other, as well as (3) 
analysis methods whereby primary treatment effects are discriminated from secondary effects, 
helps to provide a clear answer to the question as to whether treatment augmentation is useful 
or not. The glycine uptake inhibitor with the codename Org 25935 barely distinguished itself 
from placebo in this trial, so that further development of this product was deemed pointless 
and the project abandoned. A competitive company, which examined a compound with 





significant improvement on placebo at the lowest dose tested) in parallel.2  However, their 
studies were devoid of aforementioned, sophisticated techniques, so that stakeholders in that 
company decided it was worth to embark on the subsequent conduct of large-scale Phase III 
studies. After investment of an estimated $100 million, there was still no convincing evidence 
of the product’s effectiveness collected, so that further research was discontinued.3,4  This 
shows that the implementation of advanced methods, although costly, can be of great value 
for a timely discontinuation of fruitless development programs, especially when 
investigational products exhibit a novel mechanism of action. 
In Chapter 4, results from a large-scale, Phase III study are described, conducted under 
more or less ‘naturalistic’ conditions, whereby most patients are allowed to participate when 
meeting appropriate diagnostic criteria. In earlier research phases, patients are frequently 
excluded from study participation, especially when using certain (legal or illegal) 
psychotropic drugs, suffering from a chronic disease or infection, or any other condition that 
might put a participant at increased risk for drug interactions or side effects, compromise 
compliance, or complicate the collection of clean data and interpretation of research results. 
The advantage of a naturalistic study is that its results can be regarded as more representative 
for daily practice than when large groups of patients had to be excluded. On the other hand, it 
may also be detrimental to the sponsor of the study if the results appear to be less successful 
than expected. We see this happening in the study in Chapter 4, where the efficacy and 
tolerability of asenapine seem somewhat less promising in comparison with those of the 
market leading product olanzapine (except for the relatively high risk of weight gain on the 
latter). It is not surprising that reviewers, key opinion leaders and therapists look at the results 
of such large studies very critically, and are inclined to adhere more value to these than to the 
so-called pivotal, placebo-controlled studies, which are usually performed on a significantly 
smaller scale in more or less 'clean' patients.5  Finally, a naturalistic study may be an 
additional valuable source of information for the identification of potential factors 
predisposing to poor response or increased vulnerability to side effects, such as severity and 
duration of disease prior to treatment, young or high age, drug abuse, etc.. 
In order to meet the demand for continued use of a promising investigational product after 
a patient’s participation in a study, it is not unusual to carry out a so-called humanitarian 
treatment continuation according to the protocol after completion of the main study period. 
An additional advantage of such an approach is that patients are more likely to participate in 




the main study, facilitating the conduct of extensive studies within a restricted time frame. 
The alternative, allowing treating physicians compassionate use of a new remedy prior to 
registration for patients who respond poorly to already available medication, is less attractive 
due to regulatory, medical-ethical, and market-strategic constraints. After all, with 
compassionate use potential side effects will be collected under poorly controlled conditions, 
and physicians may get biased against the product before the new drug is placed on the 
market. Chapter 5 summarizes trends observed in a humanitarian extension of a study that 
was earlier presented in Chapter 4. It is interesting to see that the percentage of patients 
withdrawing from the study in both treatment groups is comparable, although in the asenapine 
group more adverse reactions are reported, and more comedication is prescribed. Also 
interesting to see is that the on average 5 kg increase in body weight within the olanzapine 
group appears irreversible, whereas body weight increase in the asenapine group is not only 
much more limited (on average 1 kg) but even shows a trend to disappear during prolonged 
treatment. Standardized documentation of this type of data would not have been possible on 
the basis of compassionate use and is relevant to any physician detecting first signs of weight 
gain in a patient after treatment start. After all, with long-term use of antipsychotics, 
metabolic disorders that result in weight gain are an important risk factor for diabetes and 
secondary cardiovascular problems.6  
Study drop-out as a result of poor efficacy, tolerability, or compliance, should always be 
anticipated and compensated for by adequate sample sizes. Drop-out tends to be high in 
clinical trials involving patients with schizophrenia, who may withdraw their consent for 
voluntary participation at any moment. As a result, not only measures to increase the 
motivation of patients to participate but also precautions to avoid drop-out are important 
means to enhance the efficiency of studies and reduction of development costs. The latter 
requires insight into the primary drivers of patient satisfaction with experimental treatment. In 
Chapter 6, a post-hoc analysis of patient data from the in Chapter 4 reported study seeks to 
provide an answer to the question why many participants in schizophrenia studies withdraw 
prematurely, often despite initial signs of good response. Large-scale, naturalistic studies are 
particularly useful for this kind of exploratory research because, unlike in a sample of 
independent studies, all patients receive the same treatment under similar conditions. 
Unfortunately, no explanation could be found for this phenomenon, so that study continuation 





When a sponsor seeks market expansion for a currently registered product within the 
region where the guidelines of the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) are endorsed, one 
can rely on the E5 Directive on Acceptance Of foreign data.7  Ideally, records of results 
obtained elsewhere can be used to apply for registration in the new region, provided it is made 
likely (on basis of a bridging study) that ethnic differences will not influence the efficacy and 
safety profile established elsewhere. This prevents unnecessarily high investment and 
repetition of steps. A bridging study was conducted with the antidepressant Remeron® 
(mirtazapine) to obtain registration in Japan after the drug had been registered in the United 
States and Europe. The study was primarily designed to demonstrate non-inferiority of 
mirtazapine at doses varying between 15 and 45 mg/day in comparison with fluvoxamine at 
doses between 50 and 150 mg/day in Japanese and Caucasian patients with major depressive 
disorder. The results are described in Chapter 7. A bridging study is successful when the 
effectiveness and adverse event profile of the test product at particular dose level(s) overlap 
with the drug’s efficacy & safety profile that was earlier established outside the new region. 
Although clinical improvement on mirtazapine was at least as good in Japanese patients as in 
Caucasians, albeit at the expense of a somewhat higher incidence of somnolence, Japanese 
authorities were not immediately convinced that an identical efficacy & safety profile of 
Remeron® would apply across the ethnic regions, and requested an additional placebo-
controlled study with mirtazapine at fixed dose levels. A placebo-controlled, fixed-dose trial 
had been among the initial suggestions for a bridging study, but Japanese co-workers feared at 
that time it would be difficult to recruit patients and/or ethic committees would never approve 
a study in which part of the patients would be kept from adequate treatment. This was an 
expensive judgment error, causing two years of delay in trial registration. Although not 
stipulated as absolute requirements, it shows that in bridging studies it is always preferable to 
test at fixed doses and randomize at least a minority of the patients to placebo to serve as 
control group. 
The studies included in this thesis are just a small grip from the arsenal on possibilities for 
drug research in psychiatry to be as efficient as possible. The central goal in most clinical 
trials is to demonstrate efficacy and response to a trial drug. However, it is often non-response 
that is easier to determine, as it is not always clear when a psychiatric patient feels "better". 
Although drug treatment is primarily aimed at suppressing disease symptoms, patients often 




have hopeful expectations of an improved quality of life at the onset of pharmacological 
treatment. In order to ensure that doctors and patients have the same view of the need for and 
success of treatment, it is important that clinical investigators clearly explain the potential 
benefits and risks of study participation before asking a patient’s informed consent. At the 
same time, patients should be made aware of the fact that a certain level of responsibility and 
sincerity is expected from them as a ‘partner in science’. Till now, investigators are hardly 
trained in adequate or most appropriate methods for obtaining informed consent from their 
patients. More than any other strategy, this could contribute to the participation of motivated 
but also critical patients in clinical trials, the collection of representative and more complete 
datasets, and the increase of drug research efficiency in psychiatric diseases. 
Successful and timely completion of clinical studies depends on many factors, including 
the availability of investigators and patients, their enthusiastic willingness to participate, and 
intensive medical monitoring and follow-up during the conduct of a trial. Since expectations 
among investigators and patients are difficult to control for in an experimental setting, double-
blind randomization is essential. Blinding forms the basis for a fair, and adequate comparison 
of treatment regimes. However, enthusiasm about the promising profile of a new drug, and 
hope for improvement during its use should never be eliminated where it belongs: in clinical 
practice. Given the relatively high response rate on placebo in psychiatric illnesses and vain 
search for its proximate causes, as well as the more robust criteria for ‘non-response’ or 
‘remission’ versus ‘response’, the field might benefit from future efforts directed towards the 
identification of factors predicting poor response on placebo, or (fast) remission on active 
treatment.   
 
Epilogue 
As with most trials conducted within the context of drug development programs, the studies 
presented in Chapters 3, 4, 5, and 7 have no other aim than to provide testimony of the 
experimental drugs’ potential to be further developed and brought to market. Since these 
studies involve three different drugs that are tested in three different indications, it is difficult 
to tie the results and evaluate how these may contribute to scientific or clinical progress. The 
same for the outcome variables 'placebo response' and 'drop-out' (Chapters 2 and 6) that were 
explored in two different ways, and in two different indications (depression and 





implications for trial failure. However, main reasons for trial failure may differ considerably 
between depression and schizophrenia (although this topic is not well explored, to the best of 
my knowledge). The fact that no clear contributors to placebo response (in depression) or 
patient withdrawal (in schizophrenia) could be identified is not really helpful either when we 
want to summarize the overall merits of our work. 
In some way or another, what the studies presented in this thesis do have in common, is 
that the results of none of those appear to have been capable in changing daily clinical 
practice or reforming common approaches taken in drug development. As said, I was unable 
to identify predictors of placebo response in depression or patient withdrawal in schizophrenia 
(Chapters 2 and 6). If one or more predictors would have been found, these would certainly 
be taken into consideration when new studies are to be designed in these indications. Despite 
a meticulous study design and conduct (Chapter 3), including an innovative second-opinion 
evaluation of clinical symptoms and advanced statistics, I was unable to identify a significant 
effect of Org 25935 on negative symptoms in schizophrenia; the small effect that was 
observed appeared to be mainly non-specific, i.e., secondary to changes in positive, general 
psychopathological, depressive, neurocognitive, and extrapyramidal symptoms, and was also 
therefore unimportant. If a specific, statistically significant effect on negative symptoms 
would have been found, it is not unlikely that the innovative, expert-rater assisted score 
evaluation technique that was for the first time used in this trial, would have become more 
broadly adopted in future psychiatric drug trials to reduce bias. Especially, when post-hoc 
evaluations would have shown that effect sizes increased after raters adjusted their 
preliminary scores on the basis of second opinion. In addition, path analytic approaches could 
be more frequently added to the toolbox of drug developers and included in the primary 
analysis of trial results, when it had been demonstrated that the effect on outcome was more 
or less specific in the symptom domain of interest. Unfortunately, in the absence of any 
significant effect, the long-term merits of the innovative study approach remain speculative. 
The results from the studies presented in Chapters 4, 5 and 7 demonstrated that 
experimental treatment with asenapine and mirtazapine was non-inferior to treatment with the 
established drugs olanzapine and fluvoxamine, in schizophrenia and major depression 
respectively. On the other hand, the studies were at the same time not capable of 
demonstrating any meaningful improvement over the established products and did not provide 
new insights into optimized treatment in these psychiatric diseases.  




Nevertheless, despite a genuine lack of potentially influential results, these studies deserve 
as much attention as those with a more positive outcome.  First of all, although the potential 
relevance of the glutamatergic axis in the expression of schizophrenia symptoms appeared 
firmly established, the fact that two companies in row were unsuccessful in demonstrating the 
validity of the concept of GlyT-1 inhibition, is an important warning signal that is worth to 
note.8,9 10-13  The sharing of such negative results through publication may keep a third from 
exposing still more patients in vain to experiments with similar, ineffective drugs. Secondly, 
based on short- and long-term treatment results presented in Chapters 4, 5, and 7, both 
asenapine and mirtazapine could be regarded as useful alternatives for patients experiencing 
unacceptable side-effects from other prescribed drugs.  
The fact that I was not able to identify strong predictors of placebo response or patient 
withdrawal in depression and schizophrenia, makes it not advisable (at this stage) to try 
tweaking the most commonly applied enrolment criteria for clinical trials towards enhanced 
signal detection or trial completion rates, solely on the basis of personal judgment or 
preliminary results from published meta-analyses and surveys in these fields.  The current 
lack of evidence, however, does not necessarily imply that the conduct of meta-analyses for 
detection of new leads in trial optimization is inappropriate and to be entirely abandoned. In a 
recent paper, Cipriani and co-workers (2018) note that future research could seek to combine 
aggregate and individual-patient data from RCT in so-called network meta-analyses.14  They 
express the belief that such analyses might be better suited than currently applied methods to 
allow the prediction of personalized clinical outcomes, including the estimate of comparative 
efficacy or risk for premature discontinuation. There is a common notion that the effect sizes 
of antidepressants and antipsychotics in RCTs are rather modest, suggesting that these drugs 
as a whole are barely more effective than placebo.14,15  Previous work has suggested that 
treatment-naïve patients in their first episode of schizophrenia respond better than chronically 
ill (i.e., earlier treated) patients.16  A similar trend was observed in the naturalistic study that 
we conducted (Chapter 4, data not shown). This holds promises for RCTs involving patients 
in their first episode only, which might show higher effect sizes of drugs versus placebo (at 
least in schizophrenia) than RCTs involving more chronically ill patients. On the other hand, 
first-episode patients may be hard to find or motivate for trial participation, so that this 
population could be of particular interest only when new drugs are tested at relatively small-





evidence of efficacy has not yet been proven, and first-episode patients are hardest to enroll in 
a clinical trial. Thus, although improved patient selection could, in theory, be helpful in drug 
development, the field might still in the future benefit more from integrated data processing 
methods like the network meta-analysis mentioned above. Open access to the data of 
sponsored RCTs may be the most critical prerequisite of the latter approach to become 
successful. The identification of reliable response predictors will allow trials to become 
designed as efficiently as possible to demonstrate the effectiveness of new treatments. 
Although certainly contributing to the replicability of studies and cost savings, whether better 
insight in response mediators can also meaningfully shorten the drug development trajectory 
in neuropsychiatric diseases remains doubtful. That goal may be just too pretentious, as long 
as there are no objective criteria and/or biomarkers for the accurate diagnosis and assessment 
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De ontwikkeling van nieuwe geneesmiddelen is een langdurig, kostbaar en riskant proces, 
waarbij de totale ontwikkelingstijd als gevolg van een beperkte patentduur constant onder 
druk staat. Door het ontbreken van pre-klinische modellen, aan de hand waarvan de effecten 
van nieuwe stoffen op stoornissen in het centrale zenuwstelsel met redelijke zekerheid kan 
worden voorspeld, is de ontwikkeling van nieuwe geneesmiddelen voor psychiatrische en 
neurologische ziekten doorgaans nog lastiger dan die voor andere indicaties. Het 
ontwikkelingsproces wordt bij deze stoornissen met name ook bemoeilijkt door het ontbreken 
van objectieve criteria voor het vaststellen van de juiste diagnose en ernst van een 
aandoening. Onderzoekers zijn derhalve genoodzaakt om aan de hand van observatie en (al 
dan niet gestandaardiseerde) ondervraging van de patiënt zich een beeld te vormen van het 
ziektebeeld, met als gevolg een risico op subjectieve inschattingsfouten. Dit in tegenstelling 
tot het objectief meten van allerlei lichaamsfuncties en afwijkingen, zoals hartslag, bloeddruk, 
endocriene stoornissen, tumorgrootte en bacteriële infecties, die redelijk eenvoudig en met 
grote  nauwkeurigheid kunnen worden gemeten of afgeleid van de concentratie van bepaalde 
stoffen in het bloed. Bij het vaststellen van een depressie of ernst van een psychose, en bij het 
meten van behandelingsresultaten van dergelijke aandoeningen, resteert nog altijd veel ruimte 
voor interpretatie. Bij elkaar genomen zijn deze ongewisse factoren er mede de oorzaak van 
dat bij de ontwikkeling van geneesmiddelen tegen ziekten van het centrale zenuwstelsel de 
klinische fase gemiddeld 18% (ca. 100 miljoen euro) duurder is, 37% (ca. twee jaar) langer 
duurt, en 50% minder kans van slagen heeft (slechts 1 op de 12 stoffen haalt de eindstreep) 
dan bij de ontwikkeling van geneesmiddelen tegen somatische ziekten. Details hierover zijn 
terug te vinden in Hoofdstuk 1. Het is dan ook niet verwonderlijk dat de farmaceutische 
industrie voor de ontwikkeling van geneesmiddelen, die inwerken op het centrale 





en, anderzijds, zich meer en meer terugtrekt uit dit gebied omdat de kosten niet langer 
opwegen tegen de baten.  
In dit proefschrift komen successievelijk een aantal strategieën aan bod die zijn bedacht en 
getest gedurende de vroege en late ontwikkelingfasen van antidepressiva en antipsychotica, 
alle met het oogmerk om de kosten te drukken, de kans op succes te vergroten, en daarmee het 
ontwikkelingstraject te bespoedigen. In Hoofdstuk 2 wordt vooraleerst stilgestaan bij het op 
grote schaal optreden van placebo-respons en de achterliggende redenen hiervoor. Als in 
dubbelblind onderzoek veel patiënten goed reageren op behandeling met een placebo (stof 
zonder specifieke werking) is het lastig om aan te tonen dat een proefmiddel (met actief 
bestanddeel) werkzaam is tegen de aandoening waarvoor het wordt getest. Een hoge placebo-
respons leidt dan al gauw tot het falen van een studie, die dan opnieuw moet worden 
uitgevoerd met de hoop op beter resultaat. Met name in depressie-studies vormt placebo-
respons een omvangrijk probleem, en er wordt al jaren door middel van zogenaamde meta-
analyses gezocht naar factoren die placebo-respons beïnvloeden. De resultaten van alle 
bekende meta-analyses zijn in Hoofdstuk 2 op een rij gezet en met elkaar vergeleken. Daaruit 
blijkt dat de ‘meta-analyses’, zoals die zijn uitgevoerd, in strikte zin niet eens meta-analyse 
mogen worden genoemd, in vele gevallen tegenstrijdige resultaten opleveren, en weinig 
inzicht verschaffen in de patiëntkenmerken of proefmethoden, die de respons op placebo 
faciliteren of juist beteugelen. Prospectieve studies, die het optreden van een placebo-respons 
gericht onderzoeken in subpopulaties van patiënten die met placebo zijn behandeld onder 
bepaalde condities, zouden hier mogelijk een antwoord op kunnen geven. Echter, dergelijke 
studies zijn uiterst kostbaar en lastig uitvoerbaar, omdat er medisch-ethische dilemma’s 
kleven aan het patiënten bewust onthouden van effectieve medicatie. Concluderend kan 
worden gesteld dat men zich, na 25 jaar her-analyseren van oude studies, voorlopig nog zal 
moeten neerleggen bij het gegeven dat respons op placebo onvoorspelbaar is, in plaats van het 
ongebreideld blijven navorsen van factoren die hier mogelijk toe kunnen bijdragen. Voor de 
medische behandeling van patiënten maakt het sowieso niet uit wat de oorzaak van de 
klinische verbetering is. Elke bijdrage aan een goed resultaat van de behandeling is hier 
welkom:  of die nu door het middel zelf wordt veroorzaakt, door hoopvolle verwachtingen, of 
door andere aspecten, maakt geen verschil in de klinische praktijk.1      
Hoofdstuk 3 geeft het praktijkvoorbeeld van een vroege fase, dubbelblinde, placebo-





analysetechnieken, zo weinig mogelijk aan het toeval wordt overgelaten om aan te tonen dat 
toevoeging van een nieuw middel op de bestaande behandeling werkt tegen de (veelal lastig 
herkenbare en te meten) negatieve symptomen van schizofrenie (zoals teruggetrokkenheid, 
apathie, en het gebrekkige vermogen om eigen emoties uit te drukken of die van anderen te 
herkennen). Door het gebruik van (1) second opinion, (2) aparte beoordelingschalen voor het 
toelaten van geschikte patiënten tot de studie enerzijds, en het meten van effecten anderzijds, 
en (3) opsplitsing van primaire en secundaire effecten van behandeling tijdens de analyse, 
wordt een eenduidig antwoord verkregen op de vraag of aanvulling op de bestaande 
behandeling met het nieuwe testmiddel zin heeft of niet. De resultaten laten zien dat de 
glycine opname-remmer met codenaam Org 25935 zich niet of nauwelijks onderscheidt van 
placebo, zodat verdere ontwikkeling van dit middel zinloos werd geacht. Een concurrerend 
bedrijf, dat een stof met eenzelfde werkingsmechanisme onderzocht, verkreeg in diezelfde 
periode vergelijkbare resultaten (zijnde een lichte, bijna statistisch significante verbetering op 
placebo met de laagste, geteste dosis).2  Echter, aangezien het in hun studie ontbrak aan 
verfijnde technieken en mogelijkheden ter vergelijking, zoals gebruikt in de voorbeeldstudie, 
werd door dit bedrijf wel besloten tot grootschalig fase III onderzoek. Na investering van een 
naar schatting 100 miljoen dollar bleek de stof alsnog niet te werken en werd verder 
onderzoek gestaakt.3,4  Dit maakt aannemelijk dat de introductie van geavanceerde 
meetmethoden in de vroege ontwikkeling van een stof weliswaar prijzig is maar van grote 
waarde kan zijn om, later, dure beslissingsfouten te voorkomen, vooral wanneer er sprake is 
van een totaal nieuw werkingsmechanisme van het te testen middel. 
In Hoofdstuk 4 wordt verslag gedaan van een grootschalige fase III studie onder min of 
meer ‘naturalistische’ condities, waarbij patiënten die voldoen aan de diagnostische criteria 
vrijwel allemaal zijn toegestaan om deel te nemen. In vroege onderzoeksfasen worden 
patiënten nogal eens van studiedeelname uitgesloten indien zij, bijvoorbeeld, bepaalde (al dan 
niet verdovende) middelen gebruiken of een chronische ziekte of infectie onder de leden 
hebben, die het verzamelen van zuivere gegevens en de interpretatie van onderzoeksresultaten 
kunnen bemoeilijken. Het voordeel van een naturalistische studie is dat de resultaten eerder 
representatief mogen worden geacht voor de dagelijkse praktijk dan wanneer grote groepen 
patiënten van deelname zijn uitgesloten. Anderzijds kan het ook nadelig zijn voor de sponsor 
van de studie indien de resultaten minder succesvol lijken te zijn dan gehoopt. We zien dit 





asenapine enigszins achterblijft bij die van olanzapine (hoewel veel patiënten fors in gewicht 
toenemen op laatstgenoemd middel), op dat moment een eerste keusmiddel bij de behandeling 
van schizofrenie. Het is dan ook niet verwonderlijk dat recensenten, richtlijnbepalers en 
behandelaars de resultaten van dit soort studies zeer kritisch bekijken en er soms meer waarde 
aan hechten dan aan die van zogenaamde ‘pivotal’, placebo-gecontroleerde studies, welke 
doorgaans op beduidend kleinere schaal zijn uitgevoerd in min of meer ‘schone’ patiënten.5  
Tot slot kan een naturalistische studie een belangrijke bron van informatie zijn voor het 
natrekken van verhoogde gevoeligheid voor bijwerkingen of kans op voorspoedige genezing 
bij patiënten met bepaalde basiskenmerken zoals ernst en duur van ziekte voor behandeling, 
jong of hoge leeftijd, drugsmisbruik, etc.. 
Om tegemoet te komen aan de eventuele wens van patiënten om blijvend gebruik te 
kunnen maken van een veelbelovend product na deelname aan een studie, is het niet 
ongebruikelijk om een zogenaamde humanitaire voortzetting van behandeling volgens 
protocol uit te voeren na afsluiting van de hoofdstudie. Bijkomend voordeel van een 
dergelijke aanpak is dat patiënten eerder geneigd zijn om aan de hoofdstudie deel te nemen, 
zodat ook grote studies praktisch uitvoerbaar worden binnen een acceptabel tijdsbestek. Het 
alternatief, om behandelaars door middel van “compassionate use” (dat wil zeggen, op 
artsenverklaring) in de gelegenheid te stellen nog vóór registratie een nieuw middel te laten 
gebruiken bij patiënten die slecht reageren op reeds beschikbare medicatie, is grotendeels in 
onbruik geraakt vanwege medisch-ethische en marktstrategische bezwaren. Immers, eventuele 
bijwerkingen worden dan onder slecht controleerbare omstandigheden verzameld en 
behandelaars kunnen al voordat het nieuwe middel op de markt komt teleurgesteld zijn in bij 
deze specifieke groep behaalde resultaten. De resultaten van een humanitaire extensie op de 
studie in Hoofdstuk 4 zijn beschreven in Hoofdstuk 5. Het is interessant om te zien dat het 
percentage patiënten dat zich terugtrekt uit de studie in beide behandelingsgroepen 
vergelijkbaar is, ofschoon binnen de asenapine-groep meer bijwerkingen worden 
gerapporteerd en meer comedicatie wordt voorgeschreven. Ook interessant om te zien is dat 
de gemiddelde gewichtstoename binnen de olanzapine-groep bij voortgezet gebruik 
gedurende meer dan twee jaar op hetzelfde, hoge niveau blijft (ca. 5 kg) terwijl die binnen de 
asenapine-groep beperkt blijft (ca. 1 kg) en zelfs na verloop van tijd lijkt te verdwijnen. 
Gestandaardiseerde documentatie van dit soort gegevens zou niet mogelijk zijn geweest op 





van gewichtstoename bij een patiënt bespeurt na start van medicatie. Immers, bij 
langetermijngebruik van antipsychotica zijn stofwisselingsstoornissen die uitmonden in 
gewichtstoename een belangrijke risicofactor voor diabetes en secundaire cardiovasculaire 
problemen.6      
Voortijdige stopzetting van studiedeelname als gevolg van slechte werkzaamheid, 
verdraagbaarheid of therapietrouw, moet altijd worden geanticipeerd en gecompenseerd door 
een adequate steekproefgrootte. Patiëntuitval is vaak hoog in klinische studies met 
schizofreniepatiënten, die hun toestemming voor vrijwillige deelname op elk moment kunnen 
intrekken. Dientengevolge zijn niet alleen maatregelen die patiëntmotivatie voor 
studiedeelname versterken, maar ook voorzorgsmaatregelen die patiëntuitval kunnen 
voorkomen belangrijke middelen om de efficiëntie van studies te verhogen en algehele 
ontwikkelingskosten te drukken. Dergelijke voorzorgsmaatregelen kunnen worden getroffen 
wanneer men inzicht heeft in de belangrijkste drijfveren van patiënttevredenheid met 
experimentele behandeling. In Hoofdstuk 6 werd met een post hoc analyse van 
patiëntgegevens uit de in Hoofdstuk 4 gerapporteerde studie beoogd een antwoord te 
verkrijgen op de vraag waarom veel patiënten met schizofrenie zich zonder opgaaf van 
redenen voortijdig terugtrekken uit een studie waaraan zij aanvankelijk wensten deel te 
nemen, vaak ondanks eerste tekenen van een goede respons. Grootschalige, naturalistische 
studies lenen zich bij uitstek voor dit soort exploratief onderzoek omdat, anders dan bij een 
verzameling van op zichzelf staande studies, alle patiënten exact dezelfde behandeling krijgen 
onder dezelfde condities. Helaas kon hiervoor geen verklaring worden gevonden en blijft de 
welwillendheid van schizofreniepatiënten om deel te nemen aan onderzoek en gecontroleerde 
behandeling onvoorspelbaar en moeilijk te bestendigen.  
Wanneer een sponsor marktuitbreiding zoekt van een inmiddels geregistreerd product 
binnen de regio waar de richtlijnen van de International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) worden 
onderschreven, kan men zich beroepen op de E5 richtlijn met betrekking tot acceptatie van 
buitenlandse data.7  In het gunstigste geval kan het volledige dossier van elders verkregen 
resultaten worden gebruikt om registratie aan te vragen in de nieuwe regio, mits het op basis 
van een overbruggingsstudie aannemelijk is dat etnische verschillen geen invloed hebben op 
de te verwachten effectiviteit en verdraagbaarheid van het testmiddel. Dit voorkomt een 





met het antidepressivum Remeron® om registratie te verkrijgen in Japan nadat het middel 
reeds was geregistreerd in Amerika en Europa; de resultaten hiervan worden beschreven in 
Hoofdstuk 7. De voornaamste vereiste is dat een overbruggingsstudie laat zien hoe in de 
nieuwe regio met een bepaalde dosering(en) een vergelijkbare effectiviteit en 
verdraagbaarheid wordt bereikt als elders. Ofschoon de effectiviteit en verdraagbaarheid van 
Remeron® in Japanners niet substantieel afweek van die in Caucasiërs waren de Japanse 
autoriteiten hier niet onmiddellijk van overtuigd en verzochten zij om een additionele 
placebo-gecontroleerde studie met vaste doseringen. Dit was aanvankelijk ook de bedoeling 
geweest maar er bestond in eerste instantie grote weerstand onder Japanse collega’s van 
Organon om een dergelijk onderzoek uit te voeren. Een dure inschattingsfout die laat zien dat 
het bij het ontwerpen van een overbruggingsstudie de voorkeur verdient om met vaste 
doseringen te testen en op zijn minst een bescheiden placebo-groep als controle mee te 
nemen.    
 De in dit proefschrift opgenomen studies zijn slechts een kleine greep uit het arsenaal aan 
mogelijkheden om geneesmiddelonderzoek in de psychiatrie zo efficiënt mogelijk te laten 
verlopen. Het centrale doel bij de meeste klinische studies is het aantonen van effectiviteit en 
respons op een proefmedicijn. Echter, het is vaak non-respons dat zich gemakkelijker laat 
definiëren aangezien het bij psychiatrische ziekten niet altijd duidelijk is wanneer een patiënt 
zich ‘beter’ voelt. Hoewel het gebruik van medicijnen er primair op is gericht om 
ziektenymptomen te onderdrukken, koesteren patiënten vaak tevens hoopvolle verwachtingen 
op een verbeterde kwaliteit van leven bij aanvang van een behandeling. Teneinde te bereiken 
dat artsen en patiënten een zelfde opvatting hebben over de noodzaak tot, en succes van een 
behandeling is het belangrijk dat een onderzoeker duidelijk de mogelijke voordelen en risico’s 
van studiedeelname aan een patiënt uitlegt voordat deze daartoe vrijwillig besluit. Maar 
daarbij moet tevens benadrukt worden dat van een patiënt als ‘partner in de wetenschap’ een 
zekere mate van verantwoordelijkheid en oprechtheid wordt verwacht. Een aanpak die tot nu 
toe grotendeels onbenut is gebleven binnen het klinisch onderzoek, is het onderrichten van 
onderzoekers met betrekking tot een daarop toegespitste, gestandaardiseerde procedure voor 
het verkrijgen van een patiënten-bewustzijnsverklaring bij aanvang van een studie. Meer dan 
enig andere methode zou dit kunnen bijdragen tot studiedeelname van gemotiveerde maar 





datasets, en het verhogen van de efficiëntie van geneesmiddelenonderzoek bij psychiatrische 
patiënten.  
Een succesvolle en tijdige afronding van de in dit proefschrift opgenomen, klinische 
studies hangt af van vele factoren, waaronder de beschikbaarheid van onderzoekers en 
patiënten, hun enthousiaste bereidheidwilligheid om deel te nemen, intensieve medische 
begeleiding tijdens de uitvoer van het onderzoek, en een goede follow-up. Aangezien 
verwachtingen bij onderzoekers en patiënten moeilijk zijn te controleren in een experimentele 
setting is het principe van dubbelblinde randomisatie een uitkomst. Blindering vormt de basis 
voor een eerlijke, adequate vergelijking van behandelingsregiems, maar het enthousiasme 
over een nieuw geneesmiddel en de hoop op verbetering behoort nimmer te worden 
weggenomen daar waar het thuishoort: in de klinische praktijk. Gezien de relatief hoge 
respons op placebo in psychiatrische studies en het vergeefs zoeken naar factoren die hiertoe 
bijdragen, in combinatie met het bestaan van harde criteria voor de vaststelling van non-
response of genezing versus verbetering, kan het lonen om in de toekomst met meer nadruk te 
zoeken naar voorspellende factoren van een slechte respons op placebo en (voorspoedige) 
genezing bij actieve behandeling.   
 
Epiloog  
Zoals met de meeste onderzoeken die worden uitgevoerd in het kader van programma's voor 
de ontwikkeling van geneesmiddelen, hebben de studies die worden gepresenteerd in 
Hoofdstuk 3, 4, 5 en 7 geen ander doel dan om te getuigen van het potentieel van de 
testmiddelen om verder te worden ontwikkeld en op de markt te worden gebracht. Aangezien 
met deze studies drie verschillende stoffen worden getest in drie verschillende indicaties, is 
het lastig om de resultaten te koppelen en te evalueren in hoe verre deze kunnen bijdragen aan 
de wetenschappelijke of klinische vooruitgang. Hetzelfde geldt voor de uitkomstvariabelen 
'placebo-respons' en 'drop-out' (Hoofdstuk 2 en 6) die op niet-identieke wijze werden 
onderzocht bij twee verschillende indicaties (depressie en schizofrenie). Wat de laatste twee 
variabelen in theorie met elkaar gemeen hebben, is dat beide gevolgen kunnen hebben voor 
het falen van gecontroleerde studies. De belangrijkste redenen voor het mislukken van 
gecontroleerde studies kunnen echter aanzienlijk verschillen in depressie en schizofrenie 
(hoewel dit onderwerp niet uitgebreid is onderzocht, voor zover ik weet). Het feit dat er geen 





respons of terugtrekking van patiënten, is ook niet echt nuttig als we de algehele verdiensten 
van ons werk willen samenvatten.  
Op de een of andere manier hebben de studies die in dit proefschrift worden gepresenteerd 
met elkaar gemeen, dat de resultaten van geen van deze zullen leiden tot hervorming van de 
dagelijkse klinische praktijk of geijkte onderzoeksmethoden bij de ontwikkeling van nieuwe 
geneesmiddelen. Zoals gezegd, was ik niet in staat om een vinger te krijgen achter de 
oorzaken van placebo-respons in depressie- of het stoppen van patiënten in schizofrenie-
studies (Hoofdstuk 2 en 6). Als er een of meer voorspellende factoren waren gevonden, 
zouden deze zeker in overweging worden genomen bij de opzet en/of uitvoer van nieuwe 
studies in de betreffende indicatie(s). Ondanks een uiterst zorgvuldige opzet en uitvoering van 
het onderzoek in Hoofdstuk 3, met innovatieve second opinion-beoordeling van klinische 
symptomen en geavanceerde statistieken, kon geen significant effect van Org 25935 op 
negatieve symptomen bij schizofrenie worden vastsgesteld; het kleine effect dat werd 
waargenomen, bleek hoofdzakelijk niet-specifiek te zijn, d.w.z. secundair aan veranderingen 
in positieve, algemene psychopathologische, depressieve, cognitieve en extrapiramidale 
symptomen, en ook daarom onbeduidend. Als een specifiek, statistisch significant effect op 
negatieve symptomen zou zijn gevonden, is het niet onwaarschijnlijk dat de innovatieve, 
second-opinion-beoordeling, die voor het eerst in deze studie werd gebruikt, in de toekomst 
meer algemeen zou worden toegepast om subjectiviteit bij geneesmiddelenonderzoek te 
verminderen. Vooral, wanneer zou zijn aangetoond dat de effectgroottes toenemen wanneer 
beoordelaars hun voorlopige scores aanpassen op basis van second opinion. En eventueel 
zouden de gebruikte analyse-methodes vaker toepassing vinden bij de evaluatie van 
geneesmiddeleffecten op nauw verweven symptoomcomplexen, wanneer was aangetoond dat 
Org 25935 daadwerkelijk een specifiek effect had op negatieve symptomen. Maar helaas, met 
het uitblijven van een gewenst effect zijn de verdiensten van deze innovatieve studieaanpak 
op langere termijn slechts denkbeeldig. 
De resultaten van studies, gepresenteerd in Hoofdstuk 4, 5 en 7, tonen aan dat een 
experimentele behandeling met asenapine en mirtazapine niet inferieur is aan een behandeling 
met de bestaande geneesmiddelen fluvoxamine en olanzapine, bij respectievelijk schizofrenie 
en depressie. Tegelijkertijd kon aan de hand van de resultaten geen betekenisvolle verbetering 





wezenlijk nieuwe inzichten op ten aanzien van de behandeling van deze psychiatrische 
aandoeningen.  
Echter, ondanks een gebrek aan potentieel invloedrijke resultaten, verdienen dit soort 
studies evenveel aandacht als die met een positiever resultaat. Ten eerste: hoewel er duidelijk 
aanwijzingen zijn dat sommige symptomen bij schizofrenie samenhangen met een 
ondermaatse, glutamaterge neurotransmissie, is het falen van twee bedrijven om door middel 
van glycine-opnameremming de symptomen te doen verbeteren een belangrijk 
waarschuwingssignaal dat aandacht verdient.8-13 Het delen van dit soort negatieve 
resultaten door middel van publicatie blijft belangrijk om derden ervoor te behoeden dat zij 
opnieuw patiënten onnodig blootstellen aan experimenten met vergelijkbare, niet-werkzame 
stoffen. Ten tweede: Op basis van zowel korte-, als lange-termijn-resultaten, gepresenteerd in 
Hoofdstuk 4, 5 en 7, kunnen zowel asenapine als mirtazapine worden genomen als bruikbare 
alternatieven voor patiënten die vervelende bijwerkingen ondervinden van voorgeschreven 
geneesmiddelen. 
Het feit dat ik geen voorspelbare oorzaken van placebo-respons in depressie of het 
voortijdig stoppen van patiënten in een schizofrenie-studie kon identificeren, maakt het in dit 
stadium niet wenselijk om bepaalde patiënten uit te sluiten van geneesmiddelonderzoek op 
basis van enquête-uitslagen of gepubliceerde meta-analyses, in een poging om snel een 
gewenst resultaat boven tafel te krijgen. Evenmin, om het verder speuren naar mogelijkheden 
voor proefoptimalisatie door middel van meta-analyses als ongepast te beschouwen en maar 
volledig op te geven. In een recent artikel opperen Cipriani en collega's (2018) goede 
mogelijkheden voor het combineren van individuele patiëntgegevens uit gerandomiseerde 
studies in zogenaamde netwerk-meta-analyses.14  Ze spreken de verwachting uit dat dergelijke 
analyses beter geschikt zijn dan de conventionele, om de uitkomst van patientgerichte 
behandeling, de relatieve werkzaamheid van bepaalde middelen, of het risico op vroegtijdige 
beëindiging te voorspellen. De effectgroottes van antidepressiva en antipsychotica zijn bij 
klinische studies doorgaans vrij bescheiden, wat volgens menigeen suggereert dat deze 
geneesmiddelen in hun geheel nauwelijks effectiever zijn dan placebo.14,15  Er zijn gegevens 
die erop wijzen, dat nog niet eerder behandelde patiënten vaak beter reageren op een medicijn 
dan chronische zieke (al eerder behandelde) patiënten met schizofrenie.16  Deze trend was ook 
waarneembaar in de naturalistische studie die we hebben uitgevoerd (Hoofdstuk 4, gegevens 





patiënten, die in hun eerste episode verkeren, mogen deelnemen teneinde de efficiëntie van 
programma’s voor geneesmiddelontwikkeling te verhogen. Daar staat tegenover, dat nieuwe 
patiënten relatief dun gezaaid zijn en moeilijk te motiveren voor deelname aan een studie, 
zodat een dergelijke strategie slechts beperkt kan worden toegepast. Kleinschalige studies 
worden doorgaans tijdens de vroege ontwikkeling van een geneesmiddel uitgevoerd. Het is 
echter precies dan, wanneer het bewijs van de werkzaamheid nog niet is bewezen en patiënten 
het moeilijkst zijn te motiveren om zich vrijwillig in te schrijven voor een klinisch onderzoek. 
Hoewel verbeterde selectie van patiënten in theorie nuttig zou kunnen zijn bij de ontwikkeling 
van geneesmiddelen, zou het veld in de toekomst toch meer baat kunnen hebben bij een 
geïntegreerde verwerking van inmiddels verzamelde gegevens, zoals door middel van de 
hierboven genoemde netwerk-meta-analyse. Open toegang tot de gegevens van zoveel 
mogelijk (liefst alle) gerandomiseerde studies is cruciaal om deze benadering een kans van 
slagen te geven. Het vaststellen van responsbevorderende factoren maakt het mogelijk, dat 
klinische studies optimaal worden ingericht om de effectiviteit van een nieuwe behandeling 
aan te tonen. Ofschoon dit zeker zal bijdragen tot de repliceerbaarheid van studies en 
kostenbesparingen, is het maar de vraag of we daarmee tevens in staat zullen zijn om het 
algehele ontwikkelingstraject van nieuwe geneesmiddelen tegen neuropsychiatrische 
aandoeningen te verkorten. Dat doel kan gewoonweg te ambitieus zijn, zolang er geen 
objectieve criteria en / of biomarkers zijn voor de etiologie, diagnose en beoordeling van 
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5-HT  Serotonin / 5-hydroxytryptamine (neurotransmitter)  
ACTAMESA Active-Controlled, Two-Armed, Multicenter, Efficacy and Safety Assessment 
trial (acronym) 
ADR Assessment of Drug Relationship of an AE (safety parameter) 
AE  Adverse event (safety parameter) 
AIMS  Abnormal Involuntary Movement Scale (rating instrument) 
ALT  Alanine Aminotransferase (liver health biomarker in plasma) 
ANCOVA Analysis Of Covariance (statistical method) 
ANOVA Analysis Of Variance (statistical method) 
AST  Aspartate Aminotransferase (liver health biomarker in plasma), or 
  All-Subjects-Treated (trial participants having received medication) 
BARS  Barnes Akathisia Rating Scale (rating instrument) 
BID  Twice Daily (Latin: bis in die) 
BL  Baseline (cut-off point for evaluation of efficacy and safety) 
BMI  Body Mass Index (health measure) 
CATIE Clinical Antipsychotic Trials of Intervention Effectiveness (acronym) 
CDSS  Calgary Depression Scale for Schizophrenia (rating instrument) 
CFB  Change From Baseline (outcome measure) 
CGI  Clinical Global Impression scale (rating instrument) 
CGI-I  Clinical Global Improvement score (rating instrument) 
CGI-S  Clinical Global Severity score (rating instrument) 
CI  Confidence Interval (summary statistics) 
CNS  Central Nervous System (brain and spinal cord) 
CPT  Continuous Performance Test (cognitive test) 
CSF  Cerebro-Spinal Fluid (body fluid) 
CYP  Cytochrome P450 (liver metabolizing enzyme) 
D (d)  Delta value (difference in response between groups)  
D2  Dopamine-2 (neurotransmitter subtype) 
D-15  Farnsworth Dichotomous test (color vision test) 
DSM-IV Diagnostic and Statistical Manual, 4th edition (disease criteria) 
ECG  Electrocardiogram (electrical heart activity recording) 
ECT  Electro-Convulsive Therapy (seizure-inducing shock treatment) 
EP  Endpoint (cut-off point for evaluation of efficacy and safety) 
EPS  Extra-Pyramidal Symptoms (parkinson’s disease mimicking effects) 
ERASE Expert Rater Assisted Score Evaluation (rating control method) 
ESRS  Extrapyramidal Symptom Rating Scale (rating instrument) 
ETDRS Early Treatment Diabetic Retinopathy Study (visual acuity test) 





GAF  Global Assessment of Functioning (rating instrument) 
GCP  Good Clinical Practice (international ethical and scientific quality standard) 
GIANT Glycine uptake Inhibitor Add-on in Negative symptoms Trial (acronym) 
GLP  Good Laboratory Practice (quality standard) 
GlyT-1 Glycine Transporter Type 1 (co-agonist transporter molecule) 
GSR  Gold Standard Rating (rater validation criterion) 
γ-GT  Gamma-Glutamyl Transferase (liver health biomarker in plasma) 
HAM-D Hamilton Depression Rating Scale (rating instrument) 
IP  Investigational Product (experimental treatment) 
ISST  InterSePT Scale for Suicidal Thinking (rating instrument) 
IST  Investigator Satisfaction with Treatment (outcome measure) 
ITE  Insufficient Therapeutic Effect (outcome measure) 
ITT  Intent-To-Treat (trial participants with 1 post-baseline assessment) 
Ki  Inhibitory Constant (pharmacodynamic parameter) 
LFU  Lost to Follow-Up (outcome measure) 
LOCF  Last Observation Carried Forward (statistical method) 
LOF  Level of Function (rating instrument) 
LS  Least Square (summary statistics) 
MADRS Montgomery & Åsberg Depression Rating Scale (rating instrument) 
MDD  Major Depressive Disorder (disease) 
MMRM Mixed-Effect Model Repeated Measure (statistical method) 
N (n)  Number (count) 
NCI  Neuro-Cognitive Index (cognitive functioning measure) 
NDA  New Drug Application (full dossier for requesting registration of a new drug) 
NES  Neurological Evaluation Scale (rating instrument) 
NMDA Glutamate / N-methyl-D-aspartate (neurotransmitter) 
NSS  Neurological Soft Signs (rating instrument) 
OC  Observed Cases (statistical method) 
OQAQ  Overview Quality Assessment Questionnaire (quality measure) 
P (p)  Probability Value (statistical significance of evidence) 
PANSS Positive and Negative Syndrome Scale (rating instrument) 
PANSS-M PANSS Marder factor score for negative symptoms (symptom subscore) 
PET  Positron Emission Tomography (imaging technique) 
PK/PD  Pharmacokinetics / Pharmacodynamics (pharmacology) 
POET  Perception Of Emotions Test (cognitive test) 
PST  Patient Satisfaction with Treatment (outcome measure) 
QD  Once daily (Latin: quaque die) 
QTc  Corrected heart frequency QT interval (conduct velocity measure) 
RCT  Randomized, Controlled Trial (research method) 
R&D  Research & Development (industrial term) 
RDC  Research Diagnostic Criteria (disease criteria) 
SAD  Schizo-Affective Disorder (DSM-IV differential diagnosis) 
SAE  Serious Adverse Event (safety parameter) 
SANS  Scale for Assessment of Negative Symptoms (rating instrument) 
SAS  Simpson-Angus Scale (rating instrument), or 
  Statistical Analysis System (software) 
SCZ  Schizophrenia (DSM-IV differential diagnosis) 
SD  Standard Deviation (summary statistics) 




SE  Standard Error (summary statistics) 
SF-12  12-Item Short Form health survey (rating instrument) 
SGA  Second Generation Antipsychotics (drug class) 
SGOT  Serum Glutamic Oxaloacetic Transaminase = AST 
SGPT  Serum Glutamate-Pyruvate Transaminase = ALT 
SOHO  Schizophrenia Outpatient Health Outcomes trial (acronym) 
SPSS  Statistical Package for the Social Sciences (software) 
SWN Subjective Well-being under Neuroleptic treatment scale (rating instrument) 
TCA Tricyclic antidepressant (drug) 
WHO World Health Organization (specialized agency of the United Nations) 
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metingen – ieder onderzoek binnen deze gebieden een speciale benadering vereist, waarbij 
niet alleen gestandaardiseerde patiënteninterviews maar ook therapietrouw en een doordachte 
onderzoeksopzet vaak aan de basis staan van een geslaagde studie. Geconfronteerd met 
voortdurend nieuwe uitdagingen, heeft Joep door de jaren heen diverse onderzoeksstrategieën 
uitgedacht en/of uitgeprobeerd, met wisselend succes. Bundeling van deze strategieën heeft 
uiteindelijk aan de basis gestaan van dit proefschrift. Onder supervisie van zijn promotoren 
heeft hij in aanvulling hierop een tweetal generieke factoren die vaak afbreuk doen aan 
studies binnen de psychiatrie nader onderzocht, te weten: placebo respons en voortijdige 
studie-uitval. In de hoop dat eventuele, gunstige resultaten hiervan mede zouden kunnen 
bijdragen tot een zo efficiënt mogelijk maken van toekomstig geneesmiddelenonderzoek in 
neuro-psychiatrische aandoeningen.     
 
